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1.0 Introduction: 
 
“Detect prostate cancer early, it offers a better chance of cure and will reduce 
cancer specific mortality”. The concept speaks for itself and seems convincing. 
Yet, prostate cancer screening is perhaps the most debated and controversial 
topic in the urological world at the moment. Just typing the words prostate, 
cancer and screening in PubMed, the online search engine of the National 
Library of Medicine, results in a listing of more than 24,000 scientific papers. 
 
Since the early nineties there have been two mainstreams of thinking about 
prostate cancer screening. One extreme is represented by those who are 
definitely against screening for prostate cancer and consider it as unethical 
[1,2]; the opposite view is represented by those investigators who argue that 
men should not be denied the opportunity of early detection and treatment 
[3,4].  
In the past 10 years no consensus has emerged and prostate cancer 
screening is still a controversial issue [5,6,7,8,9], resulting in very different 
screening policies in different countries, varying from very aggressive 
screening protocols, where men are screened every 6 to 12 months starting 
as early as the age of 40, to no screening at all. [11,12,13,14]. 
 
What causes these great differences of opinion between specialists in the field?  
Apart from the lack of convincing evidence that early detection indeed will 
reduce prostate cancer mortality, arguments against early detection of 
prostate cancer are basically based on the lack of a specific screening test, 
the poor understanding of the natural history of screen detected prostate 
cancer and doubt over the effectiveness of the different treatment possibilities 
of prostate cancer.   
Although serum PSA testing is now widely used as a screening test for 
prostate cancer it is commonly known that PSA is not specific for prostate 
cancer, and that there is considerable overlap between serum PSA levels in 
men with normal prostates, benign prostatic hyperplasia (BPH) and those with 
clinically localized prostate cancer. The major reason for the wide spread use 
of PSA as a screening test  is not its higher specificity but the fact that PSA 
was more sensitive as a first line screening test for prostate cancer compared 
to a digital rectal examination (DRE) [15].  
In general, prostate cancer is a slow growing tumor in elderly men. The 
median age at onset of clinically apparent disease is 72 years, and median 
age at death is 79 years [16]. The question is whether early detection and 
available treatment, with related morbidity, will reduce prostate cancer 
mortality. 
Any attempt to detect cancer early implies some degree of overdiagnosis, i.e. 
the identification of cancer which, in absence of screening, would never have 
reached the threshold of clinical diagnosis, as the subject would have died of 
some other disease before the cancer could become symptomatic. This is 
more likely in a cancer with a low average growth rate, a long preclinical 
detectable phase for which sensitive tests are available, and which affects 
subjects with a relatively low life expectancy, as is the case in prostate cancer. 
It has been estimated that for a 50-year-old man with a life expectancy of 25 
years, there is a 42% lifetime risk of having microscopic cancer, a 9.5% risk of 
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having clinically evident cancer, and a 2.9% risk of dying from prostate cancer 
[17]. Clearly, more men will die with prostate cancer than of it. 
 
An important argument in favor of early detection is the fact that more than 
30% of men with clinically diagnosed prostate cancer have locally advanced 
or metastatic disease [18,19]. Prostate cancer diagnosed at this stage has a 
poor prognosis; in some men the disease kills the patient within a year after 
diagnosis.  It has been estimated that men with clinically diagnosed prostate 
cancer will lose an average of 40 % of their life expectancy compared to an 
age matched control group without prostate cancer [20,21]; therefore the 
disease should be detected at an earlier, more curable stage. Data from 
Swedish studies showed that the life expectancy of men with clinically 
diagnosed, organ confined disease exceeded 10 years and that the cancer 
specific mortality at 15 and 20 years was high. [18,22,23].  
 
The majority of cases detected by screening are organ confined and well 
differentiated and thus eligible for curative treatment [24, 25] by radical 
prostatectomy [26] or radiotherapy [27]. For any medical treatment, informed 
decisions about treatment choice can only be made if unbiased, 
representative data on outcomes, i.e. from a randomized controlled trial, are 
available. Recently a prospective randomized trial of 695 Scandinavian men 
randomised to observation or radical prostatectomy showed a clear 
improvement in disease specific and overall survival in patients who 
underwent radical prostatectomy compared with those in the observation arm 
[28]. 
 
The only scientifically valid way to determine whether early detection has an 
effect on prostate cancer mortality is by means of a randomized controlled trial 
with prostate cancer death as the main endpoint. Two large trials are ongoing 
namely the European Randomised Study of Screening for Prostate Cancer 
(ERSPC) [29] and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial [30] from which an answer can be expected within the next 
five years.  
The ERSPC was initiated in 1993 and has app. 205,000 men randomized in 
eight different centers in Europe. The PLCO was initiated in 1993 and has 
included app. 74,000 men randomized to the prostate arm of the trial [31]. 
Conditions for a possible common analysis of ERSPC and PLCO were 
defined and described in 1996 [32].   
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1.1 Scope of the thesis: 
 
 
Apart from the lack of evidence that early detection of prostate cancer will 
indeed reduce prostate cancer mortality the differences of opinion about 
prostate cancer screening are based on two issues relating to specificity. The 
first is the lack of a screening test or combination of tests that can efficiently 
identify men with an elevated risk of having prostate cancer in an 
asymptomatic population in order to avoid unnecessary testing and secondly 
the lack of knowledge about which prostate cancers are life threatening, and 
need to be detected, and which are not. 
This thesis concentrates not on the debate whether prostate cancer screening 
should be common practice or not, nor on which prostate cancers should be 
detected or not, these decisions can only be made after completion of the 
ongoing randomized trials. Whatever the outcome of these randomized trials 
will be, it is unrealistic to think that prostate cancer screening can be stopped 
at this point in time. This makes an acceptable and efficient screening 
algorithm much-needed.  
This thesis focuses specifically on the value of the available screening tests, 
and their algorithm, in identifying men with an elevated risk of having prostate 
cancer in an asymptomatic population in the ERSPC (section Rotterdam).  
 
The first part of this thesis consists of some background information on the 
prostate, prostate cancer, screening and a general description of available 
diagnostic tests and statistical techniques used. Furthermore the different 
screening algorithms used in the Dutch center of ERSPC are discussed. The 
second part discusses possible changes in the screening algorithm and the 
value of different diagnostic tests both at initial and subsequent screening 
rounds. Data coming from the first four pilot studies are included. This offers 
the opportunity to discuss results with respect to the final outcome of the 
ERSPC trial. Finally the results are summarized and other (new) possible 
predictors for biopsy outcome are discussed. 
 
 

 
 
 
 
 
2.0 
 
Prostate, Prostate Cancer, Screening and Statistics. 
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2.0  Prostate, Prostate Cancer, Screening and Statistics. 
 
 
2.0 The prostate: 
 
The prostate is situated at a low level in the true pelvis, behind the inferior 
border of the symphysis pubis and the pubic arch, and anterior to the rectum, 
through the wall of which it may be palpated (Figure 1). It is somewhat conical 
in shape, resembling a chestnut, and thus presents for examination a base or 
vesical aspect, an apex, and posterior, anterior and two posterolateral 
surfaces. The prostate consists of groups of exocrine glands that are packed 
in dense fibromuscular tissue. The glandular tissue can be divided into two 
main zones, the transition zone (central and surrounding the urethra) and the 
peripheral zone (laterally located). The glands in the transition zone are the 
main sites for the development of benign prostate hyperplasia (BPH), while 
glands in the peripheral zone are more prone to malignant transformation 
[33,34].  
Together with the seminal vesicles, the prostate produces proteins and 
enzymes that control the liquidity of the semen.  
 
 
 
Figure 1: Position of the prostate 
 
 
 
2.1 Prostate cancer: 
 
As a man ages, the epithelial cells and the stroma of the transition zone of the 
prostatic gland become hyperplastic and the gland increases in size. This 
relatively common condition is called “benign prostatic hyperplasia” (BPH). 
Prostate cancer appears to begin as a small focus or several foci within the 
peripheral zone (stage T0). In most men, these small cancers remain dormant 
for a long time and may be found only at autopsy or not at all. When the 
dormant focus becomes active and grows into a prostatic nodule, the tumor is 
in stage T2. This nodule is palpable and most men presenting with a nodule at 
this stage may fail to receive proper treatment. As the prostatic nodule grows, 
eventually it perforates the prostatic capsule (stage T3). At this stage, there 
may be partial or complete obstruction of the urethra or one or both ureters 
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the seminal vesicles and the pelvic lymph nodes. Once these nodes are 
involved (N+) the chances of cure are greatly reduced [35]. Unfortunately, 
even in this stage, the disease may not be recognized and the symptoms 
blamed on other age related factors resulting in the presence of metastases 
(M+) at diagnosis.  
 
 
2.2 Prostate cancer epidemiology: 
 
 
Prostate cancer is the sixth most common cancer in the world (in the number 
of new cases) and the third most common cancer in men. In 2002, the number 
of new cases was estimated at 679,000 worldwide [36] and accounted for 
11.7% of all cancers in men (19.0% in developed countries and 5.3% in 
developing countries). In Europe, prostate cancer incidence is lower in the 
southern part (Mediterranean countries) than in Northern Europe. In the 
Netherlands 6900 new cases emerged in the year 2000, being the most 
common cancer in men (19% of all cancers in men). The cumulative risk for 
prostate cancer in men 0-74 years in The Netherlands is 7.03 % [37]. The 
highest incidence rates are found in the United States (33% of all newly 
diagnosed malignancies among men, with a cumulative risk of 16%), Canada 
and Scandinavia, though the lowest rates are found in China and other parts 
of Asia [38]. A recent study reports a trend towards an increasing incidence of 
prostate cancer in Asia [39]. The differences in incidence are caused by 
genetic susceptibility, exposure to unknown external risk factors, differences 
in health care and cancer registration, or a combination of these factors [40].  
 
 
 
Figure 2:  Incidence of prostate cancer (age >= 55-yrs), 
age standardized rates per 100,000 men 
 
Prostate cancer mortality also varies worldwide. The highest rates are 
reported in the Caribbean and Scandinavia and the lowest rates in China, 
Japan, and countries of the former Soviet Union [41,42,43].  
 - 19 -
Few cancers vary as widely in incidence and mortality between and within 
countries as prostate cancer. So far no single risk factor for prostate cancer 
has been identified with sufficient certainty to advocate its use in a primary 
prevention regimen. Secondary prevention through screening is therefore the 
only population-based approach available. 
Approximately 85% of all cases of prostate cancer are diagnosed in men older 
than 65 years. The number of men >= 65 years is expected to increase 4-fold 
worldwide between the years 2000 and 2050, representing an increase from 
12.4% of the total population in 2000 to 19.6% in 2030 [44, 45]. This increase 
in male longevity will lead to a substantial increase in the number of men who 
will be diagnosed with prostate cancer and who will require treatment for their 
malignancy. 
 
 
 
 
2.3 Clinical staging. 
 
 
Multifocality of prostate cancer has been known for many years [46]. As many 
as five separate tumors may be found in the same prostate. Most frequently, 
one dominant tumor can be identified and associated with one or more 
microscopic small independent lesions. The dominant or largest tumor can be 
considered the primary, clinically most important, or best detectable tumor. 
The 1992 TNM classification [47], used in this thesis, translates the extent of 
the tumor (T), and reflects its state of progression (N,M). (See table I). T1 
represents incidental carcinoma found upon a trans urethral resection of the 
prostate (TURP) or needle biopsy; T2 corresponds to organ confined while 
non-organ-confined disease can be divided into (a) capsular penetration only 
with extraprostatic extension (T3a-T3b), (b) extension into adjacent organs i.e. 
seminal vesicles (T3c) and bladder (T4a), and (c) distant metastases (T4b). 
Metastases to lymph nodes are separately staged (N). 
 
 
 
2.4 Histologic grading. 
 
 
The degree of differentiation of malignant tumors, being the degree in which 
tumors show features similar to the benign tissue from which they arise, is 
often highly predictive of their biologic behavior. The Gleason score method 
[48, 49] is the most commonly used grading system in the world. In the 
Gleason score system growth patterns are divided into five categories by the 
degree of glandular differentiation. The total score is obtained by adding the 
growth pattern of the most dominant pattern to that of the second most 
dominant pattern. If only one pattern is present, that grade is multiplied by two. 
The Gleason scores therefore range from 2 to 10. 
 
The determination of a clinical stage and grade provides a systematic way to 
describe the amount, extent and degree of differentiation of the tumor. The 
extent and degree of differentiation of the tumor strongly predicts its natural 
course. In combination with patient characteristics such as age and 
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comorbidity the knowledge of stage and grade strongly influence therapeutic 
decisions. 
 
T0 No pathologic evidence of tumor 
(note that clinical stage T0 does not exist) 
T1 No clinical evidence of tumor. Tumor is an “incidental finding” 
(note that a pathologic stage pT1 does not exist) 
T1a Tumor found incidentally at transurethral resection in <= 5% of tissue. 
T1b Tumor found incidentally at transurethral resection in > 5% of tissue. 
T1c Tumor found incidentally at needle biopsy. 
T2 Tumor is confined to the prostatic gland 
T2a Tumor in one side of the prostate, smaller than half a lobe. 
T2b Tumor in one side of the prostate, larger than half a lobe. 
T2c Tumor in both sides of the prostate. 
T3 Extraprotatic extension 
T3a Tumor extends into the periprostatic tissue on one side. 
T3b Tumor extends into the periprostatic tissue on both sides. 
T3c Seminal vesicle invasion  on one or both sides. 
T4 Invasion of other organs… 
T4a Bladder neck or rectal wall invasion. 
T4b Levator musculature or pelvic wall invasion. 
  
N Invasion of regional lymph nodes. 
NX Regional lymph node invasion cannot be assessed. 
N0 No regional lymph node invasion. 
N1 Metastasis in a single regional lymph node <= 2 cm in diameter. 
N2 Metastasis in a single regional lymph node > 2 cm in diameter. 
N3 Metastasis in regional lymph nodes, either multiple or > 5 cm. 
  
M Presence of distant metastasis 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph nodes 
M1b Bone metastasis 
M1c Metastasis to other site 
 
Table I: the 1992 version of the TNM system for prostate cancer. 
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Prostate cancer screening and available diagnostic tests. 
 
 
2.5 Screening. 
 
 
Screening differs from the clinical use of tests in several important ways. In 
the clinical situation patients consult their physician about complaints or 
problems resulting in testing to confirm or exclude a diagnosis. Because the 
patient requests help, the risk and expense of the tests are usually deemed 
acceptable by the patient. Screening however, engages apparently healthy 
individuals who are not seeking medical help. Consequently the medical and 
ethical standards justifying a screening programme must be of a higher level 
than those related to a diagnostic process in the hope of avoiding any adverse 
effect of screening.  
Even after a disease is determined to be suitable for screening and a valid 
test becomes available, it does not necessarily follow that a widespread 
screening program should be implemented. Evaluation of a potential 
screening program involves consideration of three main issues, namely 
feasibility, effectiveness and costs. Feasibility will depend on how easy it is to 
organize the population to attend for screening, whether the screening test is 
acceptable, and whether facilities and resourses exist to carry out the 
necessary further tests and treatment following screening. Effectiveness is 
evaluated by the extent to which implementing a screening program affects 
the subsequent outcomes. This is difficult to measure because of a number of 
biases that affect most of the study designs used: 
 
a. Selection bias - people who participate in screening programs often 
differ from those who do not with respect to the parameters which 
may be important for the outcome of the study. 
b. Lead time bias - because screening identifies disease that would 
otherwise be identified at a later stage there may be an apparent 
improvement in the length of survival resulting from screening and 
thus earlier diagnosis. 
c. Length time bias - as some tumors develop more slowly, they have 
a longer pre clinical stage and are more likely to be detected at that 
stage. They may also have a more favorable prognosis leading to 
the false conclusion that screening is beneficial in prolonging life in 
those who test positive. 
 
These biases can be avoided by performing a randomized controlled trial with 
disease specific mortality as the endpoint, as is done in the ongoing prostate 
cancer screening trials, of the ERSPC and PLCO [29, 30]. 
 
The cost of screening programs is also important. There will always be 
competition for the resources for health care. The relative cost-effectiveness 
of a screening program compared with other forms of healthcare should 
therefore be considered. Costs relate not just to the implementation of the 
screening program but also to the additional diagnostic tests and the 
subsequent cost of treatment. On the other hand, in the absence of screening, 
costs will be generated later by the diagnosis and treatment of patients in 
more advanced stages of the disease.  
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Screening studies also have to live up to the usual pre-requirements of all 
randomised trials: the experimental group must have a realistic chance of a 
better outcome than the control group. This is of particular importance 
because screening will always cause some initial mental and physical damage 
and because of the fact that overdiagnosis (and treatment) is immanent to 
screening.   
 
 
2.6 Screening tests: 
 
 
For a screening test to be useful, certain conditions must be met: firstly the 
screening test must be valid. The validity is measured by its ability to 
distinguish between subjects with the condition and those without. The validity 
of a screening test is determined by its sensitivity and specificity. These vary 
with the screening test, not the population. A good screening test preferably 
will have a high sensitivity and specificity and must be rapid, simple and 
ideally noninvasive and acceptable for the population screened. Sensitivity is 
defined as the proportion of men with a positive test result of those who truly 
have the disease. Specificity is defined as the proportion of men with a 
negative test result of those patients who are known to be free of the disease. 
A positivity criterion can influence the sensitivity and specificity of a test. If the 
positivity criterion is moved up (e.g. a PSA cut-off value for the indication of 
prostate biopsy) the specificity increases but the sensitivity decreases. The 
number of false-positives would decrease, but the number of false-negatives 
(those with the disease, but missed by the given test) increases. Also to be 
considered in the evaluation of a screening test is the positive predictive value 
(PPV), which reflects the possibility that if the test is positive, the patient has 
the disease in question. To calculate the true sensitivity the underlying 
prevalence of the disease should be known. This is not the case for prostate 
cancer. Therefore, sensitivity is based on the number of positive biopsies in 
the screened population as a “gold standard”.  Sensitivity defined in this way 
is termed “relative sensitivity” [50]. Next to the sensitivity of a screening test 
the specificity is of great importance in a population based screening program, 
simply because all those with a positive screening test(s) need further workup 
(i.e. prostate biopsy), which may cause unnecessary damage, mental stress 
and costs.  
 
In the prostate cancer screening trial in Rotterdam three tests serve(d) as 
indicators for the need of further testing, the digital rectal examination (DRE), 
transrectal ultrasonography (TRUS) and the serum prostate specific antigen 
(PSA) level. 
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2.7 Digital rectal examination of the prostate (DRE). 
 
 
As the name says DRE is an examination of the prostate with the digit (index 
finger) via the rectum. Performing a DRE gives the physician information on 
the size of the prostate and the character of the prostate tissue (hard -> weak). 
There is a tendency to detect larger tumors with DRE, and the risk of 
detecting clinically insignificant tumors with DRE is low. On the other hand, 
small multi focal lesions with an aggressive biologic potential may not be 
detected with DRE alone. The general belief is that DRE is highly subjective. 
The findings within the same prostate on the same day by two different 
examiners are often divergent [51], although there is one study [52] that found 
a good correlation between different observations of examiners when 
assessing the prostate in a systematic way.  
In a screening algorithm the result of a DRE is mostly given as abnormal (i.e 
feeling a hard nodule) or normal. In the case of an abnormal finding the 
corresponding clinical stage is determined by DRE and recorded (see TNM 
1992,[47]). 
The inter examiner variation makes the DRE less suitable in population based 
screening programs.  Several studies have already questioned the use of 
DRE in screening programs [53, 54, 55] and found little or no additional 
beneficial effect of a DRE in men with PSA levels >= 4.0 ng/ml. The value of 
DRE in detecting (clinically significant) cancer in men with a low “normal” 
range of PSA (< 4.0 ng/ml or < 3.0 ng/ml) remains controversial [56, 57, 58, 
59]. 
Data of the Dutch part of ERSPC [60, 61, 62, 63], have shown that on 
average, in men with a PSA level < 3.0 ng/ml, 96 DRE’s are needed to 
diagnose one prostate cancer. 
The controversy about the value of DRE as a screening test (at low PSA 
levels) is a topic of ongoing studies.  
 
 
2.8 Transrectal ultrasonography of the prostate (TRUS). 
 
 
With TRUS, an ultrasound probe is inserted into the rectum. It emits sound 
waves that bounce off the prostate gland, producing echoes that a computer 
uses to create a picture of the prostate. This picture, called a sonogram, can 
show abnormal areas (hypo echoic areas), including tumors, within the 
prostate [64].  As with the DRE the interpretation of TRUS is highly dependent 
on the investigator which makes it less suitable as a screening test. 
Furthermore it has been shown that hypo-echoic lesions are not specific for 
prostate cancer [65] and that cancers can have ultrasonic characteristics 
ranging from non hypo echoic to hypo echoic  and to hyper echoic [66, 67]. 
It is recognised that the value of TRUS as a screening test is limited [68, 69, 
70, 71,72].  It is now generally accepted that TRUS is not useful as a 
screening test but is indispensable for guiding prostatic biopsies and 
assessing prostatic volume. 
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2.9 The serum prostate Specific Antigen (PSA). 
 
 
PSA is a glycoprotein, encoded by the KLK3 gene that is almost exclusively 
produced by the epithelial cells of the prostate, and is perhaps more a specific 
organ marker rather than a tumor marker [73]. In the normal prostate most of 
the PSA produced will be excreted into the semen where it acts as an 
androgen related serine protease (controlling the liquidity of the semen fluid). 
It is speculated that, due to tumor development, the tissue architecture is 
altered by the disruption of the basal cell layer and basement membrane 
causing leakage of PSA into the blood stream [74]. PSA can be measured 
reliably either by a monoclonal immuno radiometric assay or by a polyclonal 
radioimmunoassay [75]. The calculated half-life of serum PSA ranges from 2.2 
to 3.2 days.  
Digital rectal examination, cystoscopy and prostate biopsy all can cause 
spurious elevations of the serum PSA level. Conditions such as bacterial 
prostatitis and acute urinary retention can also elevate the serum PSA level. 
There is also a considerable overlap in PSA levels between patients with 
organ-confined cancer and those with benign prostatic hyperplasia (BPH). As 
a result, approximately 38% to 48% of the patients with organ confined 
prostate cancer, the candidates for curative therapy; show no elevation of 
serum PSA [76].  
The problem with PSA testing is the choice of a cut off value for the decision 
to continue with more invasive examinations such as the prostate biopsy. 
Important positive characteristics of PSA determination for screening are the 
high acceptance of a blood test by the general population, and the fact that 
the result is objective and the test is easy to perform. 
Choosing a PSA cut off level in a screening setting will thus be a trade off 
between sensitivity and specificity. There have been several attempts to 
improve the specificity of total PSA including the use of PSA density (relating 
the serum PSA value with the volume of the prostate), PSA velocity (changes 
in serum PSA level over time), PSA doubling time (the time that is needed to 
double its value, expressed in years) and the use of other molecular forms of 
PSA as tumor markers. The value of these forms of PSA, as predictor for 
biopsy outcome will be discussed. 
 
 
 
2.10 Prostatic biopsy. 
 
 
Screening tests are used to identify men with an elevated risk of having 
prostate cancer. This suspicion must however be confirmed. The gold 
standard to prove the presence or absence of prostate cancer is the surgical 
removal of the entire prostate followed by a histological analysis of the entire 
gland. Next to this clinically and ethically impossible maneuvre, there is no 
superior method to prove the presence or absence of prostate cancer than a 
prostate biopsy, recognising that prostate cancers may be missed with this 
procedure [77,78,79]. 
Historically, the diagnosis of prostate cancer has been limited to a DRE and a 
digitally directed biopsy (taking a tissue sample of the palpable nodule). With 
the increasing use of PSA as a screening test the systematic sextant biopsy 
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performed under ultrasound guidance was introduced [80]. With the original 
sextant technique six sites were biopsied; the apex, middle and base of the 
prostate in the mid plane of each lobe of the prostate. The sextant technique 
was more effective in detecting prostate cancer than the digitally directed 
technique. Several years later, the sextant technique was modified in that 
sextant biopsies were taken laterally to the mid plane in the peripheral zone 
where most prostate cancers are located (figure 3) [81,82,83]. This latter 
technique is used within ERSPC (section Rotterdam). 
 
 
 
Figure 3: Schematic sextant transrectal biopsy. Left: dorsal view, upper right: 
transverse view, lower right sagittal view. 
 
 
Prostatic biopsy is in general a safe procedure though some local pain with or 
without urethral or rectal bleeding and haematospermia is common. In order 
to avoid infectious complications an antibiotic prophylaxis is usually given. The 
most feared complications are febrile reaction with prostatitis, septicemia and 
gross rectal blood loss. These severe complications are rare. There are 
however several case reports of death as a possible complication of a 
prostate biopsy [84,85,86].  
Within ERSPC the rate and type of complications after prostate biopsy have 
been studied. In a cohort of 1687 biopsied men within the ERSPC Rietbergen 
et al. [87] reported mild complications such as haematospermia in 45.4% and 
haematuria in 23.6% of the men. This was later on confirmed by Raaijmakers 
et al. in a study were complications after 5802 biopsies done in ERSPC 
(section Rotterdam) were reviewed [88]. Although severe complications are 
rare these can lead to a negative effect and considerable costs since many 
men are involved in a population based screening setting. 
 
 
In addition to the three tests mentioned above; DRE, TRUS, PSA ( and PSA-
D and PSA-V) additional information known before the actual performance of 
the sextant biopsy can be of help in determining the probability of detecting 
prostate cancer, e.g. age, prostate volume (determined at TRUS), results of 
earlier screening visits and family history of prostate cancer. 
The value of all the predictors mentioned above is measured against the used 
standard for the detection of prostate cancer within ERSPC, section 
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Rotterdam, namely the TRUS guided lateral sextant prostate biopsy described 
above. Recognizing the fact that all sampling procedures, such as the 
prostate biopsy, incur the risk of being falsely negative (i.e. cancer is present 
but missed by the biopsies), the calculation of statistical performance 
characteristics of the screening tests are inherently incorrect and biased.  
 
 
2.11  Assessing the predictive value of a screening test for the presence or 
absence of prostate cancer. 
 
 
As mentioned above part of this thesis concentrates on the ability of a 
screening test to identify men with an elevated risk on having prostate cancer 
(assessed by a sextant prostate biopsy!) in an asymptomatic population.  
Predictive modeling in medicine entails making predictions about patient 
outcomes based on available parameters such as clinical and pathologic 
variables. Rarely does any single variable provide sufficient predictive value to 
be a definitive predictor of an outcome of interest. To improve the predictive 
value of a single clinical parameter it is often helpful to consider it in 
combination with other variables in a multivariate analysis.  
A regression analysis makes it possible to predict the value of a dependent 
variable with using one or more independent variables. To assess the 
predictive value of an independent variable (i.e. result of screening test) to a 
dichotomous dependent variable (having cancer yes or no) the use of a 
logistic regression model is the correct choice [89]. 
A logistic regression model gives probabilities that an individual, for whom 
results of different screening tests are known, e.g PSA value, outcome of DRE 
and outcome of TRUS, belongs in group 1 ( e.g. having cancer) or group 0 
( no cancer). 
 
In two of the following chapters this technique is used and in order to 
understand the outcomes of such analyses an example of a logistic 
regression analysis will be discussed. 
Before that it is necessary to clarify the following terms: 
 
- Probability: the chance, in % terms, of an event occurring: 20/100 = 
20%. 
- Odds: the probability of an event occurring divided by the probability of 
it not occurring: 20% / 80 % = 0.25. 
- Odds ratio: the ratio of two sets of odds (e.g. positive test versus 
negative test): 1.0 /0.25 = 4.0 
 
The odds ratio (OR) is a measure of the association between two variables. 
An OR of 1 means there is no association, odds are equal. An OR < 1 means 
that the odds of an event occurring decreases by moving between values of 
the explaining variable. An OR > 1 means that the odds of an event occurring 
increases by moving between values of the explaining variable. For example if 
the outcome variable is having grey hair or not, and the OR for age is > 1, this 
means that with higher age the odds of having grey hair increases. 
The OR is however asymmetrical, the lower bound is fractionally above zero 
and there is no upper bound. For modeling purposes this is problematic and 
therefore the OR is transformed by taking the natural logarithm, the OR is 
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transformed to the logit. This purely mathematical procedure has one goal 
namely that the logit has symmetrical properties, zero means no association 
and negative values means odds decrease and positive values means odds 
increase. It is however hard to think with values such as the natural log of the 
OR. Therefore the logit is transformed back to an OR. This so called exp (B) is 
the output in statistical packages such as SPSS (version 10.0, Chicago, 
Illinois, USA), used in this thesis.  
Exp (B) gives us the percentage increase or decrease in the odds. When the 
OR > 1, the % increase in odds is “OR – 1”. When the OR < 1, the % 
decrease in odds is “1 – OR”. 
For example, an OR = 3 means an increase of the odds by 200 % (3 – 1). An 
OR of 0.42 implies a decrease in odds of (0.42 – 1) = 58%. 
 
In order to explain the interpretation of a logistic regression analysis the 
following example is used: 
Some men hate soccer, other men love soccer.  A researcher, for some 
reason, wants to examine the determinants of such behavior.  Hence, a 
sample of men is asked whether they hate or like soccer.  The height, weight, 
age, and wage of these individuals are also assessed.  An extract of the data 
is displayed in the following table. 
 
Order Height Weight Age Wage 
Hate 192 71 21 34,509 
Hate 184 84 34 29,500 
Like 203 92 42 41,600 
Hate 185 63 27 38,456 
Like 191 84 41 48,670 
Hate 194 81 55 29,698 
Like 173 64 44 49,569 
.. .. .. .. .. 
.. .. .. .. .. 
Hate 162 87 23 58,598 
 
Presumably, the researcher could undertake a series of t-tests to ascertain 
whether or not the age, height, weight, and wage of individuals differs 
between individuals who hate or like soccer.  The outcomes that arise from 
these analyses are summarized in the table below. 
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Measure Average 
if hate 
soccer 
Average 
if like 
soccer 
T-value P-value 
Height 191 173 4.92 0.001 
Weight 67 61 4.84 0.001 
Age 45 32 6.03 0.001 
Wage 39,658 31,483 5.85 0.001 
 
In this instance, all of the measures clearly differentiate the two groups. 
Nevertheless, these t-tests do not provide a comprehensive account of the 
data.  In particular, these analyses do not indicate whether or not each 
measure differs between the two groups after controlling the other 
measures.  In other words, these analyses do not demonstrate that each 
measure would differ between groups that are equivalent on the other 
measures.  For example, weight might not differ between individuals who hate 
or like soccer if these groups were equal in height.  That is, weight might not 
differ between the two groups after controlling for height, age, and wage. 
Logistic regression provides a means to explore these issues.  Specifically, 
logistic regression determines whether or not the two groups differ from one 
another on each measure after controlling the other variables.  Logistic 
regression is applicable only when the researcher compares two groups (0 = 
hate soccer and 1 = like soccer).   
After a logistic regression analysis is executed, the above mentioned exp(B) 
and its significance (Sig) is displayed ( B = estimated effect on the logit 
( natural log of the odds), S.E its standard error). 
 
 B S.E Sig. Exp(B) 
Height -0.47 0.24 0.03 0.62 
Weight 0.37 0.20 0.05 1.44 
Age 0.16 0.32 0.61 1.17 
Wage 0.11 0.23 0.64 1.12 
Constant 2.12 1.68 0.10 16.04 
 
In this example, two of the p values are less than or equal to 0.05.  These p 
values reflect measures that differ significantly between the two groups, after 
controlling the other variables.  In this instance:  
Height depends on whether individuals hate or like soccer, after controlling 
weight, age, and wage (p=0.03). 
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Weight depends on whether individuals hate or like soccer, after controlling 
height, age, and wage (p=0.05). 
Neither age nor wage depends on whether individuals hate or like soccer after 
controlling the other measures (p= 0.61 and p=0.64). 
These p values, however, do not indicate which group generated greater 
height and weight.   
The column labeled Beta (B) can be utilized to determine the direction of any 
significant effects.  In this instance, the Beta value associated with height is 
negative.  This negative value indicates that height is inversely correlated with 
the grouping variable.  Recall that 0 reflects hating soccer and 1 reflects liking 
soccer.  Accordingly, the negative Beta value indicates that individuals who 
are taller are more likely to hate soccer.  
In contrast, the Beta value associated with weight is positive.  This positive 
Beta value suggests that individuals who are heavier are more likely to like 
soccer. 
The Beta values can also be utilized to predict the group to which individuals 
belong from their measures alone.  That is, in this example, whether 
individuals hate or like soccer can be predicted from their height, weight, age, 
and wage.  To predict group membership, the Beta values can be substituted 
into the following formula: 
Probability the individual is in group 1 = e(Constant + B1 x Var1 + B2 x Var2...)/( 1 - 
e(Constant + B1 x Var1 + B2 x Var2...) ) 
This formula may appear to be complex, but is actually reasonably 
straightforward to use.  Specifically, e refers to the base of natural logarithms 
and approximates 2.7.  'Constant' denotes the Beta value in the row labeled 
'Constant' and represents the intercept of the fitted hyper plane.   'B1' refers to 
the beta value associated with the first measure, and so forth.  Hence, when 
the Beta values that were derived earlier are substituted into this equation, the 
following formula emerges: 
Probability the individual is in group 1 = e(2.12-0.47 x Height + 0.37 x Weight + 0.16 x Age + 
0.11 x Wage) divided by (1 - e(2.12-0.47 x Height + 0.37 x Weight + 0.16 x Age + 0.11 x Wage)  ) 
To illustrate this formula, consider an individual who is 173 cm tall, 78 kg in 
weight, 37 years old, and earns € 76,000.  These values can be entered into 
the equation.  Suppose this equation yields an answer of 0.78.  This finding 
indicates that such an individual is more likely to pertain to group 1, who likes 
soccer.  Specifically, the probability this individual likes soccer rather than 
hate it is 0.78. 
The Beta values also provide some insight into the extent to which the 
measures differentiate the groups.  Specifically, the column labeled ‘Exp (B)' 
equals e (i.e. 2.7) to the power of each Beta value.  These values give some 
insight into the magnitude of each effect.  The column ‘Exp (B)' presents the 
extent to which the corresponding measure influences this odds ratio.  In 
particular, this value represents the extent to which raising the corresponding 
measure by one unit influences the odds ratio.  For example, the Exp (B) 
 - 30 -
value associated with Weight is 1.44.  Hence, when weight is raised by one 
unit, the odds ratio is 1.44 times as large. Specifically, when weight is raised 
by one kilogram, individuals become 1.44 more times as likely to like soccer.   
Examples of logistic regression models in prostate cancer research are the 
Partin tables [90]. The Partin tables were developed to predict pathologic 
stage in men undergoing radical prostatectomy for clinically localized cancer. 
Other models have been developed to predict outcomes such as disease 
recurrence and prostate cancer survival [91,92]. The logistic regression 
analysis is widely used and is available in most statistical packages.  
Another, newer and more complicated way to retrieve a model which can be 
used to estimate the probability that an individual belongs to group 1 or group 
0, is an artificial neural network (ANN). ANNs represent a relatively new 
methodology for predictive modeling in medicine. ANNs are computer 
software constructs based on concepts in neural anatomy and physiology 
designed to mimic the way the brain learns.  In contrast with traditional 
statistical techniques, ANNs are capable of automatically resolving 
relationships between variables without the need for a priori assumptions 
about the nature of the interactions. Although promising, ANNs have inherent 
limitations and are not free of controversy in medical applications [93,94,95]. 
The primary disadvantage of an ANN is its “black box” quality, that is, without 
extra effort, it is difficult if not impossible to gain insight into a problem based 
on an ANN model. Regression techniques allow the user to sequentially 
eliminate possible independent variables that do not contribute to the fit of the 
model and thus allow hypothesis testing regarding both the univariate and 
multivariate association between each independent variable and the outcome 
of interest. These features are not as standards available for ANN. Additional 
drawbacks of ANN included the computational resources required and the 
lack of standard software. Many authors have analyzed the same data set by 
using both approaches, with the outcomes of these comparisons varying as 
much as the data sets them selves. A review of 28 studies concluded that 
ANN should not replace a standard statistical approach. Both methods should 
be continued to be used and explored [96].   
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Abstract: 
 
OBJECTIVE 
To describe the preliminary results of the Dutch section of a large multicentre 
study of screening for prostate cancer, the European Randomized study of 
Screening for Prostate Cancer (ERSPC), initiated in the Netherlands and 
Belgium in 1991. 
MATERIALS AND METHODS 
After a series of five pilot studies which started in 1991, full-capacity screening 
started in 1994 with the use of a serum prostate-specific antigen (PSA) 
determination, a digital rectal examination (DRE) and transrectal 
ultrasonography (TRUS) as screening tests. Depending on the results and the 
screening protocol used, men were referred for further examination by sextant 
biopsies (extended with a seventh biopsy if TRUS showed abnormality). The 
protocols used, efficiency of the different screening tests, number of cancers 
detected in the pilot studies, initial screening round and preliminary results of 
the second screening round are described. 
RESULTS 
After the pilot studies it became clear that a study of prostate cancer 
screening was feasible in the Rotterdam area. The screening protocol was 
workable and the recruitment rate acceptable (39.5%). An inventory of the 
population registries of Rotterdam and surrounding municipalities, and the 
known recruitment rate, made it clear that a contribution of 40 000 men (aged 
55–74 years) from the Dutch centre to the ERSPC was feasible. The initial 
screening round started in December 1993 and lasted until December 1999 
(protocol 5–10). In all, 42 376 men were randomized and 1014 cancers 
detected (5.1%). During this screening the protocol was simplified. After 
evaluating the different screening tests abnormal results of the DRE and 
TRUS were omitted as an indication for a sextant biopsy. Only a serum PSA 
level of ≥ 3.0 ng/mL is now used as the indication. The second screening 
round started in December 1997 and continues. To December 2002, 9920 
men were screened for the second time, 4 years after their initial screening 
visit. To date 446 cancers have been detected (4.5%); this round will last to 
December 2003. Further evaluation of the screening regimen and 
characteristics of the cancers detected are constantly assessed within the 
Dutch ERSPC. Meanwhile a third screening round has also been initiated, 
which will last to December 2007. 
CONCLUSION 
A prostate cancer screening study of the projected magnitude is feasible in 
Rotterdam; the recruitment rate is acceptable and the screening tests well 
tolerated. The study has generated many scientific publications and will be of 
great value in determining whether prostate cancer screening should be part 
of general healthcare. 
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Introduction: 
 
 
In the 1980’s carcinoma of the prostate was (and still is) the second leading 
cause of cancer deaths among men in the European community [1]. From 
1979 to 1988 the number of deaths due to prostate cancer in The Netherlands 
had increased by 2% annually over the past 10 years [2]. During the same 
period the identification of prostate specific antigen (PSA) had increased the 
number of methods available (adding toDRE and TRUS) for the early 
detection of prostate cancer [3,4]. With the increasing incidence and mortality 
on one hand, and the availability of several very promising detection 
techniques on the other hand, the question arose whether early detection or 
screening for prostate cancer would be feasible and effective in reducing 
prostate cancer mortality. That a cancer can be detected earlier in its natural 
history is no guarantee that benefits will follow. Numerous studies (case-
finding, retrospective and prospective) were already undertaken to determine 
the efficacy of cancer screening. However there are three important biases 
(Lead-time, length- and selection) pertinent to many of these studies, causing 
serious problems with interpreting the study results. The most elegant way to 
account for these biases is a randomized controlled trial with cancer specific 
mortality as the main endpoint [5].  
 
In 1990 Schröder et al. [6,7] started to pursue the idea of a randomized study 
of screening for prostate cancer. From the start it was clear that it would be 
impossible to conduct such a costly trial in one European country; 
international cooperation was necessary.  Based on institutional investments 
and a grant by the European Community program “Europe against Cancer” it 
was possible to initiate randomized pilot studies in Belgium (Antwerp, 1992-
1993) and the Netherlands (Rotterdam, 1991-1994) [8]. At the same time the 
contours of the European Randomized study of Screening for Prostate Cancer 
(ERSPC) emerged [6,9]. 
 
 
Material and Methods. 
 
ERSPC Rotterdam started with a series of 5 pilot studies in October 1991 
which served to obtain an impression of the logistics involved in setting up a 
screening study of the projected magnitude. Full capacity screening started in 
June 1994.  
Apart from the main endpoint (prostate cancer mortality) the Dutch centre also 
assessed the efficiency of the different screening tests, pathological features 
of the cancers detected, treatments applied and quality-of-life related issues. 
With the use of MISCAN computer program the screening process is being 
modelled.  
The first part of this paper describes the results of the pilot studies and the 
initial screening round of the Dutch center located in Rotterdam.  
The second part describes the preliminary results of the ongoing second 
screening round 4 years after the initial screening, a screening interval that 
was chosen on the basis of the ratio between prevalence in the first pilot 
screening and the incidence in the general population [8]. 
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1. The pilot studies (1991-1993). 
 
Men aged 55-74 years of age, selected from the population registry of 
Rotterdam were invited for screening. The only exclusion criterion was a 
previous diagnosis of prostate cancer. Men who responded by returning the 
intake questionnaire and who provided a signed informed consent were 
randomized and notified of the outcome. The screening protocol consisted of 
three tests, i.e. serum PSA determination,  a DRE and TRUS. The findings of 
these three tests resulted in a re-screening visit after 1 or 4 years, or a sextant 
biopsy, depending on the used protocol. Men with a benign biopsy result were 
re-invited after 1 year. 
During the first four pilot studies the logistical and screening procedures were 
tested and optimized to a workable and acceptable protocol, which was finally 
tested in the fifth pilot study.  
The characteristics of all protocols used are shown in Table I. The first 
protocol started in October 1991. A total of 1186 men were randomized in a 
period of 15 months. The most important characteristic in this first pilot study 
was the randomization after PSA testing. No further screening tests were 
done if the serum PSA level was >= 10.0 ng/ml; these men were directly 
referred to their GP. The protocol changed in January 1993; men were 
randomized before PSA testing, meaning that only men randomized to the 
screening arm were PSA tested. Protocol 2 was used until March 1993 (256 
men).  
 
In March 1993 the screening procedure after blood sampling was changed. If 
possible the biopsy was performed directly after the DRE and TRUS. Protocol 
3 lasted until May 1993 (297 men). Protocols 4 and 5 had some minor 
changes in logistic procedures and the indication for sextant biopsy was 
simplified and became partly PSA driven (Table I). 
 
The mean recruitment rate (Table I) over the five pilot studies was 39.5%. 
Recruitment procedures proved to be relevant for establishing higher 
participation rates. Eliminating the need for the control group to visit the study 
centre introduced with protocol 2 led to an increase of the recruitment rates 
(Table I). The screening tests were well accepted and tolerated [10].  
 
As noted, PSA driven biopsies were not taken in pilot study 1 and were rare in 
pilot study 2 and 3 (biopsy was indicated at a PSA of >= 20.0 ng/ml). This 
resulted in a detection rate of app. 9% in men with a PSA of 4.0 – 10.0 ng/ml. 
In pilot study 4 and 5 (biopsy indicated if PSA was >= 4.0 ng/ml, irrespective 
of DRE and TRUS results) the detection rate increased to 24%. This finding 
was one reason to decide on a PSA-driven screening protocol, i.e. a PSA 
threshold of >= 4.0 ng/ml, in the future. Furthermore the rate of false positive 
findings (i.e. unnecessary sextant biopsies) was extremely high in protocols 5 
and 6 (76 biopsies to detect two cancers) in men with PSA levels of < 2.0 
ng/ml. Further analysis showed that the proportion of false-positive TRUS 
(24%) was about twice that of false-positive DRE (13%) in men with PSA 
levels of < 4.0 ng/ml. If both tests had been omitted in the group of men with a 
PSA of < 2.0 ng/ml, 69.3% of the study population, only two prostate cancers 
would have been missed. These findings showed that the role of the three 
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available tests in prostate cancer screening was still to be determined for their 
predictive value and, obviously also with respect to the final study outcome, 
preventing death from prostate cancer [8].   
 
 
 
 
Protocol 
number 
Period Recruit- 
ment rate 
(%) 
Men 
(n) 
Biopsy indication used 
1 10/’91 - 
01/’93 
35.6 1186 DRE and/or TRUS abnormal with lesion >= 8 mm. 
PSA done in all men. 
2 01/’93 - 
03/’93 
36.5 256 DRE and/or TRUS abnormal with lesion >= 8 mm or 
PSA >= 20.0 ng/ml. 
3 03/’93 - 
05/’93 
42.4 297 DRE and/or TRUS abnormal with lesion >= 8 mm or 
PSA >= 20.0 ng/ml. 
4 05/’93 - 
11/’93 
42.4 679 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
     
5 12/’93 - 
05/’94 
40.6 450 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
6 06/’94 - 
11/’95 
43.4 8642 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
7 11/’95 - 
01/’96 
03/’96 - 
10/’96  
53.9 4147 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
No screening if PSA < 1.0 ng/ml. 
8 01/’96 - 
03/’96 
52.8 1404 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
No screening if PSA < 1.0 ng/ml. 
9 10/’96 - 
04/’97 
50.7 6000 DRE and/or TRUS abnormal or PSA >= 4.0 ng/ml. 
No screening if PSA < 1.0 ng/ml. 
     
10 05/’97 - 
12/’99 
48.0 21733 PSA >= 3.0 ng/ml. No screening if PSA < 3.0 ng/ml. 
     
Total Protocol 
5-10 
 42376  
 
Table I: Characteristics of the screening protocols 1 – 10. 
 
 
 
Evaluating all procedures related to recruitment of participants, to applying the 
screening tests and to data collection during the pilot studies resulted in an 
infrastructure as shown in fig 1. (section A).  
An inventory of the population registries of Rotterdam and surrounding 
municipalities and a known recruitment rate of app. 40% made it clear that a 
contribution of 40,000 men (aged 55-74 years), from the Dutch centre to 
ERSPC, was feasible. 
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Fig. 1. The ERSPC, section Rotterdam. Infrastructure of the screening process. 
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2. The initial screening round (1994 – 2000). 
 
 
In June 1994 protocol 6 started (Table I). This protocol was used until 
November 1995 and consisted of 8642 men. During this period again the 
value of PSA, DRE and TRUS was assessed to identify possible 
improvements in the accuracy of the screening procedures. Bangma et al 
[11,12] studied the use of the ratio between free and total PSA (F/T ratio), age 
specific reference ranges and PSA density and the possibility to improve the 
specificity of total PSA, DRE and TRUS in prostate cancer screening. These 
studies resulted in positive findings for all three items. Using of these 
detection techniques could reduce the number of biopsies with app. 35%, with 
a reduction in cancer detection of 11%. The most cost-effective screening 
protocol was pre-screening with total serum PSA and exclusion of DRE and 
TRUS at PSA values of  <= 2.0 ng/ml. 
 
Rietbergen et al [13] also found that total PSA was the most powerful tool for 
predicting biopsy outcome in a group of 3963 men (981 sextant biopsies taken 
and 172 cancers found). In that study it became clear that most cancers were 
found within the PSA range of >= 4.0 ng/ml and that within this PSA range 3.6 
biopsies had to be taken to detect one case of prostate cancer. At PSA levels 
of < 4.0 ng/ml 14.2 biopsies were necessary to find one cancer. In the PSA 
range 0.0 – 1.0 ng/ml, 43 sextant biopsies were taken to detect one case of 
prostate cancer. Furthermore it became clear that the cancers that were found 
through a positive DRE or TRUS findings alone (at PSA levels of < 4.0 ng/ml) 
only amounted to respectively 8.1% and 7% of the cancers detected. If PSA 
had not been used as a screening test, DRE would have detected 47.1% and 
TRUS 45.3% of all cancers. Calculations on the use of a PSA threshold value 
to avoid unnecessary prostate biopsies resulted in an optimal PSA threshold 
value of 1.7 ng/ml. When using this value 33.9% of the biopsies would have 
been avoided at the expense of 5.3% of the prostate cancer detected. As 
there were relatively few cancers detected at PSA levels of < 4.0 ng/ml, on 
which these calculations were based, it was decided to change the protocol to 
a pre-screen PSA threshold of 1.0 ng/ml, meaning that men with a PSA level 
of < 1.0 ng/ml were not screened further and directly scheduled for their next 
screening visit after 4 years. 
 
Another reason for changing the protocol was related to the fact that men 
invited for ERSPC at that time lived in surrounding municipalities. To maintain 
a good recruitment rate it was necessary to reduce the number of visits to the 
University Hospital. Therefore it was decided that blood samples should be 
taken in the municipality and, if necessary, subsequent screening tests (DRE, 
TRUS and sextant biopsy) were to be performed at the University Hospital in 
Rotterdam. Doing so, only app. 20% of the participants had to travel to the 
University Hospital. Protocol 7- 9 were conducted accordingly, with some 
minor changes in the logistic procedures after PSA testing. Protocol 7- 9 were 
used from November 1995 until April 1997 (a total of 11,551 men). This 
change in the screening procedure resulted in a considerable increase of the 
recruitment rate (Table I). 
 
During protocol 6 - 8 a study was done to evaluate the value of a 1-year re-
screening after a benign biopsy result. Rietbergen et al. [14] found that biopsy 
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at repeat screening diagnosed prostate cancer in 11% of the men biopsied 
(442 men biopsied, 49 cancers detected). Of the 984 men who were eligible 
for repeat screening after one year only 442 men were actually biopsied. A 
large proportion of the men (42.2%) had PSA levels of < 4.0 ng/ml and 
abnormalities found at initial screening could not be reproduced, or serum 
PSA was below the cut-off value of 1.0 ng/ml.  Furthermore, the clinical 
characteristics of the tumors detected after repeat screening were more 
favourable, with an increased proportion of stage T1C tumours, than those 
detected at initial screening. 
In October 1996, having available more results of a re-screening after 1 year, 
it was decided to stop the re-screening procedure after 1 year. With the start 
of Protocol 9 this change was implemented. (Table I). Men with a benign 
biopsy result were re-invited after 4 years. 
Since deciding to take a sextant biopsy in participants with PSA values of <= 
4.0 ng/ml  (from pilot 4), the DRE was the mainstay of early diagnosis at lower 
PSA ranges.  
As noted [13], the DRE as a screening test at low PSA levels ( i.e. PSA <= 4.0 
ng/ml) performed very poor (only 8.7% of all cancers detected were detected 
by DRE), so a further evaluation was indicated.  
Schröder et al. [15] studied the value of DRE as a screening tool at low PSA 
ranges in a screening population consisting of 10,523 men. The data 
confirmed that DRE has a low predictive value in men with low PSA levels. 
When PSA levels were < 3.0 ng/ml, 11 biopsies were necessary to detect one 
cancer. Beemsterboer et al. [16] used a logistic regression model in order to 
predict the number of cancers for PSA of <= 4.0 ng/ml if all men were biopsied 
(so called Predictive Index) [17]. The effects of a change in PSA threshold on 
the outcomes of screening were explored in a group of 8600 men. Applying a 
DRE and TRUS only in the PSA-range 1.5 – 3.9 ng/ml and 2.0 – 3.9 ng/ml to 
indicate that a biopsy was required, would result in a decrease of biopsies by 
29% - 36%, respectively, and a decrease in cancers detected of 5% - 8% 
respectively.  In addition DRE and TRUS are difficult to reproduce because 
they are  investigator-dependent. A protocol with only PSA of >= 3.0 ng/ml as 
a direct biopsy indication resulted in a decrease of biopsies by 12% and a 
decrease of detected cancers by 7.6% and above all a much more simple 
screening procedure.  
 
A protocol change which permits to miss otherwise detectable tumors, could 
in theory result in missing those cancers with the largest potential to contribute 
to the reduction in disease specific-mortality. In a study by Hoedemaeker et al. 
[18] the group of tumors detected by DRE and/or TRUS below a PSA level of 
4.0 ng/ml was examined. This group had low pathological stages with a 
considerable fraction (43%) meeting the criteria for a ‘minimal tumor’ (one < 
0.5 ml, lacking Gleason pattern 4 or 5 and being confined to the prostate); 
86% had a tumour volume of < 0.5 ml. Men with low PSA levels are therefore 
most likely to harbor clinically insignificant tumors. These findings were 
confirmed by Vis et al [19], who also showed that the DRE as screening test 
at low PSA values (i.e. <= 3.0 ng/ml) was inefficient; 289 DREs were needed 
to find one case of clinically significant disease and 96 DREs were needed to 
diagnose a prostate cancer of any size, grade or stage. These data indicated 
that a change in protocol where DRE and TRUS are omitted in lower PSA-
ranges was likely not to result in significant loss in potential mortality reduction, 
providing that re-screening was used after an adequate interval. In addition, 
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the sextant biopsy procedure is bothersome and not without danger for the 
participants. On the basis of the data noted a final protocol change took place 
in May 1997 (protocol 10, table I). From this point all men with PSA of < 3.0 
ng/ml were not screened further and men with PSA of >= 3.0 ng/ml were 
invited for further examination (DRE, TRUS and sextant biopsies, fig 1, 
section B).  
During the period of screening according to protocol 10 (table I) there was a 
validation study of the effects of the change in protocol [20]. In this study the 
cancer detection rates and tumor characteristics of the cancers detected in 
the “old protocols”, (protocol 6 – 9), and the “new protocol (protocol 10)” were 
compared. The cancer detection rates were similar in the two screening 
regimens, because there were many more prostate cancer cases per biopsy 
in the PSA range 3.0 – 3.9 ng/ml in protocol 10. The positive predictive value 
of the PSA range 3.0 – 3.9 ng/ml was 6.4% in the “old protocols” and 18.0% in 
the “new protocol”. 
Prostate cancers detected with the new screening regimen had a similar 
distribution of Gleason scores but a larger proportion of confined disease. 
Final conclusion of this validation study was that the overall characteristics of 
the cases detected at PSA threshold of 3.0 ng/ml differed very little from those 
detected with the regimen based on PSA, DRE and TRUS.  
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Fig. 2:  Results of the initial screening round ERSPC, Rotterdam section, from 
November 1993 (pilot 5) through December 1999 (protocol 10). Numbers are 
not definite. 
 
 
Recruitment and randomization lasted until December 1999. Fig 2 shows the 
final data (number randomized, actually screened, biopsied and cancers 
detected) of protocols 5 – 10. These data became part of the central data set 
administered at the central database of ERSPC in Edinburgh (from July 2003, 
London). 
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3. The second screening round. 
 
 
For the second screening round we address three important questions: what 
will be the compliance and the detection rate at the subsequent screening 
round and what has happened during the chosen 4-year interval with regard 
to interval cancers? 
In December 1997 the second screening round started (according to protocol 
10) for men initially screened in protocol 5 – 10. Until December 2002, 14695 
men were eligible for a second screening visit. Men who had reached the age 
of 75 years or died within the 4-year interval (2455men, 16.7 %) were not 
invited for re-screening. This resulted in 12240 men who were actually invited. 
9920 responded to the invitation and were invited for blood sampling. The 
response in the second screening round so far is thus high, at 81.0 %. 
The main reasons for non-response were bad health (5.4%), moving out of 
the region (5.8 %) and unknown in 7.8 % of the men invited. Figure 3 shows 
preliminary results (number of men screened, number of men biopsied and 
cancers detected) in the second screening round. 
 
Through linkage with the Cancer Registry (fig 1) and active medical record 
follow-up the Dutch centre is also able to assess the number and 
characteristics of the clinically diagnosed cancers found elsewhere in the 
population randomized.  
The number of these “interval cancers” gives an indication on the 
effectiveness of the screening tests used and of the correctness of the chosen 
screening interval. At present the definitions of interval cancers are being 
established and data on interval cases obtained through linkage with the 
Cancer Registry are being evaluated. Although data on the complete 4-year 
interval were not yet available the available data show a very low number of 
interval cancers [21].  
 
Through linkage, not only the number interval cancers can be assessed, but 
also the number of clinically detected cancers in the control arm during the 
screening period. Comparing the tumor characteristics of screen-detected and 
a clinically detected cancer is an important intermediate endpoint of the 
ERSPC. Results show a favorable prognostic shift for the screen-detected 
cancers [22]. 
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Fig. 3: Preliminary results of the second screening round ERSPC, Rotterdam 
section, from November 1997 through December 2002. Numbers are not 
definite. 
 
 
Using a second screening round also enables the validation of more 
predictors of biopsy outcome, e.g. PSA velocity, defined as the difference 
between the PSA value at initial screening and the PSA value at subsequent 
screening divided by the number of interval years, and new serum markers 
such as pro-PSA and hK2. Data from the initial screening round already 
showed that a considerable proportion of the cancers that can be detected by 
screening are in men with low PSA levels [23] and that a part of these cancers 
have potentially aggressive characteristics, are organ confined, and thus 
suitable for treatment. As mentioned above DRE and TRUS were not very 
efficient as screening tools in these low PSA ranges. In order to investigate 
the possibilities for effective screening at low PSA ranges, two side studies 
were initiated during the second screening round. 
 
The first side study (fig 3, side study 1) ordered after review of our protocol by 
one of the review committees, was set up in order to evaluate the value of 
PSA velocity as a predictor for biopsy outcome at low PSA levels. During the 
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period December 1997 and April 2001 men with a PSA level of 1.0 - 3.0 ng/ml 
and a doubling of their PSA level within the 4-year interval were also biopsied. 
In this side study 214 men were biopsied and 34 cancers were detected. The 
final evaluation of this study is in detail in chapter 5 [24].  
 
The second side study (fig 3, side study 2) focused on the value of free-PSA 
and hK2 as predictor of biopsy outcome at low PSA levels (2.0 – 4.0 ng/ml). 
However, a more important goal of this study is however not only to establish 
their value as predictor for biopsy outcome but also their value as predictors of 
the aggressiveness of screen detected-tumours. This side- study lasted from 
April 2001 until October 2002. In the PSA range 2.0 – 4.0 ng/ml 734, men 
were biopsied and serum free-PSA and hK2 were determined. Together with 
the data of the radical prostatectomy specimen of the cancers detected the 
value of free-PSA and hK2 as screening tests was determined [25]. 
 
Another point of interest at a subsequent screening round are those men with 
a negative biopsy result at initial screening and a biopsy indication, based on 
an elevated PSA level, at the second screening round. As the PSA level is 
also strongly related with BPH, it is possible that men with persistently 
elevated PSA levels will be biopsied at every screening round. The cancer 
detection rate, PPV and tumor characteristics of cancers detected in men with 
elevated PSA levels biopsied at the second screening round were assessed 
with a further evaluation of predictors for biopsy outcome in this particular 
group of men, chapter 7 [26]. 
  
The second screening round will last to December 2003. Further evaluation of 
the screening regimen and characteristics of the cancers detected are the 
subjects of constant attention within the Dutch center of ERSPC.  In the mean 
time a third screening round is also initiated which will last to December 2007. 
 
Conclusion. 
 
Setting up a prostate cancer screening study of the projected magnitude is 
feasible in Rotterdam. International cooperation was established and a central 
database containing all data of ERSPC set up. The recruitment rate is 
acceptable and the screening tests used well tolerated. Data of this study 
have so far led to at least 93 scientific publications from the Dutch center and 
app. 175 scientific publications from all ERSPC centers together. This study 
will certainly be of great value in determining whether prostate cancer 
screening should be part of general health care.  
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Abstract: 
 
Objectives.  
The evaluation of the screening procedures for prostate cancer (Pca) was a 
part of the protocol of the European Randomized Study of Screening for 
Prostate Cancer (ERSPC), section Rotterdam, The Netherlands. We sought 
to establish an improved strategy for the early detection of Pca using a 
prostate specific antigen (PSA) cut off of 3.0 ng/mL or greater as the only 
indication for prostate biopsy with omission of the digital rectal examination 
(DRE). 
Methods.  
In June 1996, 8612 men, 55 to 74 years old, were randomized to screening 
and were screened within the ERSPC Rotterdam by a PSA level of 4.0 ng/mL 
or greater or positive DRE or transrectal ultrasound findings as the indication 
for biopsy. Four hundred thirty men had Pca. Those treated by radical 
prostatectomy provided the tumor characteristics considered essential for a 
change in the screening strategies. Various options were evaluated and 
predictions made by logistic regression analyses. The protocol change was 
implemented in May 1997. Another 7943 men were screened according to the 
new protocol (PSA 3.0 ng/mL or greater). The resulting data were used to 
compare the two protocols. 
Results.  
The detection rate (proportion of Pca in those screened) turned out to be very 
similar, with rates of 5.0 and 4.7 at a PSA cut off of 4.0 ng/mL or greater and 
3.0 ng/mL or greater, respectively. This was due to a much larger number of 
cases of Pca per biopsy in the PSA range of 3.0 to 3.9 ng/mL than expected. 
The positive predictive value of the PSA range 3.0 to 3.9 ng/mL in the two 
protocols was 6.4 % and 18.0%, respectively. Tumor characteristics were 
studied on radical prostatectomy specimens from the original protocol. Pca 
detected with the new screening regimen had a similar distribution of Gleason 
scores but a larger proportion of confined disease. Tumor volumes were 
smaller in patients with PSA levels of less than 2.9 ng/mL; the proportion of 
“minimal disease” in that group was 50% compared with 28% in the group 
with a PSA level between 3.0 and 3.9 ng/mL. 
Conclusions.  
Lowering the biopsy indication to a PSA cut off of 3.0 ng/mL or greater without 
a DRE improved the positive predictive value from 18.2% to 24.3%. The 
number of biopsies necessary to detect 1 case of Pca accordingly changed 
from 5.2 to 3.4. The overall characteristics of the cases detected at that PSA 
cut off differed very little from those detected with the regimen based on PSA, 
DRE, and transrectal ultrasound.  
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Introduction. 
 
 
 
Screening for prostate cancer (Pca) is controversial at this time because it has 
not been shown to decrease Pca mortality. Regimens for early detection have 
been widely applied in large studies, such as the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) and in screening on request 
(opportunistic screening). 
Optimization of the screening tests is warranted. More definite screening 
regimens for Pca can only be identified after completion of randomized 
studies as the algorithm that maximizes potential advantages in Pca mortality 
or overall survival. Unfortunately, such data are not yet known. However, the 
application of screening regimens within large scale studies and with 
screening by request in urologic practices warrants a preliminary optimization 
of the available strategies. Within the ERSPC, section Rotterdam, we 
evaluated the PSA cut off level of 4.0 ng/mL or greater and positive digital 
rectal examination (DRE) and/or transrectal ultrasound (TRUS) findings as an 
indication for biopsy according to protocol since June 1, 1994. The first 
evaluation showed that 4 of 5 men underwent an unnecessary biopsy. This 
rate was in part due to the very low positive predictive value (PPV) of only 2% 
in the PSA range 0 to 0.9 ng/mL and led to a change in the protocol in 1996, 
the details of which were reported by Beemsterboer et al.[1] Modification of 
the screening procedure according to PSA level had already been suggested 
in 1992 by Labrie et al. [2] to maximize the relative sensitivity and specificity of 
the screening procedure. Within the European study, the Swedish group has 
used a PSA cutoff of greater than 3.0 ng/mL as the only screening parameter 
since December 1994.[3] The European study group did not accept this 
procedure as general policy because the impact on the detection rates, PPV, 
and tumor characteristics was not known at that time; however, they have 
recently been described for data resulting from the ERSPC. [4,5] The 
parameters of aggressiveness, especially tumor volume, and the proportion of 
potentially non-aggressive (minimal) disease correlated with the PSA values. 
A major change in the screening regimen was implemented in May 1997 on 
the basis of the results of the logistic regression estimates performed in June 
1996. [1,5] Here, we report the results of a prospective validation study of the 
effects of the change in the protocol. Important lessons for clinical routine can 
be learned with respect to the use of the DRE and the biopsy indications in 
men with low PSA values who undergo screening on request in urologic 
practice.  
 
 
Material and Methods. 
 
 
THE ERSPC 
The ERSPC is a large randomized screening study conducted in seven 
European countries (Belgium, Finland, Italy, The Netherlands, Portugal, 
Spain, and Sweden) since 1994 and has a close association with the Pca arm 
of the Prostate, Lung, Colon, and Ovary Screening Study of the National 
Cancer Institute of the United States.[6] The ERSPC aims to show or exclude 
a difference in Pca mortality between screening and control arms of 20% with 
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a power of 90%. To achieve this, 191,000 men will have to be randomized to 
screening versus control and followed up for 10 years. This sample size 
accommodates a contamination rate by opportunistic screening of 10%. By 
March 2000, more than 180,000 men had been randomized in Europe. Within 
the ERSPC, re-screening intervals of 2 and 4 years are used. A central 
database and an effective committee structure have been established. The 
ERSPC is supervised by an independent Data Monitoring Committee. The 
individual national contributions are approved by the respective ethical 
committees and national rules for population based screening studies are 
applied. Other recent reports related to the ERSPC give more details on the 
method and background. [4-9] 
 
 
ERSPC ROTTERDAM 
The screening procedure and the numbers of participants are detailed in 
Figure 1. Men 55 to 74 years old were identified in the population registry and 
invited to participate. After receipt of full written informed consent, the men 
were randomized to the screening group or control group. After a number of 
pilot studies,[7] the ERSPC Rotterdam started in June 1994. 
 
An evaluation of the screening tests was part of the Rotterdam protocol and, 
on the basis of the data produced and reported here, the European study 
group decided in February 1997 to screen using PSA determination only and 
to biopsy all men with PSA values of 3.0 ng/mL or greater. This group 
decision was based on the results obtained after screening 8612 men for 
whom the biopsy indication was a PSA value greater than 4.0 ng/mL and 
positive DRE and/or TRUS findings and the results of estimates based on 
logistic regression analysis of the numbers of Pca detectable in men with PSA 
values of 3.0 to 3.9 ng/mL.[1,5]  
 
All participants were screened only once and for the first time (prevalence 
screen). The evaluation also included the results of a detailed study of the 
histopathologic features determined from radical prostatectomy specimens, 
which allowed an estimate of the aggressiveness of the cases of Pca missed 
with the change of protocol and those detected with the change in the biopsy 
indication.[4] In the text and Figure 1, protocols 5 to 9 and protocol 10 are 
referred to as “PSA 4.0 ng/mL or greater” and “PSA 3.0 ng/mL or greater” or 
the “old” and “new” protocols, respectively. 
The prospective validation of the change in the biopsy indication is based on 
the population of 8726 men randomized to screening after May 1997. 
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Fig 1: Consort diagram of ERSPC Rotterdam old protocol (biopsy indication PSA 
4.0 ng/mL or greater and/or abnormal DRE and/or TRUS findings) (June 1994 
to January 1997) and the new protocol (biopsy indication PSA 3.0 ng/mL or 
greater) (May 1997 to May 1999). 
 
The numbers and proportions of biopsy indications, biopsies performed, and 
Pca cases found overall, as well as in the relevant PSA  ranges, were 
compared between the original protocol (PSA 4.0 ng/mL or greater) and the 
new protocol (PSA-driven biopsy indication with a PSA cutoff of 3.0 ng/mL or 
greater) and the a priori prevalence assessment (APPA) estimates made in 
June 1996. Lateral sextant biopsies were carried out in diverting from the 
original recommendation of Stamey [9] and in line with the later 
recommendations of Eskew et al.[10] A seventh biopsy was taken of visible 
(hypoechogenic) lesions. Some of the data are inconsistent because of two 
factors: (a) the omission of DRE and TRUS in January 1996 in men with a 
PSA level of less than 1.0 ng/mL because an interim evaluation revealed that 
in 1702 screened men, 183 biopsies were necessary to find four 
tumors,[11,12] and (b) a delay in putting into effect the protocol change from 
June 1996 to February 1997, affecting the statistics on the characteristics, and 
small errors in group  assignment. 
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PATHOLOGIC FINDINGS 
The evaluation of the histopathologic parameters included the number of 
positive biopsies, location of the positive biopsies, proportion of individual 
cores with Pca, grade of differentiation, tumor volume determined in radical 
prostatectomy specimens, Gleason grade of the radical prostatectomy 
specimens, determination of positive margins, and other parameters 
according to a previously agreed protocol. These procedures and an arbitrary 
classification model that considers PSA, radical retropubic prostatectomy-
based Gleason score, and tumor volume to assign the categories of minimal, 
moderate, and advanced disease are described in greater detail by 
Hoedemaeker et al.[11] Tumor volume was determined in 4-mm step sections 
and by morphometry. 
 
STATISTICAL ANALYSIS 
The number of Pca cases per biopsy found in the original protocol were 
compared with the number of Pca cases per biopsy detected in the new 
protocol, in which a biopsy was indicated irrespective of the DRE and TRUS 
findings (ie, PSA 3 ng/mL or greater). The calculation of the P values was 
based on the comparison of the proportions of independent samples. Fisher’s 
exact test was used in the comparisons. The results and method of the logistic 
regression analysis are described elsewhere [5]. 
 
Results. 
 
The evaluation leading to the major protocol change of using a PSA cut off of 
3.0 ng/mL or greater as the indication for biopsy was performed on the basis 
of the results of the logistic regression estimates in June 1996. After this, the 
old protocol continued to be active until a group consensus could be reached 
in November 1996 and until the necessary administrative steps were taken to 
change the protocol and obtain approval from the ethical committees. In this 
report, the data obtained in June 1996 are presented in Table I (8612 men 
were screened and 430 Pca cases found). The data on the tumor 
characteristics (Table II) were updated to the situation in February 1997 when 
a total of 474 Pca cases had been detected in 10,450 men randomized to 
screening. Figure 1 reveals a loss of participants in the screening arms after 
randomization. In the original protocol and in the new protocol, 6.4% and 9%, 
respectively, of randomized men did not undergo screening for various 
reasons (see the following section). 
Table I presents a comparison of the results of the biopsies in the original and 
the validation sample (new protocol). In June 1996, 8612 men had been 
screened; 7.5% had a PSA level between 3 and 3.9 ng/mL and 21.1% had a 
PSA value of 3.0 ng/mL or greater. A total of 430 Pca cases were found, 
compatible with a detection rate of 5.0%. Of these, 41 were diagnosed by 
DRE and/or TRUS in the PSA range of 3 to 3.9 ng/mL (6.4% of all cases). The 
validation sample consisted of 7943 men screened between May 1997 and 
May 1999. Of these, 1552 men (19.5%) had a PSA level of 3.0 ng/mL or 
greater and should have undergone biopsy; 250 of these men (16.1%) did not 
undergo biopsy. The detection rate was 4.7%, similar to that for the original 
protocol (5.0%). The rate of Pca detection with a PSA cut off of 3.0 ng/mL or 
greater per number of indicated biopsies was 24.3% as opposed to 18.2% 
with a PSA cut off of 4.0 ng/mL or greater (old protocol) (Table I) and a 
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detection rate of 29.0% in those who in fact underwent biopsy compared with 
19.1% at a PSA cut off of 4.0 ng/mL or greater (Table I). 
 
In Table II, the characteristics of the 166 cases of Pca detected by biopsy in 
men with a PSA value of 4.0 ng/mL or greater or positive DRE and/or TRUS 
findings are described. The cases of Pca with a PSA between 3.0 and 3.9 
ng/mL were detected by DRE and TRUS. In the original screening protocol, 
the rate was only 9.2% of all Pca cases; in the new protocol, to date 25.5% of 
all Pca cases detected were found in this PSA range.  
 
 
 
Numbers in parentheses are the 95% confidence intervals. 
*Fishers exact test 
† By extrapolation from 183 men who underwent biopsy with a PSA level of 0.0 – 0.9 ng/ml, to 3045 men in the 
same PSA range without DRE/TRUS, 5 cases of Pca and 327 biopsies were added. 
 
Table I:   Biopsy indications and cancer detection with PSA, DRE, and TRUS (n= 
8612) vs. PSA-driven screening (biopsy with PSA >3.0 ng/mL) without DRE 
or TRUS (n = 7943) 
 
 
The PPVs of the DRE and TRUS findings are about equal.[4] The histologic 
features of the radical prostatectomy specimens from the new protocol will be 
reported elsewhere. 
In both protocols, the proportion of Stage cT2 or lower tumors was rather 
similar at approximately 80%. The proportion of moderately differentiated Pca 
did not vary very much between the different PSA ranges but was lower for a 
PSA level less than 3.0 ng/ml. 
Poorly differentiated disease with Gleason score 8–10 only occurred in men 
with PSA values greater than 4.0 ng/mL. The tumor volumes were low and the 
proportion of minimal disease was high in those cases of Pca detected at a 
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low PSA. Relatively large proportions of advanced disease were present in all 
subgroups. With PSA-based screening and a biopsy cut off of 3.0 ng/mL or 
greater, 13% minimal disease and 28% of cases beyond the reach of cure 
were seen (on the basis of DRE/TRUS-detected tumors and their 
characteristics).  
 
 
 
  Numbers in parentheses are percentages 
 
Table II: Characterization of 166 cases detected by biopsy in men with >4.0 ng/mL 
PSA or positive DRE and/or TRUS (June 1994 to January 1997) treated by 
radical prostatectomy 
 
 
In Table III, the proportion of biopsy indications, biopsies done, and cases 
found within the two different protocols are directly compared. It is evident that 
with the new protocol (PSA of 3.0 ng/mL or greater), more men failed to 
undergo biopsy than in the old one, which included the DRE and TRUS 
findings. Overall, 16.1% of men in the new protocol failed to accept the biopsy 
recommendation. The failure to undergo biopsy was about equally distributed 
among the PSA ranges indicated in Table III. The percentage of Pca detected 
in men with PSA values greater than 4 ng/mL in relation to the number of men 
screened (detection rate) was about equal in both protocols (27.7% versus 
27.6%). This comparison obviously could not take into account the 250 men 
who failed to undergo biopsy in the new protocol when a biopsy was 
indicated. Their inclusion would increase the detection rate further to about 
32%.  
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Numbers in parentheses are percentages. 
* See table 1 for explination 
‡ Extra polated from 244 biopsy indications in 1702 men. 
† Extra polated from 180 biopsies in 1702 men with 4 cases of PCh, resulting in 376 biopsies and 9 
cases of Pca 
 
Table III: Biopsies and Pca detection per PSA range in the original protocol and new 
protocol. 
 
Discussion. 
In several ways, it was premature to write this report. A conclusive evaluation 
of the value of the screening tests for Pca will only be possible after the 
conclusion of randomized screening studies in which a difference in Pca 
mortality is shown. Meanwhile, the problem remains that the sensitivity of the 
tests cannot be calculated because the underlying prevalence remains 
unknown and a proper definition is missing. Eventually, the screening 
procedure will have to be adjusted to the appropriate “window of opportunity,” 
the type of cancer that can be associated with an effect on Pca mortality. This 
will lead to identification and eventually to a reduction of what might be called 
“overdiagnosis” in terms of identifying Pca that for whatever reason does not 
pose a threat to the life of the patient and avoiding treatment or, preferably, 
diagnosis. Still, since screening algorithms are used in opportunistic screening 
that occurs on a large scale in current clinical practice and in large case-
finding and randomized screening studies, it is appropriate to use current 
knowledge, especially with respect to the prognostic factors, to streamline the 
screening procedure in such a way that unnecessary biopsies and 
unnecessary treatment are avoided through the screening procedure itself. 
 
Prediction by a priori prevalence assessment 
Logistic regression analysis was used to predict the number of tumors that 
would have been found if every participant in each of the PSA ranges had 
undergone biopsy. The methodologic details and results of this exercise have 
been described elsewhere. [1,5] 
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This resulted in the estimate of what might be called “study sensitivity,” the 
proportion of Pca per total number of participants that would have been found 
if every participant had undergone a sextant biopsy. 
This would have resulted in a detection rate of 7.2% in the original as opposed 
to the empirically found 4.9%, indicating that, overall, 31% of Pca was missed 
by the current procedures. This figure was found to amount to more than 60% 
in men presenting with PSA values of 0 to 4.0 ng/mL.[5,7] The results were 
used to change the screening procedure within the ERSPC after a 
comparative evaluation was performed together with the Swedish study group 
who  performed biopsies without prior knowledge of the tumor characteristics 
in every man presenting with a PSA level greater than 3.0 ng/mL. The results 
were confirmatory [5]. 
 
Validation 
In the present report, a prospective validation of screening with PSA only 
(biopsy with PSA of 3.0 ng/mL or greater) without DRE (new protocol) was 
carried out by using a sample of 7943 screened men in whom 1302 biopsies 
detected 377 tumors. The relevant data with respect to biopsy indications, 
biopsies performed, Pca found, and derived parameters are given in Tables I 
and III. The validation study found similar detection rates and a more 
favorable PPV for screening with PSA alone at a cut off value of 3.0 ng/mL or 
greater. It is obvious from Table I that avoidance of DRE and TRUS in 78.9% 
of participants can be considered a great potential advantage of the new 
protocol in terms of cost and invasiveness. It turned out, however, that in the 
validation study of the 1552 men with a PSA value of 3.0 ng/mL or greater and 
thus a biopsy indication, only 1302 men underwent biopsy. The proportion of 
men not undergoing a biopsy for various reasons in the old protocol was only 
10.7% compared with 16.1% in the new protocol (Table III). The reasons 
include a delay in biopsy processing in the new protocol before the cutoff date 
of this evaluation. However, other factors such as direct contact with a 
urologist at the time of the DRE may play a role, which did not occur in the 
validation (new) protocol. As Table I indicates, the proportion of Pca found in 
the range of PSA 3 to 3.9 ng/mL was very high. The proportion of Pca found 
in this range was 6.4% with the old protocol and 18.0% with the validation 
study (Table I). If all 534 men in the new protocol with a PSA value between 3 
and 3.9 ng/mL had undergone biopsy (instead of the 446 men who did), the 
number of tumors detected would have been 115 (instead of 96) (Table III). 
This would have led to a detection rate (or PPV) in this PSA range of 21.5% 
(instead of 18.0%). This unexpected high detection rate (and PPV) 
overcompensates for the loss of Pca cases by not doing a DRE and TRUS 
with PSA values between 1 and 2.9 ng/mL, as shown in Table III. No other 
confounding factors, such as age, regional variation in incidence, or changes 
in biopsy procedures, can be identified to explain this difference. It is evident 
from Figure 1 that another group of men drop out of the study after 
randomization, those who were randomized but did not show up for screening 
(6.4% in the old protocol and 9% in the new protocol). Also, this group was not 
taken into account in the 1996 estimates. This dropout rate may be less 
important in daily practice, since it may be assumed that men who present for 
opportunistic screening will usually undergo all the necessary procedures. 
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Tumor characteristics 
A complete comparison of the characteristics of the biopsies in terms of the 
numbers of cores involved, the proportion of all cores involved, and the 
Gleason scores was performed between the old and new protocols (Table II). 
It was, however, elected to present these data together with the 
characterization of the radical prostatectomy specimens done within the new 
protocol in a separate report. The attempt to characterize Pca, Pca expected 
to be missed by omitting DRE and TRUS at a PSA level of less than 2.9 
ng/mL, Pca expected to be found in the PSA range of 3 to 3.9 ng/mL, and Pca 
expected to be found using the new protocol by biopsying everyone with a 
PSA level of 3.0 ng/mL or greater is entirely based on the findings related to 
166 radical prostatectomies performed within the old protocol (PSA of 4.0 
ng/mL or  greater). These data have previously been used to evaluate the 
efficacy of DRE [4] and to evaluate the characteristics of Pca detected at low 
PSA ranges.[12] In the latter report, the characteristics of DRE findings 
positive and negative for tumors were also compared. The figures on the DRE 
findings in the validation study were not reported; these were biased by 
knowledge of the PSA at the time of the DRE. A number of investigators 
[12,13–18] have dealt with this issue in previous publications. Agreement has 
been reached on the following: screen detected Pca, even in the low PSA 
ranges, is most frequently moderately differentiated (Gleason score 5–7), 20% 
to 30% of non palpable tumors are classified as minimal according to criteria 
by Hoedemaeker [11] adapted from those described by Epstein et al., [13] and 
the proportion of Pca that has a volume of less than 0.02 mL and may be 
compatible with the frequently found autopsy tumors is very low. The only 
report giving detailed information on the characteristics of Pca detected in the 
PSA range of 3 to 4 ng/mL comes from the ERSPC, section Göteborg, 
Sweden. [3] That group found that 32 (23.4%) of 137 tumors detected by 
sextant biopsy taken because of PSA values of 3.0 ng/mL or greater in men, 
50 to 65 years old, fell into the PSA range of 3 to 3.9 ng/mL. The detection 
rate in total during the first round of screening was 137 (2.3%) of 5859 men, 
50 to 65 years old, who agreed to undergo screening. Fourteen of these men 
underwent radical prostatectomy. Eight (57%) of these 14 men had 
histologically organ-confined disease (Stage pT2 or lower). Of the 14 tumors, 
13 were classified as Gleason score 5–7 and 3 as Gleason score 7.3 As one 
would expect, the proportion of histologically organ-confined tumors was 
slightly lower in men with PSA values of 3.0 ng/mL or greater than in the 
original protocol, which included all cases found with low PSA values (0.0 to 
2.9 ng/mL). The proportion of minimal disease was 13.4% in Pca detected at 
a PSA level of 3.0 ng/mL or greater; the proportion of minimal disease was 
50% in Pca found at a PSA level of 0 to 2.9 ng/mL. With the new regimen, 79 
(16.7%) of 447 cancers would have been missed, as estimated by the logistic 
regression model. [5] One half of these cases were classified as either 
moderate or advanced disease. The uncertainty concerning the possible 
impact of these cases on the improvement of Pca mortality in this randomized 
study represents a considerable risk taken by the study group. We 
acknowledge that the number of biopsies needed to detect one case of Pca 
may be influenced by other (time-dependent) factors. Such influences cannot 
be evaluated within the existing database. “Contamination” by opportunistic 
screening has increased only slightly, from about 9% to about 13%.[19]  
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Comparison of biopsy indications and biobsy outcome between original 
and new protocols 
Table III gives a comparison of the biopsy indications, biopsies that were 
done, and Pca detection per PSA range in the original and new protocols. 
Table III shows that in all PSA ranges and in both protocols, some men did 
not follow the advice to have a biopsy. This proportion was highest in men 
with PSA values less than 1.0 ng/mL in the original protocol. This is 
understandable, since the outcome of screening is known to the participants   
who often consult with their family physician for further advice. The low 
prevalence of biopsy-detectable Pca in this PSA range is general knowledge 
and is documented in Table III. The proportion of men who for some reason 
did not undergo an indicated biopsy, however, was much larger if screening 
by PSA only was used. In that case, numbers did not relate to the PSA levels 
and remain unexplained. Table III also shows that the large differences seen 
using the PSA cutoff of 3.0 ng/mL or greater for screening with respect to the 
detection rate, PPV, false-positive rate of biopsy indications, and proportion of 
biopsies per Pca detected were not due to men with PSA values of 4.0 ng/mL 
or greater.  
 
Conclusions. 
The data presented illustrate the effect of a major change in the screening 
procedures within the ERSPC. The data establish the value of a PSA cutoff of 
3.0 ng/mL or greater as an indicator for biopsy in the early detection of Pca. 
The PPV and false-positive biopsy rates improved significantly at equal 
detection rates compared with the previously used standard regimens. 
However, 75 (16.0%) of 470 cancers were missed in the PSA range of 1.0 to 
2.9. A comparison of tumor characteristics revealed that the proposed 
regimen avoids many of the cases classified as “minimal” that are found with 
lower PSA values. The avoidance of DRE and TRUS in about 80% of cases is 
advantageous for population- based screening but not to the same degree for 
clinical practice, where a DRE is often done before knowing the PSA value 
and not for the sole purpose of diagnosing Pca. The results of this study 
demonstrated that the characteristics of Pca with PSA values between 3.0 
and 3.9 ng/mL may be expected to be similar to those of standard regimens. 
The need to diagnose Pca at PSA values of less than 3.0 ng/mL is debatable. 
The improvement of the screening procedure by the addition of other 
parameters is especially desirable in the PSA range of 2 to 2.9 ng/mL. On the 
basis of this validation study, the decision to change the screening regimen 
within the ERSPC to performing biopsies in all men with PSA values of 3.0 
ng/mL or greater is considered justified. 
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Abstract. 
 
Objectives.  
To study retrospectively whether the prostate-specific antigen (PSA) velocity, 
that is, the change in PSA level over time, might serve as a screening tool in 
this PSA range. It is estimated that 40% of detectable prostate cancers are 
present in men with a PSA level of 4.0 ng/mL or less. Digital rectal 
examination and/or transrectal ultrasonography have been used as screening 
tools at these low PSA levels, but this approach is not very efficient. 
Methods.  
The possible predictors (including PSA velocity) for biopsy outcome were 
studied using univariate and multivariate logistic regression analysis in 774 
men who underwent biopsy between November 1997 and January 2002 in the 
second screening round of the European Randomised Study of Screening for 
Prostate Cancer (ERSPC). The clinical stage of the tumors was determined, 
and the Gleason scores of the biopsies were studied. 
Results.  
A total of 149 cancers were found (positive predictive value 19.2%). The odds 
ratio for the PSA velocity determined by univariate logistic regression analysis 
was 2.2 (95% confidence interval 0.7 to 6.9, P = 0.19) and was 0.73 (95% 
confidence interval 0.20 to 2.6, P = 0.64) by multivariate analysis. The 
distribution of the clinical stage of the detected tumors was 64.4% T1c, 32.2% 
T2, and 3.4% T3. The biopsy Gleason score was 6 in 84.5%, 7 in 14.2%, and 
8 in 1.3%. 
Conclusions.  
The number of cancers detected in this study and the distribution of clinical 
stage and biopsy Gleason score confirmed that a relatively large proportion of 
potentially curable cancers can be found in the low PSA ranges. The PSA 
velocity did not appear to be a useful screening tool for the identification of 
these cancers. 
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Introduction. 
 
Prostate cancer is the most commonly diagnosed cancer and the second 
leading cause of cancer death in Western Europe and the United States.[1,2] 
Most prostate cancer is found in men with a prostate-specific antigen (PSA) 
level greater than 4.0 ng/ mL. It has been estimated, however, that roughly 
40% of all detectable cancers are in men with a low PSA level (less than 4.0 
ng/mL).[3] A considerable proportion of these cancers have potentially 
aggressive characteristics and are organ confined and thus suitable for   
treatment. Digital rectal examination (DRE) and/or transrectal ultrasonography 
(TRUS) may be used as screening tools at these low PSA levels; however, 
this approach is not very efficient.[4–6] For example, at the initial screening 
visit of the European  Randomised Study of Screening for Prostate Cancer 
(ERSPC), Section Rotterdam, in the PSA range between 1.0 and 4.0 ng/mL, 
102 cancers were detected in 822 biopsies indicated on the basis of 
suspicious DRE and/or TRUS findings in 4398 men. A logistic regression 
model using PSA level and prostate volume, in addition to DRE and TRUS 
findings as predictors for biopsy outcome, estimated that 254 cancers would 
have been found if all 4398 men had undergone biopsy (39.6% of all those 
detectable by sextant biopsy).[7] It has been recently suggested that the rate 
of change of PSA (PSA velocity) may be of use to detect prostate cancer 
more efficiently at low PSA values.[8] Using data from the ERSPC, we 
retrospectively studied this hypothesis. 
 
 
Material and methods. 
 
 
Between November 1997 and January 1, 2002, 1681 of 7570 men underwent 
biopsy in the second screening round of the ERSPC, 4 years after the initial 
screening visit. The ERSPC was approved by the institutional review board of 
the Erasmus Medical Centre and by a national board (required by Dutch law 
for population screening studies). All participants provided written informed 
consent. Of the 1681 men who underwent biopsy, 894 (53%) had a PSA level 
of less than 4.0 ng/mL. Of these 894 men, 777 (87%) did not undergo biopsy 
at the initial screening visit. At the initial screening visit, biopsies were only 
indicated for a PSA level of less than 4.0 ng/mL if the DRE and/or TRUS 
findings were suspicious. The biopsy indication applied in the second 
screening round of the ERSPC varied according to the PSA range (Fig. 1). 
Biopsy was indicated for all men with a PSA level greater than 3.0 ng/mL (n = 
367). Biopsy was indicated for participants with a PSA level in the range of 2.0 
and 3.0 ng/mL who participated in a sub-study that investigated the utility of 
human kallikrein 2 in prostate cancer screening or in a sub-study after PSA 
doubling with respect to the initial screening visit (n = 294). Biopsy was 
indicated for participants with PSA in the range between 1.0 and 2.0 ng/mL 
who participated in a sub-study after PSA doubling with respect to the initial 
screening value (n = 113). For PSA values lower than 1.0 ng/mL, no biopsies 
were done. Neither the DRE nor TRUS findings influenced the biopsy 
indication. 
 
 
 - 72 -
 
 
Fig1: Consort diagram of screening procedure of second screening round, 
November 1997 through December 2001. Study population consisted of 
774 biopsied men with PSA less than 4.0 ng/mL. 
 
 
PSA ASSAYS AND BIOPSY PROCEDURE 
 
From November 1993 to October 1994, the IMX (Abbott) assay was used for 
PSA determination. From November 1994 to the time of this report, the 
Hybritech Tandem E/Access assay was used. We standardized the PSA 
values on the Hybritech Tandem E assay by adding 8% to the Abbott 
IMXdetermined PSA values, because these values  were on average 8% 
lower than those determined by the Hybritech Tandem E assay for the same 
sample.[9] Lateralized sextant biopsies (augmented with a seventh biopsy   
directed toward a hypoechoic lesion if present) were taken. Three men who 
took Proscar were excluded from the study.  
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STATISTICAL ANALYSIS 
 
Summary statistics for the 774 men who underwent biopsy and met the above  
mentioned inclusion criteria were calculated for the TRUS-assessed prostate 
volume,  DRE outcome, TRUS outcome, PSA level at the second screening 
round, PSA velocity, and PSA density stratified for the PSA ranges of 1.0 to 
1.9, 2.0 to 2.9, and 3.0 to 3.9  ng/mL. The positive predictive value, defined as 
the number of cancers detected divided by the number of biopsies done, was 
calculated per PSA range. 
PSA density was calculated as the PSA value divided by the TRUS-estimated 
prostate volume in the second round. The PSA velocity was calculated as the 
(second PSA value minus the first PSA value) divided by the calculated delay 
in months between the first and second screening visits. We calculated the 
relative sensitivity (those diagnosed as sick among all those sick) and the 
relative specificity (those diagnosed as healthy among all those healthy) as a 
function of the PSA velocity cutoff (using cutoff values of 0.1, 0.2, and 0.3 
ng/mL per year). These relative sensitivities and specificities differ from the 
true sensitivity and specificity because a negative sextant biopsy will not rule 
out the presence of prostate cancer. A univariate logistic regression analysis 
using the presence of cancer as a dichotomous dependent variable (true or 
false) and the PSA velocity as the sole independent variable (the predictor) 
was performed. Multivariate logistic regression analysis was used to study the 
predictive value of PSA velocity, controlling for age, prostate volume, and 
DRE and TRUS findings suspicious for prostate cancer with respect to the 
same dependent variable. Suspicious DRE and TRUS findings were coded as 
0 if no abnormalities were found and 1 if otherwise. The continuous variables 
PSA velocity and prostate volume were first categorized according to the 
quartiles of their distribution. The multinomial variables thus obtained were 
coded in the regression analysis using dummy variables. A backward deletion 
procedure based on the likelihood ratio test was applied to select a final 
model, which included the most important predictors for the outcome of a 
biopsy. The outcomes of the logistic regression models are reported in terms 
of odds ratios.[10] Interaction terms were not removed from the model if the 
main effect terms involved were still included.  
 
The clinical stage (TNM 1992) of the tumor and the Gleason scores of the 
biopsies were studied.  
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Table I: Descriptive statistics of selection of predictors for outcome of biopsy in 
second screening round, stratified by PSA range. 
 
 
Results. 
 
The summary statistics of the 774 biopsied men in the second screening 
round of the ERSPC (Rotterdam) are given in Table I; 159 cancers were 
found (positive predictive value 19.2%). The PSA velocity varied widely, with a 
modest, but statistically significant, correlation with the absolute PSA level 
(0.279, P <0.001, Spearman’s rank correlation). The prostate volume 
correlated positively with the PSA levels (0.317, P < 0.001, Spearman’s rank 
correlation). Table II displays the different sensitivities and specificities of the 
PSA velocity for several cut-off values in the second round of the ERSPC, 
Rotterdam. The odds ratio for PSA velocity as determined by the univariate 
logistic regression analysis was 2.2 (95% confidence interval 0.7 to 6.9, P = 
0.19, not  statistically significant). No odds ratios that were significantly 
different from 1 were found for the PSA ranges of 1 to 2, 2 to 3, and 3 to 4 
ng/mL. In the multivariate regression analysis, no interactions between the 
different predictors were found. The odds ratios for the main effects are given 
in Table III. The clinical stage was T1c in 96 men (64.4%), T2 in 48 men 
(32.2%), and T3 in 5 men (3.4%).  
The biopsy Gleason score was 3 + 3 in 126 men (84.5%), 3 + 4 in 21 men 
(14.2%), and 4 + 4 in 2 men (1.3%). 
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* All biopsy detected prostate cancers (n=149) were the 
denominator in “relative sensitivity”  
 
Table II: Sensitivity and specificity of PSA velocity 
for several cut off values in second 
round of ERSPC, Rotterdam 
 
 
Comment. 
 
On the basis of the data from the Baltimore Longitudinal Study on Aging 
(BLSA), it was recently suggested that the PSA velocity may be of use to 
detect prostate cancer in men with low PSA values. [8] The reported 
sensitivity and specificity of the PSA velocity using a cut off value of 0.1 ng/mL 
per year was 81% and 50%, respectively. We studied the application of the 
suggested biopsy strategy (i.e. biopsy for all men with a PSA velocity of 0.1 
ng/mL or greater) using data from the ongoing ERSPC, as well as some 
alternative biopsy strategies. The distribution of the clinical stage of the 
detected tumors and the biopsy Gleason scores confirmed that a relatively 
large proportion of potentially curable cancers could be found in men with low 
PSA ranges. 
In general, any test may be of use as a screening tool for prostate cancer if its 
outcome adds information with respect to the presence of prostate cancer in a 
subsequent biopsy compared with the situation in which all men undergo 
biopsy. For example, greater PSA values are associated with a greater 
probability of detecting cancer during prostate biopsy.[11–13] The outcome of 
the univariate logistic regression analysis for PSA velocity was, however, not 
very convincing in this respect. Although the odds ratio was greater than 1 
(odds ratio 2.2), the associated P value was only 0.19 (not statistically 
significant). 
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  * as determined in second screening round 
  † P < 0.05, two sided 
  ‡ Not statistically significant   
 
Table III: Odds ratios for predictors for presence 
of cancer studied by multivariate logistic 
regression analysis. 
 
 
Univariate analysis does not take into account all the other factors that may 
affect the outcome of a biopsy and that are known before the biopsy. We, 
therefore, studied the value of the absolute PSA levels, prostate volume, 
TRUS and DRE outcomes (suspicious or not), and age in the second 
screening round in this respect using a multivariate logistic regression 
analysis. The data in Table III demonstrate that the PSA velocity was not an 
important predictor for the presence of cancer. In fact, the backward deletion 
procedure excluded only the PSA velocity; all other predictors remained in the 
model. Therefore, despite the sensitivity of PSA velocity (using a cut off value 
of 0.1 ng/mL; Table I), the PSA velocity per se is not an important predictor of 
the presence of prostate cancer in a sextant biopsy in men who had been 
previously screened. The interpretation of the univariate and the multivariate 
analyses may be that the detection of prostate cancer is conditionally 
independent of the PSA velocity (i.e. if only the PSA velocity is known [as in 
the univariate analysis], the prostate cancer risk will depend on the PSA 
velocity, although not significantly in our data set). However, if other factors 
are also known, the information concerning the presence of cancer provided 
by knowing the PSA velocity is completely overwhelmed by the information 
present in the other variables (in this case, primarily the PSA level and 
prostate volume). 
It is important to note the differences between the BLSA and ERSPC. The 
PSA velocity was 0.1 ng/mL per year or greater in nearly all men who 
underwent biopsy in the ERSPC, Rotterdam with a PSA level less than 4 
ng/mL (83%). In the BLSA study, 42% of the men had a PSA velocity of 0.1 
ng/mL per year or greater. Such an observed difference for a PSA level of 1 to 
2 ng/mL is easy to explain because in the ERSPC only men with a PSA 
doubling in this PSA range underwent biopsy. This explanation did not hold for 
the 3 to 4 ng/mL PSA range in which all men underwent biopsy in the ERSPC. 
Even in this range, the percentage of men with a PSA velocity of 0.1 ng/mL 
per year or greater was 82.6%. Possible explanations for the observed 40.6% 
difference (82.6% - 42%) in the proportion of men with a PSA velocity of 0.1 
ng/mL per year or greater include the effects of processing stored samples for 
those men in whom cancer was detected before 1991 in the BLSA or the use 
of different PSA assays (we standardized our PSA values to Hybritech 
Tandem E). Another explanation may be that the age range in which the PSA 
velocity was determined was completely different in both studies. 
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Table II of the BLSA report provided some information on the age distribution. 
In the ERSPC, Rotterdam, all men were between 59 and 75 years old (about 
evenly distributed) at the time of the second screening biopsy. In the BLSA, 
some PSA samples from very young men (41.2 years) and very old men (87.3 
years) were included. Another difference was that although the reference 
standard for the presence of cancer in the BLSA study was the biopsy 
outcome, the type of biopsy was not specified and may very well have been 
different from the procedure used in the ERSPC in which systematic sextant 
biopsies were taken. Most importantly, in the BLSA, an increased PSA 
velocity was not an indication for biopsy. The hypothesized merits of the use 
of PSA velocity were based on a retrospective study. The real value of the 
PSA velocity can only be tested by actually using it as a biopsy indication, 
such as was (at least in part) done in the present study. To assess the 
discrepancy between the ideal situation in this respect (biopsy on the basis of 
a PSA velocity of 0.1 ng/mL per year or greater) and the approach in the 
present study, the following calculation may be informative. 
Of the 3942 men who, between November 1997 and January 2002, had a 
PSA value greater than 1.0 but less than 4.0 ng/mL, 1683 (82.7%) had a PSA 
velocity of greater than 0.1 ng/mL per year. In this retrospective study, 
approximately 40% of these men actually underwent biopsy. In contrast, 134 
men with a PSA velocity less that 0.1 ng/mL per year were biopsied. Finally, 
neither in the BLSA study nor in the present work, was the value of the PSA 
velocity assessed with respect to the outcome of an initial biopsy in an 
individual. In the BLSA, this was not done, because no PSA velocity-based 
biopsy indication was used. In the present work, a considerable number of 
men underwent biopsy at the initial screening round of the ERSPC and the 
value of the PSA velocity was assessed between the initial screening round 
(in which some men with cancer were filtered out) and the second screening 
round. 
 
 
Conclusions. 
 
The risk of biopsy-detectable prostate cancer in the second round of the 
ERSPC, Rotterdam even for those with a PSA value less than 4.0 ng/mL was 
high (positive predictive value 19.3%). In the current study, prostate volume, 
TRUS findings, age and PSA level were statistically significant predictors for 
the outcome of a biopsy, but an increased PSA velocity was not. Because 
several different parameters apparently provide independent information with 
respect to the outcome of a biopsy, it makes sense to derive a biopsy strategy 
on the basis of a mixture of parameters (e.g. PSA level, prostate volume, and 
DRE and TRUS findings). The predicted cancer probability determined using 
the multivariate logistic regression model presented in this study might serve 
this purpose. 
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Abstract: 
 
 
Objectives.  
Currently, several prostate cancer re-screening intervals are in use in different 
countries worldwide, varying from 1 to 4 years. Recently, it has been 
proposed to determine the re-screening interval relative to the initial prostate-
specific antigen (PSA) level and possibly to extend the re-screening interval 
up to 5 years. 
Methods. 
We evaluated the screening results of two subsequent screening visits (4-year 
interval) of 1703 men aged 55 to 65 years with an initial PSA level of 1.0 
ng/mL or less within a randomized screening trial. We assessed the PSA 
values, numbers of men biopsied (biopsy indication: PSA level of 3.0 ng/mL or 
greater), and numbers of cancers detected at the second and third screening 
visits. 
Results.  
A total of 1327 men (79.3%) attended the second screening visit. Of these 
men, 13 (0.98%) had a PSA level of 3.0 ng/mL or greater, and three cancers 
were detected (cancer detection rate 0.23%). At the third screening visit, 1017 
men (76.8%) attended, 34 men (3.3%) had a PSA level of 3.0 ng/mL or 
greater, and five cancers were detected (cancer detection rate 0.49%). The 
2344 subsequent PSA determinations in an 8-year period after the initial 
screening resulted in eight cancers detected, for an overall cancer detection 
rate of 0.47%. Through linkage of all men with the cancer registry, no 
additional cancers were found. 
Conclusions. 
A strategy of PSA screening every 8 years for men with a PSA level of 1.0 
ng/mL or less will lead to a considerable decrease in the number of screening 
visits (with the associated costs and stress), with a minimal risk of missing 
aggressive cancer at a curable stage. 
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Introduction. 
 
Although the introduction of serum prostate-specific antigen (PSA) 
determination has led to a favorable stage migration, allowing for early 
treatment, prostate cancer screening in asymptomatic men is still 
controversial. To solve uncertainties regarding screening for prostate cancer, 
prospective randomized controlled trials are currently ongoing in the United 
States (Prostate Lung Colorectal Ovarian Cancer Screening Trial)[1] and 
Europe (European Randomized study of Screening for Prostate Cancer 
[ERSPC]).[2] An optimal screening algorithm will be crucial in the evaluation of 
population-based prostate cancer  screening programs, not only in terms of 
decreasing the prostate cancer mortality rate,  but also for cost-effectiveness 
evaluations. Currently, several re-screening intervals are in use in different 
countries worldwide, varying from 1 to 4 years.[3–6] The choice of a  re-
screening interval was made with the knowledge of the lead-time based on 
serum banks used for PSA determinations and the subsequent diagnosis of 
clinical cancer. In 1997, Carter et al.[7] suggested that re-screening intervals 
should be linked to the baseline PSA level and that a re-screening interval 
longer than 1 year could be used for men with low PSA levels. Recent studies 
have proposed extending the re-screening intervals to up to more than 4 
years. [4,8,9] We evaluated the screening results of two subsequent 
screening visits, each at a 4-year interval, of men with an initial PSA level of 
1.0 ng/mL or less in the Dutch part of the ERSPC. 
 
 
Material and Methods. 
 
The total screening cohort of ERSPC (section Rotterdam) consisted of 21,210 
men (aged 55 to 74 years), of whom 19,970 men were actually screened. Of 
these men, 8036 (40.2%) presented with a PSA value of 0.1 to 1.0 ng/mL. 
The study population consisted of all men (n = 1703) aged 55 to 65 years with 
a PSA level of 1.0 ng/mL or less who were screened between October 1991 
and March 1996 (initial screening visit). This period and age selection was 
made to get a cohort of eligible men for two subsequent screening visits, each 
with an interval of 4 years. We assessed the PSA values (Beckman-
Hybritech), number of men biopsied and number of cancers detected at the 
second (October 1995 to March 2000) and third (October 1999 to March 
2004) screening visits. 
During the second screening visit, the indication for biopsy changed. Up to 
May 1997, the biopsy indication was a PSA level of 4.0 ng/mL or greater or a 
lower PSA level (1.0 ng/mL or greater) with abnormal digital rectal 
examination and/or transrectal ultrasound findings. From May 1997 to date, 
the indication for biopsy has been a PSA level of 3.0 ng/mL or greater. The 
tumor and screening characteristics of the cancers detected at the 
subsequent screening visits were examined. Through linkage of all men with a 
PSA level of 1.0 ng/mL or less (n = 8036) with the Cancer Registry, we 
obtained information on possible interval cancers or cancers detected in men 
who refused further screening after attending the initial screening visit. The 
institutional review board of the Erasmus Medical Center and a national board 
(required by Dutch law for population- screening studies) approved the 
ERSPC. All participants provided written informed consent. 
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Results. 
 
 
The 1703 screened men had a mean PSA level of 0.63 ng/mL at the initial 
screening. The mean PSA value at the second screening visit was 0.87 ng/mL 
(range 0.1 to 6.2 ng/mL) and was 1.09 ng/mL (range 0.1 to 11.0 ng/mL) at the 
third screening visit. Table I shows the PSA distribution of men at initial 
screening and the number and PSA distribution of men attending the second 
and third screening. Of the eligible 1703 men, 1327 (79%) attended the 
second screening visit. Loss was owing to death (3.3%), comorbidity (5.1%), 
moved from the region (5.1%), and refusal (10.1%). Of the 1327 men, 13 men 
(0.98%) had a PSA level of 3.0 ng/mL or greater, 10 men actually underwent 
biopsy, and three cancers were detected (positive predictive value 30%, 
cancer detection rate 0.23%). At the third screening visit, 1017 (76.8%) of the 
1324 eligible men attended, and 34 (3.3%) had a PSA level of 3.0 ng/mL or 
greater, 30 actually underwent biopsy, and five cancers were detected 
(positive predictive value 16.7%, cancer detection rate 0.49%). 
At the second screening visit, the clinical stage of the three cancers detected 
was T1c in 2 cases and T3a in 1 case. One of the three cancers detected 
(clinical Stage T3a, Gleason score 3 + 4) showed a rapid rise in the PSA level 
during the 4-year interval (1.38 ng/mL/yr). At the third screening visit, the 
clinical stage distribution was 3 cases of T1c and 2 cases of T2c. In two of the 
five cancers detected (both T2c, Gleason score 4 + 4 and 4 + 5), the PSA 
level increased rapidly in the second 4-year interval (PSA velocity 2.4 
ng/mL/yr and 1.9 ng/mL/yr. 
Through linkage of all 8036 men with the Cancer Registry, no additional 
cancers were found (data complete to January 2003). 
 
 
 
Comment. 
 
 
The determination of an optimal re-screening interval in a population-based 
screening setting is important for many reasons. Shorter intervals are 
preferable to avoid the risk of missing prostate cancers that might be of 
influence to the main endpoint, decreasing prostate cancer-specific mortality. 
Longer screening intervals, however, are preferable to avoid over-diagnosis, 
which is substantial in prostate cancer screening,[10] and to reduce costs. 
The latter will be a key factor in decision making for population-based 
screening programs. In this study, we evaluated the screening results of two 
subsequent screening visits, each with a 4-year interval, of men with a 
baseline PSA level of 1.0 ng/mL or less, representing 42% of the total 
screening population aged 55 to 65 years. 
The data showed that the total of 2344 (1327 + 1017) subsequent PSA 
determinations resulted in 41 sextant biopsies and 8 cancers detected; an 
overall cancer detection rate of 0.47% (8 of 1703) at 8 years. In 5 (0.7%) of 
the 672 men with a baseline PSA level of 0.5 ng/mL or less (39.5% of the 
study cohort), the PSA level increased to 3.0 ng/mL or greater and one cancer 
was detected. These findings are in line with those of Ito et al.[9] in their study 
of 4794 men with a baseline PSA level of 1.0 ng/mL or less, a total of four 
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cancers (0.08%) were found after a mean follow-up of 4 years. Two patients 
had had a rapid PSA increase 5 and 9 years after the baseline PSA 
measurement. Therefore, PSA measurements were recommended every 4 or 
5 years. Hugosson et al.[4] found that in a cohort of 5267 men screened two 
times at an interval of 2 years (PSA cutoff 3.0 ng/mL), 3 of the 111 cancers 
detected were detected in men with baseline PSA levels less than 1.5 ng/mL. 
None of the 2950 men with a PSA level less than 1.0 ng/mL at the initial 
screening had a PSA increase above the cutoff level used. Hugosson et al. [4] 
concluded that men with a PSA level of less than 1.0 ng/mL did not need to be 
screened yearly and probably not as often as every second year. Recently, 
Candas et al. [11] published a study of 5387 men (Laval University Cancer 
Screening Program) with an initial PSA level of less than 3.0 ng/mL and a 
median number of seven annual follow-up visits. They concluded that 
compared with annual screening visits, the number of screening visits could 
be reduced by 45% in men with a PSA level less than 3.0 ng/mL, with almost 
the same cancer detection rate after a median follow-up of 7 years (range 1 to 
14 years). Our current data, with a follow-up of 8 years, have shown that after 
this relatively long period, the number of cancers detected was very limited. 
No screening policy for any cancer is capable of avoiding all related mortality. 
A longer screening interval or perhaps even a single screening visit might be 
possible in men with these low PSA levels, without missing substantial cancer 
diagnoses, which could influence the effectiveness of a population-based 
screening program. Finally, it is an unresolved issue whether it is possible to 
identify the cancer cases detected at subsequent screening   visits at the 
initial screening to avoid unnecessary testing in a large group of men.  
Of the 8 cancer cases detected, 3 at second round screening and 5 at the 
third   screening visit, all, except 1, had an initial PSA level greater than 0.5 
ng/mL. Also, 3 of the 8 cases, detected at a more advanced stage, showed a 
rapid PSA increase in the 4-year interval before diagnosis. However, the 
baseline PSA levels of the cancer cases at the third screening visit were not 
indicative of the presence of prostate cancer. At the time of detection, the 
digital rectal examination findings were abnormal in 3 cases and not 
suspicious in 5. Digital rectal examination might have detected additional 
cancers during the first and subsequent round. Arguments for omitting digital 
rectal examination as a screening test in exchange for biopsying every man 
with a PSA level of 3.0 ng/mL or greater have been presented elsewhere. 
[12,13] The numbers of prostate cancers missed are likely to have been very 
small, considering the previous reported positive predictive value of 2%.[14] 
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The rapid rise in PSA levels could point toward the possible use of the PSA 
velocity for detecting these cancers. The PSA velocity of the cancers detected 
at repeat screening was 1.38, 0.50, and 0.63 ng/mL/yr. The cancers detected 
at the third screening had a PSA velocity (calculated as the mean PSA 
velocity of the two intervals[15] of 0.41, 1.30, 0.31, 0.35, and 1.03 ng/mL/yr. 
The PSA velocity of the 3 advanced cases was 1.38, 1.30, and 1.03 ng/mL/yr. 
These data, although based on a very small sample, showed a wide 
distribution in PSA velocity values. This will make it difficult to use PSA 
velocity, in population-based setting, as an indicator for the presence of 
prostate cancer at low PSA levels. This becomes even more evident if we 
consider the PSA velocity values of the men with a PSA level of 3.0 ng/mL or 
greater who underwent biopsy at the second screening (n = 7) or third 
screening (n = 25) in whom no cancer was detected. The PSA velocity values 
varied from 0.53 to 1.27 ng/mL/yr (mean 0.86) for men biopsied at the second 
screening (of whom 4 men who attended the third screening again had no   
cancer found). For men who underwent biopsy at the third screening with a 
PSA value of 3.0 ng/mL or greater with no cancer detected, the PSA velocity 
values varied from  - 0.27 to 1.43 ng/mL/yr (mean 0.52). The rapid rise in PSA 
in the 4-year interval in the more advanced cancer cases is in line with the 
findings of Carter et al.,[16] in which an exponential rise in PSA level was 
found 4 to 5 years before clinical diagnosis. 
In men who did not reach the PSA threshold value of 3.0 ng/mL during the 8-
year period, the PSA velocity values varied from - 0.29 to 0.56 ng/ mL/yr 
(mean 0.004). Other parameters known at initial screening, such as age, 
family history, prostate volume, and PSA density showed no remarkable 
differences between the cancer and non-cancer cases. Statistical testing was 
not done because of the very small number of cancer cases.  
 
 
Conclusion. 
 
The numbers of cancers detected after 8 years of follow-up with two 
subsequent screening visits were very low in men with a PSA level of 1.0 
ng/mL or less, which represented 42% of men screened in the age range of 
55 to 65 years in our study. In a population-based screening setting, a trade 
off is always present between the specificity (ie, unnecessary screening) and 
sensitivity (i.e, number of cancers detected). A strategy of PSA screening 
every 8 years for men with a PSA level of 1.0 ng/mL or less will lead to a 
considerable decrease in the number of screening visits (with the associated 
costs and stress) with a minimal risk of missing aggressive cancers at a 
curable stage. 
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Abstract. 
 
 
Objectives. 
In the early detection of prostate cancer (Pca) uncertainty exists concerning 
the most appropriate biopsy procedure. Within the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) lateralized sextant biopsies 
are used. False-negative results of sextant biopsies have led to the extensive 
use of procedures using 12 or more biopsy cores. The ERSPC offers the 
opportunity to study the yield of repeat biopsies after 4 years in men who had 
negative sextant biopsies and a prostate-specific antigen (PSA) level of 4.0 
mg/mL or more at the first screening round. 
Methods.  
Between August 1996 and May 1998, a total of 6876 men (age 55 to 74 
years) were randomized to the screening arm and actually underwent 
screening. The numbers and levels of biopsy indicators, as well as possible 
predictors for biopsy outcome, in the  second screening round, such as 
prostate volume, volume change over time, prostate-specific antigen density 
(PSAD), PSA velocity, and age, were calculated and compared for 
participants with positive and negative biopsies in round 2. The positive 
predictive value (PPV) and detection rates, as well as parameters of 
aggressiveness, were evaluated for second-round biopsy detected and 
interval Pca cases. 
Results.  
Of the 728 men with a PSA level of 4.0 mg/mL or more who underwent biopsy 
at initial screening, 553 were eligible for a second screening visit after 4 years. 
Of these, 272 (49.2%) actually underwent screening. Eighteen Pca cases 
were detected with 217 biopsies, indicated by a PSA level of 3.0 ng/mL or 
more (PPV 8.3%). Eight interval cases were identified by linking to the Cancer 
Registry. These 26 cases would have increased the PPV and detection rate of 
the initial screening round from 36.1% to 39.7% and from 3.8% to 4.2%, 
respectively. Most of these cases (23 of 26 or 88.5%) were organ confined 
and amenable to potentially curative treatment. 
Conclusions.  
Although the results of this study may have been biased by the low rate of 
availability/eligibility of participants for re-screening (after 4 years), the 
proportion of cancers detected after a previous lateral sextant biopsy indicated 
by a PSA value of 4.0 mg/mL or more (PPV 8.3%) fell far short of the overall 
PPV at re-screening (PPV 20%). The features of most cancers that were 
possibly missed during the first round allowed a potentially curative approach. 
The ERSPC study group found no reason to change the ERSPC protocol. 
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Introduction. 
 
 
Since Hodge et al. [1] demonstrated that the ultrasound-guided transrectal 
sextant prostate biopsy is superior to digital guidance; this technique has 
become the most commonly used procedure for diagnosing prostate cancer 
(Pca), in both clinical and screening settings. However, some recent studies 
have suggested that the sextant prostate biopsy may underestimate the 
presence of Pca. The false-negative rate of the standard sextant biopsy has 
been reported to be as high as 15% to 31%. [2–7] Several series have shown 
that additional biopsy samples or lateralization of the sextant biopsies may 
increase the diagnostic yield by 30% to 35%. Repeated sextant biopsies or 
more extended systematic sampling in men in whom screening findings are 
suspicious for Pca (such as an elevated prostate-specific antigen [PSA] level) 
and a prior negative prostate biopsy have, therefore, been recommended in 
several studies.[8–13] 
Using a more extensive biopsy regimen will most certainly lead to an 
increased Pca detection rate. It is, however, known that most Pca develops 
slowly in elderly men. This results in a substantial risk that cancer will be 
detected for which treatment cannot bring any benefit. Over-detection or over-
diagnosis is a considerable problem in Pca screening. [14–16] Whether an 
increased cancer detection rate through early detection will influence Pca 
mortality remains uncertain. The critical question is which of the cancer cases 
detected by early detection are clinically significant and need to be detected at 
this stage or later during the life of the host, or at all. 
In the European Randomized Study of Screening for Prostate Cancer 
(ERSPC, Rotterdam), additional biopsies are only performed in the case of a 
high-grade prostatic intraepithelial neoplasia lesion or a “suspicious for 
malignancy” diagnosis. Men with a normal biopsy result do not undergo 
immediate repeat biopsy irrespective of the PSA level and/or suspicious digital 
rectal examination (DRE) and/or transrectal ultrasound (TRUS) findings. Their 
next screening visit is scheduled 4 years after the initial screening visit. This 
screening regimen was fixed at the start of the study, and, unless convincing 
evidence becomes available that makes it necessary to change the screening 
regimen, it will continue, preferably unadjusted, to remain consistent over time 
within the established, multinational approach. 
In this study, we focused on the repeat screening results of those participants 
who underwent biopsy at the initial screening (PSA level of 4.0 mg/mL or 
more) but in whom the biopsy result was benign.  
 
 
Material and Methods. 
 
 
 
STUDY POPULATION AND SCREENING ALGORITHM 
Our study population consisted of 6876 men, aged 54 to 74 years, who were 
randomized to screening and underwent screening between August 1996 and 
May 1998. At the initial screening visit, until May 1997, a PSA value of 4.0 
mg/mL or more and/or suspicious DRE findings and/or suspicious TRUS 
findings were used as biopsy indications. After May 1997, sextant biopsies 
were suggested in all men who had a PSA value of 3.0 ng/mL or more, and 
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DRE and TRUS were no longer used as screening tests.[17] Men who had 
undergone biopsy after May 1997, with a PSA value between 3.0 and 4.0 
ng/mL at initial screening, were not included in this study. The period of 
August 1996 until May 1998 was chosen to obtain a homogeneous sample 
with respect to the re-screening interval and to obtain the group of participants 
who were eligible for the second screening round 4 years later between 
August 2000 and May 2002. A total of 816 men (11.9%) had a PSA level of 
4.0 mg/mL or more. Men in whom no Pca was detected at initial screening 
were eligible for second-round screening (PSA cut off 3.0 ng/mL or greater). 
Details of the study population are given in Figure 1. A permit for conducting 
this study was obtained from the institutional review board of the Erasmus 
Medical Centre and the Dutch Health Council Committee.  
 
BIOPSY TECHNIQUE 
Lateralized sextant biopsies were obtained using a Bard 18- gauge biopsy 
needle. In the case of a hypoechogenic lesion, one extra biopsy was taken 
toward the suspicious lesion. Needle biopsy diagnoses of normal prostate, 
benign prostatic hyperplasia, atrophy, prostatitis, atypical adenomatous 
hyperplasia, and low-grade prostatic intraepithelial neoplasia were 
categorized as benign and those participants were invited or their next 
screening visit after 4 years. 
 
STATISTICAL ANALYSIS 
For all the participants who underwent biopsy at repeat screening, the positive 
predictive value (PPV; number of cancers detected divided by number of 
biopsies done) and cancer detection rate (number of cancers detected divided 
by number of men screened) were calculated. The association between the 
categorical variables (DRE and TRUS, coded as 0 [benign] or 1 [suspicious]) 
and diagnostic groups (cancer or no cancer detected at repeat screening) was 
tested by the chi-square test. Distinction was made between the DRE and 
TRUS results of the initial and repeat screening. Differences in the continious 
numeric variables (i.e, total PSA [visit 1 and visit 2], PSA velocity [PSAV; PSA 
level of visit 2 - PSA level of visit 1 divided by 4], prostate volume [visit 1 and 
visit 2], prostate volume velocity [prostate volume at visit 2  - prostate volume 
at visit 1], PSA density [PSAD; PSA divided by prostate volume], and PSAD 
velocity [PSADV; PSAD of visit 2 - PSAD of visit 1], and age [visit 2]) were 
tested by the Mann-Whitney U test. 
Data on the clinical stage, Gleason score, and treatment applied to the 
cancers detected at repeat screening were assessed. Through linkage with 
the National Cancer Registry, possible interval cancers within the 4-year 
period were identified for all men with a PSA level of 4.0 mg/mL or more and 
no cancer detected at initial screening. 
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Results. 
 
 
Of the 6876 participants at the initial screening, 816 men had a PSA level of 
4.0 mg/mL or more (11.9%), 728 men underwent biopsy (89.2%), and 263 
cancers were detected (PPV 36.1%, cancer detection rate 3.8%). In total, 272 
(49.1%) of the 553 men who were eligible for second screening were 
screened, and 217 men (39.2%) underwent biopsy (Fig. 1). In the 217 men 
who underwent biopsy, 18 cancers were detected (PPV 8.3%). Table I shows 
the distribution of possible indicators for a positive or negative result for these 
217 men. Table I separates the 199 participants who had a negative biopsy 
from the 18 with cancer detected at the second screening. The numeric 
distributions of abnormal DRE or TRUS findings during the first and second 
visits, as well as the average values and ranges for PSA, prostate volume, 
volume change over time, PSAV, PSAD, PSADV, and age distribution (only 
visit 2) between the first and second visit were compared. The P values relate 
to these comparisons and were probably influenced by the very small 
numbers of cancers detected in round 2. The PSA level was not significantly 
different between the cancer and non-cancer cases; statistically significant 
differences were found for PSAV and PSADV. Although not displayed in Table 
I, the mean prostate volume of men with Pca detected at a second screening 
visit with abnormal DRE findings was 45.5 cm3. This was substantially lower 
than the 60.1 cm3 in men with Stage T1c Pca detected at second screening. 
The clinical stage distribution of the 18 cancers detected was T1c in 8, T2 in 
9, and T3c in 1. The Gleason scores were as follows: 3 + 3 in 16 and Gleason 
3 +4 in 2 cases. Fifteen men had one positive biopsy core. All men were 
treated with curative intent, five radical prostatectomy, six radiotherapy, one 
brachytherapy and six by watchful waiting. 
 
Through linkage with the Cancer Registry (data complete until June 2002), 8 
cases of cancer were identified within the 312 men who were not screened in 
the second round (Fig. 1). These cancers were detected at either the Erasmus 
Medical Centre or hospitals within the region where, at least until 2002, 
sextant biopsies were used. Six cases were found in men who were too old to 
attend their second screening visit, of whom three had refused biopsy at the 
initial screening. In men eligible for the second screening visit, two interval 
cancer cases were detected. In 1 of those 2 cases, biopsy had been indicated 
but was not performed at initial screening (refusal). The available data on 
clinical stage showed that most Pca cases were organ confined: T1a in 1, T1b 
in 1, T2a in 3, T3a in 1, and T3c in 1 case. Most Pca cases were treated with 
curative intent (radiotherapy in 4, radical prostatectomy in 1, watchful waiting 
in 1); the 2 patients with non-organ-confined Pca underwent hormonal 
therapy.  
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Fig 1. Consortdiagram of study population. 
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Data in parentheses are ranges (minimum to maximum), unless noted otherwise. 
* Test result remained statistically insignificant (P = 0.562) if men with VolV  < - 20.0 (n = 15) are excluded from 
analysis. 
† Test result remained significant (P = 0.017 and P = 0.009, respectively) if men with VolV < -20.0 (n = 15) are 
excluded from analysis. 
 
Table I: Patient characteristics of 217 men who underwent biopsy at second 
screening visit 
 
 
 
Comment. 
 
 
Performing lateral sextant biopsies at repeat screening (4-year interval) in 
men with a previous benign biopsy and an elevated PSA level (4.0 mg/mL or 
more) resulted in the detection of 18 cases in 217 biopsied men (overall PPV 
and cancer detection rate at repeat screening 20.0% and 4.1%, respectively). 
Through linkage with the Cancer Registry, 8 additional cases of Pca were 
identified. Most cancers were organ confined and were treated with curative 
intent. The diagnosis of these 26 Pca cases, if added to the PPV and 
detection rate in round 1 increased these values by only 3.6% for the PPV 
(36.1% to 39.7%) and 0.4% for the cancer detection rate (3.8% to 4.2%). 
These findings do not correspond with the findings of other studies. Roehl et 
al. [2] found a cancer detection rate of 18% at a second series of prostate 
biopsies in men with a PSA level of 4.0 mg/mL or more after an initial cancer 
detection rate of 30%. This difference can be explained by the use of quadrant 
biopsies at the start of the study that was later changed to the use of sextant 
biopsies and the composition of the study population. Part of their study 
population consisted of men who were considered to be at high risk of Pca.  
The results presented here may have been adversely influenced by the low 
compliance rate at repeat screening. Only 272 (49.2%) of the 553 men invited 
underwent screening and only 217 men underwent biopsy (39.2%). 
Considering the men who did not respond, one can argue the benefit of an 
additional sextant biopsy. Other than the men who died within the 4-year 
interval, 132 men were older than 74 years and 91 men did not participate 
because of poor physical condition or cancer diagnosed elsewhere. General 
agreement has been reached that screening does not make sense for men 
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with a life expectancy of less than 10 years.[18] In older men or those with  
serious comorbid conditions, a competing hazard is much more likely to result 
in morbidity or death than Pca. Furthermore, it was found that side effects 
after Pca treatment (eg, incontinence, impotence) are also greater in older 
men.[19] Removing these men (24 dead, 132 too old to participate, and 91 
with comorbidity) from the calculation resulted in a compliance rate of 70.9% 
(217 of 306). Therefore, taking into account that early detection is done to 
have some benefit during a patient’s lifetime, the ERSPC decision to not 
change the biopsy protocol was made from a compliance rate of 71% 
combined with a linkage procedure that included all eligible men. 
The linkage with the Cancer Registry resulted in another 8 Pca cases. This 
number is certainly not negligible. Six cases surfaced in men older than 74 
years during the interval before their second screening visit. Three had 
refused biopsy and three had been missed. It is unknown what benefit would 
have been achieved if the detection had been 1 or 2 years earlier through 
screening. One of the other two clinically detected cancers would probably 
have been detected at the initial screening if the patient had not refused at 
that time, leaving a total of 4 Pca cases that were most probably missed at the 
initial screening, of which 3 were detected in men already older than 74 years. 
These findings, together with the low cancer detection rate at the second 
screening visit, caused us to determine that a change in the biopsy protocol 
within the ERSPC is not required for participants with a previous benign 
biopsy result. More important was the evaluation of the characteristics of the 
screen-detected cancers missed at initial screening and identifying possible 
reasons for a missed diagnosis. 
Uzzo et al. [20] and Karakiewicz et al. [21] showed that the yield of the sextant 
biopsy decreases with increasing prostate volume. Our data and those 
published by Feneley et al. [22] showed that patients with Stage T1c Pca and 
those without Pca had a larger prostate volume. Although the latter study was 
not a detection study, but a retrospective analysis of radical prostatectomy 
specimens, its conclusion was that using PSA testing (as done in our 
screening setting) results in a selection of men with larger prostates owing to 
the effect of benign prostatic hyperplasia on the serum PSA level. Combining 
the results of Uzzo et al., [20] Karakiewicz et al., [21] and Feneley et al. [22] 
suggests that the group of men in our study in whom no Pca was detected at 
the second screening visit consisted, in part, of men who already did have 
Pca. Increasing the number of biopsy cores in men with prostate volumes 
greater than 50 cm3, as suggested by Uzzo et al. [20] could, therefore, be an 
option. However, this would mean that men with benign prostatic hyperplasia 
and an elevated PSA level would also have to undergo this extensive biopsy 
scheme at successive screening visits. 
Our data showed that the screening test used (PSA level) is not a very 
powerful discriminator between malignant and benign disease in this particular 
group of men at repeat screening (PSA 4.0 mg/mL or more). Also DRE and 
TRUS examinations showed no statistically significant differences in the risk 
of a second-round positive biopsy. This implies that the tests used to predict 
the biopsy outcome at initial screening are not suitable at repeat screening. 
Finding suitable markers for the further refinement of the re-screening 
algorithm and, perhaps more important, finding markers for the detection of 
aggressive forms of Pca will, therefore, be indispensable to avoid 
unnecessary biopsies. Although the biopsy procedure is relatively harmless 
and well accepted, [23–25] applying prostate biopsies to large populations 
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may still result in a considerable absolute number of complications. Our data 
suggest that PSAV and the PSADV can perhaps help in this matter. The 
statistically significant difference in the PSADV between the Pca and non-Pca 
cases in this group of men could indicate that the rise in PSA level within the 
4-year interval was greater in the Pca cases than what would be expected by 
normal prostate growth due to aging. Additional studies, in a multivariate 
setting, will be required to determine the value of these changes as biopsy 
indicators at repeat screening.  Although not mentioned in this report, free 
PSA has been shown to be a powerful predictor of the presence of Pca in 
several studies. [26–28] Free PSA determinations are, however, not standard 
procedure within the ERSPC, Rotterdam, and the value of free PSA in this 
particular group of men remains unclear. 
 
 
Conclusions. 
 
The results of this study did not provide a reason to adjust the screening 
protocol with regard to repeat biopsies in men with an elevated PSA level (4.0 
mg/mL or more) and benign biopsy result. The PPV of the second screening 
visit in men (age younger than 74 years) with a negative biopsy at the first 
screening round was low (8.3%). Through linkage of all eligible men, only one 
additional Pca case (probably missed at initial screening in a man younger 
than 74 years) was found. The screening tests used (PSA, DRE, and TRUS) 
were not useful in predicting the biopsy outcome at repeat screening. 
Additional refinement of the indication for biopsy at repeat screening, 
particularly in this group of men, is necessary. Perhaps the use of PSAV and 
PSADV can be useful. However, at present, the number of cancers detected 
at repeat screening was too small to reach definite conclusions concerning the 
possible use of these predictors for biopsy outcome after 4 years in men with 
an initial PSA level of 4.0 ng/mL or greater and a benign biopsy result.  
 - 96 -
References. 
 
1.  Hodge KK, McNeal JE, Terris MK, et al: Random systematic versus directed ultrasound guided 
transrectal core biopsies  of the prostate.  
J Urol 142: 71–74, 1989. 
2.  Roehl K, Antenor J-A, and Catalona W: Serial biopsy results in prostate cancer screening 
study. J Urol 167: 2435–2439, 2002. 
3.  Rabbani F, Stroumbakis N, Kava BR, et al: Incidence and clinical significance of false-negative 
sextant prostate biopsies. 
J Urol 159: 1247–1250, 1998. 
4.  Stroumbakis N, Cookson MS, and Reuter VE: Clinical significance of repeat sextant biopsies in 
prostate cancer patients. 
Urology 49(suppl 3A): 113–118, 1997. 
5.  Norberg M, Egevad L, Holmberg L, et al: The sextant protocol for ultrasound-guided core 
biopsies of the prostate underestimates the presence of cancer.  
Urology 50: 562–566, 1997. 
6.  Djavan B, Zlotta AR, Ekane S, et al: Is one set of sextant biopsies enough to rule out prostate 
cancer? Influence of transition and total prostate volumes on prostate cancer yield. 
Eur Urol 38: 218–224, 2000. 
7.  Levine MA, Ittman M, Melamed J, et al: Two consecutive sets of transrectal ultrasound guided 
sextant biopsies of the prostate for the detection of prostate cancer.  
J Urol 159: 471–475, 1998. 
8. Borboroglu PG, Stewart W, Comer R, et al: Extensive repeat transrectal ultrasound guided 
prostate biopsy in patients with previous benign sextant biopsies. 
  J Urol 163: 158–162, 2000. 
9.  Fink KG, Hutarew G, Lumper W, et al: Prostate cancer detection with two sets of ten-core 
compared with two sets of sextant biopsies. 
Urology 58: 735–739, 2001. 
10.  Chon CH, Lai FC, McNeal JE, et al: Use of extended systematic sampling in patients with a 
prior negative prostate needle biopsy. 
J Urol 167: 2457–2460, 2002. 
11.  Epstein JI, Walsh PC, and Carter HB: Importance of posterolateral needle biopsies in the 
detection of prostate cancer. 
Urology 57: 1112–1116, 2001. 
12.  Babaian RJ, Toi A, Kamoi K, et al: A comparative analysis of sextant and an extended 11-core 
multisite directed biopsy strategy. 
J Urol 163: 152–157, 2000. 
13.  Djavan B, Zlotta AR, Ekane S, et al: Is one set of sextant biopsies enough to rule out prostate 
cancer? Influence of transition and total prostate volumes on prostate cancer yield. 
Eur Urol 38: 218–224, 2000. 
14.  Etzioni R, Penson DF, Legler JM, et al: Overdiagnosis due to prostate-specific antigen 
screening: lessons from U.S. prostate cancer incidence trends.  
J Natl Cancer Inst 94: 981– 990, 2002. 
15.  Zappa M, Ciatto S, Bonardi R, et al: Overdiagnosis of prostate carcinoma by screening: an 
estimate based on the results of the Florence Screening Pilot Study.  
Ann Oncol 9: 1297–1300, 1998. 
16.  Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific 
antigen screening: estimates from the European Randomized Study of Screening for Prostate 
Cancer. 
J Natl Cancer Inst 95: 868–878, 2003. 
17.  Schro¨ der FH, Roobol-Bouts MJ, Vis AN, et al: Prostate specific antigen-based early detection 
of prostate cancer, validation of screening without rectal examination. 
Urology 57: 83–90, 2001. 
18.  Carroll P, Coely C, McLeod D, et al: Prostate specific antigen (PSA) best practice policy part I: 
early detection and diagnosis of prostate cancer. 
Urology 57: 217–224, 2001. 
19.  Potosky AL, Miller BA, Albertsen PC, et al: The role of increasing detection in the rising 
incidence of prostate cancer. 
JAMA 273: 548–552, 1995. 
20.  Uzzo RG, Wei JT, Waldbaum RS, et al: The influence of prostate size on cancer  
 detection.  
Urology 46: 831–836, 1995. 
21.  Karakiewicz PI, Bazinet M, Aprikian A, et al: Outcome of sextant biopsy according to gland 
volume.  
Urology 49: 55– 59, 1997. 
22.  Feneley MR, Landis P, Simon I, et al: Today men with prostate cancer have larger prostates. 
Urology 56: 839–842, 2000. 
 - 97 -
23.  Rietbergen JB, Kruger AE, Kranse R, et al: Complications of transrectal ultrasound guided 
systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors 
within a population based screening program. 
Urology 49: 875–880, 1997. 
24.  Djavan B, Waldert M, Zlotta A, et al: Safety and morbidity of first and repeat transrectal 
ultrasound guided prostate needle biopsies: results of a prospective European prostate 
cancer detection study.  
J Urol 166: 856–860, 2001. 
25.  Raaijmakers R, Kirkels WJ, Roobol MJ, et al: Complication rates and risk factors of 5802 
transrectal ultrasound guided sextant biopsies within a population based screening program.  
Urology 60: 826–830, 2002. 
26.  Catalona WJ, Beiser JA, and Smith DS: Serum free prostate specific antigen and  prostate 
specific antigen density measurements for predicting cancer in men with prior negative 
prostatic biopsies.  
J Urol 158: 2162–2167, 1997. 
27.  Letran JL, Blase´ AB, Loberiza FR, et al: Repeat ultrasound guided prostate needle biopsy: use 
of free to total PSA ratio in predicting prostatic carcinoma.  
J Urol 160: 426–429, 1998. 
28.  Bangma CH, Kranse R, Blijenberg G, et al: Free and total prostate specific antigen in a 
screened population.  
Br J Urol 79: 756–762, 1997. 

  
 
 
 
 
8.0 
 
A comparison of first and repeat (4 years later) prostate 
cancer screening in a randomized cohort of a-symptomatic 
men aged 55-75 years using a biopsy indication of 3.0 ng/ml 
(results of ERSPC-Rotterdam). 
 
 
 
 
 
 
M.J. Roobol 
F.H. Schröder 
R. Kranse 
 
 
 
 
 
 
 
 
Prostate 2005. 
 
 - 100 -
Abstract. 
 
 
Introduction.  
The identification of predictors for prostate biopsy outcome at two screening 
rounds using a PSA >= 3.0 ng/ml as biopsy indication. 
Materials and Methods.  
We compared predictors by means of descriptive statistics and logistic 
regression analysis in men (55 - 75 years) biopsied in either the 1st or 2nd 
screening round of ERSPC Rotterdam (interval 4 years). 
Results. 
Positive predictors for biopsy outcome in both screening rounds were an 
increased PSA level in the absence of a previous negative biopsy (PrevNB), 
DRE and TRUS suspicious and a positive family history (PFH). A higher than 
median prostate volume was a consistent negative predictor. Having had a 
PrevNB at initial screening strongly reduced the chance of cancer detection at 
repeat screening and in addition canceled the predictive potential of PSA. 
Conclusion.  
If “detecting prostate cancer efficiently” were the aim, this study indicates that 
a “PSA only based biopsy threshold” may be replaced by another criterion 
incorporating e.g. DRE, TRUS and prostate volume in men who were biopsied 
in the preceding 4 year interval. 
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Introduction. 
 
 
The European Randomized Study of Screening for Prostate Cancer (ERSPC) 
[1] was designed to show if a 20% or higher prostate cancer specific mortality 
reduction may be achieved by early detection and treatment of the disease. In 
Rotterdam a cohort of over 40,000 men aged 55-75 years was randomized to 
either the screening or the control arm of the study. Prior to randomization all 
men signed an informed consent. Men randomized to the screening arm have 
been invited to be screened every four years, men randomized to the control 
arm were informed of that fact only. The control arm will be used in the future 
as a reference cohort to study the effect of screening. Screening is a two step 
procedure. First men with a perceived elevated prostate cancer risk are 
identified. This step necessitates at least one visit to the screening center. 
Within ERSPC Rotterdam this pre-selection step is a serum PSA 
measurement.  In men with a biopsy indication (PSA greater than or equal to 
(>=) 3.0 ng/ml) a DRE, TRUS and biopsy is scheduled (lateral sextant biopsy) 
at a 2nd visit (usually within two weeks of the initial visit). 
 
At present we have screened a large cohort of men twice (1st and 2nd 
screening round, 4-year interval) using an identical biopsy indication (PSA >= 
3.0 ng/ml). 
 
The topic of this paper is the predictive value of information that is available 
before a biopsy is taken with respect to its outcome (“cancer” or “no cancer”) 
Due to the study design (identical biopsy indication at initial and repeat 
screening) we are able to study the possible differences in predictive potential 
in the initial and repeat screen of pre-biopsy available source of information. 
Additionally, the availability of second screening round biopsy data in addition 
to first screening round data allows the study of the predictive potential of a 
change in information with respect to biopsy outcome. We focus on the value 
of a change in PSA levels. In addition, we study the impact of “having had a 
previous negative biopsy at the initial screening” on the probability to detect 
the disease at the repeat screen.  
 
 
Materials and Methods. 
 
The total ERSPC Rotterdam study cohort (N = 42,376 men; screening arm 
21,210 men and control arm 21,166 men) and screening algorithm has been 
described previously [2]. The cohort of men for this study ( Fig. 1) comprises 
10191 asymptomatic men aged 55-75 year consecutively screened from May 
1997 until December 1999 for the first time using a PSA >= 3.0 ng/ml as 
biopsy indication (no further testing was done in men with PSA lower than (<) 
3.0 ng/ml).  
 
ERSPC has been approved by the IRB of the Erasmus Medical Center and by 
a national board (required by Dutch law for population screening studies). All 
participants signed an informed consent. 
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Figure 1: Consort diagram of study population at initial screening (May.1997-
Dec. 1999) and repeat screening (May. 2001 -Dec 2003). 
 
 
In the period May 2001 - December 2003 a consecutive cohort of 6220 of 
these men were screened for the second time using the same screening 
protocol (men in whom cancer was detected were not invited for the second 
round screen). Of the 10191 men screened in the first round, 1850 men were 
biopsied because of PSA >= 3.0 ng/ml. Of the 6220 men screened in the 2nd 
screening round 1040 men were biopsied using the same biopsy indication. 
Of these 1040 men 459 men were also biopsied in the first round (no cancer 
was found on that occasion). 
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The predictors for biopsy outcome studied in this paper included: PSA level, 
change in PSA level over time (for 2nd round biopsies only), TRUS estimated 
prostate volume, age, DRE and TRUS outcomes, self reported prostate 
cancer family history and “having had a 1st screen (negative) biopsy” (for 2nd 
round biopsies only). 
 
For the first and second screening round for those men who were biopsied the 
distributions of the predictors and their changes between the initial and 
second screening round were calculated. 
 
In addition two databases were created. The first database (based on 1st 
screening round data only) contained: 
- PSA level >= median PSA level (0 = ‘false’/1 = ‘true’) 
- estimated prostate volume >= median prostate volume (0/1) 
- age >= median age (0/1)  
- DRE outcome (0 (i.e. non suspicious)/1(i.e. suspicious)) 
- TRUS outcomes (0/1)  
- self (i.e. by the participant) reported prostate cancer family history (0 
(i.e. no Pca in family)/1 (i.e. father and/or brother with Pca))  
- biopsy outcome (0 (i.e. no cancer detected)/1 (i.e. cancer detected))  
 
The second database (with only information on men who were biopsied in the 
2nd screening round) contained: 
- PSA as measured in the second screening round >= median PSA 
measured in the first screening round (0/1) 
- increase in PSA level between the first and 2nd screening round >= 
median  increase in PSA level (0/1) 
- 2nd screening round prostate volume >= median 2nd screening round 
prostate volume (0/1) 
- 2nd screening round DRE outcome (0/1) 
- 2nd screening round TRUS outcome (0/1) 
- 2nd screening round age >= median 2nd screening round age (0/1) 
- having had a previous negative biopsy (in the first screening round) (0 
(i.e. no previous negative biopsy) /1 (i.e. previous negative biopsy)) 
- the self reported prostate cancer family history (0/1) 
- Biopsy outcome (0/1) 
 
Two multivariate logistic regression analyses [3] using a backwards deletion 
procedure were carried out (one for the 1st round biopsy data and one for the 
2nd round biopsy data). In the analysis for the 2nd round data interaction terms 
between the predictors and having had a previous negative biopsy were 
included into the model. The backwards deletion procedure used a parameter 
rejection threshold p-value of 0.2. 
To facilitate the study of the predictive potential of PSA levels for both the first 
and 2nd round biopsy data PSA levels were categorized into high and low 
levels compared to the median of PSA levels in the first screening round. In 
order to focus specifically on PSA levels and changes in PSA levels for 2nd 
round biopsy data only they were (separately) categorized as either high or 
low with respect to the median 2nd round levels for men with a comparable 
biopsy history.  
All p-values listed in the paper refer to 2-sided 5% probability thresholds. 
Stata software was used for all analyses. 
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Results. 
 
  
In 2048 of 10191 men entered into the study for the first screening round PSA 
was >= 3.0 ng/ml, in 1850 men a biopsy was actually done (compliance is 
86%). Some men refused to undergo a biopsy others took e.g. anti coagulant 
medication that could not be stopped. Twelvehundred and twelve (1212) of 
6220 men screened in the 2nd round had a PSA >= 3.0 ng/ml of whom 1040 
men were actually biopsied (compliance 86%). In the first screening round 
541 cancers were detected in 1850 biopsies (PPV = 0.29), in the 2nd 
screening round 197 cancers were found with 1040 biopsies (PPV = 0.19). 
The 2nd screening round data can be stratified in 581 biopsies in men not 
previously biopsied (149 cancers detected, PPV = 0.26) and 459 biopsies in 
men previously biopsied (48 cancers detected, PPV = 0.10). A quarter (48 out 
of 197) of all the cancers that were detected in the 2nd screening round was 
detected in men who had a previous negative biopsy (Fig.1).  
At first screening PSA values ranged from 3.0 ng/ml to 218.0 ng/ml, 1038 men 
(56 %) had a PSA level between 3.0 and 5.0 ng/ml. At repeat screening PSA 
values ranged from 3.0 ng/ml to 59.0 ng/ml. The percentage of men with a 
PSA level between 3.0 and 5.0 ng/ml was 82.8 % in men not previously 
biopsied and 39.4 % in men previously biopsied respectively.  Mean prostate 
volume of men biopsied at initial screening was 49.7 ml (95%CI: 48.6 – 50.7 
ml). At repeat screening the mean prostate volume of men not previously 
biopsied was 47.4 ml (95%CI: 36.8 – 58.1 ml) and 50.6 ml (95% CI:   48.7 - 
52.4 ml) for men previously biopsied. 
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Table I.  Overview of binomial predictors for biopsy outcome. Positive and negative 
changes refer to second round screening when compared to first round 
screening. Eg. A positive change (1) occurs if the initial round investigation 
was normal and the second round finding suspicious. 
 
Table I gives information for the categorical variables DRE, TRUS, prostate 
cancer family history and the changes in DRE and TRUS. For all these 
parameters the PPV is listed in the last column.  
Roughly 50% of the men biopsied in the 2nd screening round had a previous 
negative biopsy at the initial screen. Only a quarter of the 2nd round cancers 
were found in these men.   
 
Table II lists the outcomes of the multivariate logistic regression analyses 
(using a backward deletion strategy). The odds ratios (OR) of the parameters 
for 1st and 2nd round screening are in consecutive rows to allow an easy 
comparison. The OR’s show that a positive DRE and TRUS and a positive 
family history are positive predictors for biopsy outcome. The “age parameter” 
does not reach statistical significance for the 2nd screening round data but age 
is a positive predictor for the 1st screening round. Prostate volume is a 
consistent negative predictor for biopsy outcome. Having had a previous 
negative biopsy is a strong negative predictor for biopsy outcome in the 2nd 
screening round. PSA is strong positive predictor in the first screening round. 
In the 2nd screening round PSA is a strong predictor only for those men who 
were not biopsied before due to the significant interaction term (interaction 
with “having had a previous negative biopsy”). The OR for PSA for men 
without a previous negative biopsy is 6.9, it is 6.9 * 0.13 (the interaction term) 
= 0.9 (which is non-significantly different from 1) for men with a previous 
negative biopsy. 
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Table II.   Outcomes of the multivariate logistic regression analysis of 1st and 2nd 
round biopsy data. 
 
Table III illustrates the relative unimportance of PSA and changes in PSA 
levels for predicting the outcomes of 2nd round biopsies, when compared to 
biopsy status (i.e. being biopsied for the first time in the 2nd screening round or 
having had a previous negative biopsy at the initial screening). Having had a 
previous negative biopsy reduces the PPV by a factor 2.5 which is 
considerably more than the 20-25% changes in PPV related to changes in 
PSA level or “changes in PSA” level. With respect to PSA the presence of an 
interaction between PSA levels and having had a previous negative biopsy is 
illustrated by the absence of a predictive potential of high PSA levels for men 
who had a previous negative biopsy. 
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  The table illustrates three facts  
1) having had a previous negative biopsy is a much more important predictor for biopsy outcome 
in the 2nd screening round than having either a relatively high PSA level or having a relatively 
high change in PSA levels. 
2) Having a relatively high PSA level and having a relatively high change in PSA level carry 
almost identical information with respect to biopsy outcome if the previous biopsy variable is 
given. 
3) The predictive effect of having a high PSA level is affected (reduced) on biopsy outcome by 
having had a previous negative biopsy (interaction). 
 
  Ad 1) Having had a previous negative biopsy reduces the PPV more than twofold (0.26 to 0.10).  
  Ad 2) Having a relatively high PSA level in the 2nd screening round increases the PPV (relatively 
marginally) from 23 to 28 %. Having a relatively high change in PSA levels increases the PPV 
from 0.25 to 0.33 (again relatively marginally when compared to the effect of having a previous 
negative biopsy). The increase in PPV of having a high change in PSA over time is 
proportionally smaller in men with a previous negative biopsy (0.09 to 0.12). 
  Ad 3)  The predictive effect of having a relatively high PSA level is absent in men who had a previous 
negative biopsy (0.11 to 0.10 i.e. hardly any effect). 
 
Table III.  Contingency table of PSA level and PSA change in men with and without 
a previous negative biopsy.  
 
 
 
Discussion. 
 
 
We have studied a consecutive cohort of men who were biopsied in ERSPC 
Rotterdam in either the initial screening round or the 2nd screening round 4 
years later. The indication for a sextant biopsy was identical in both screening 
rounds (PSA was greater than or equal to 3.0 ng/ml). The compliance to the 
biopsy indication was equally good (86%) in both the first and second 
screening round. 
 
The observation that more than half of the men who were biopsied have a 
PSA level between 3.0 – 5.0 ng/ml illustrates the importance of the right 
skewedness of the PSA distribution of the general population (i.e. the longest 
tail of the distribution is towards larger PSA values) in relation to the workload 
generated by a given PSA based biopsy indication. Lowering the PSA cut-off 
leads to a larger than proportional increase in the number of men with a 
biopsy indication. 
Higher PSA levels are more prevalent in the 1st screening round. Apparently 
the men who were removed from the cohort in the first screening round with 
high PSA values (because cancer was detected) were not replaced in the 
intervening 4 year period by other men with lower PSA levels at the initial 
screen and high PSA velocities during the interval. Another possible 
explanation for the absence of higher PSA levels in the 2nd round might have 
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been that men with high PSA velocities were clinically detected in the 4 year 
interval (interval cancers). Considering the reported low number of interval 
cancers in ERSPC Rotterdam [4] this latter assumption is very unlikely.  
 
The PSA distribution of men biopsied for the 1st time in the 2nd screening 
round is shifted towards lower PSA values when compared to the PSA 
distribution of men with a previous negative biopsy. Prostate volumes are 
lower in men biopsied in the first screening round when compared to prostate 
volumes in men biopsied in the 2nd screening round. In the group of men who 
were biopsied for the 2nd time the mean change in prostate volume over a four 
year period was 10 ml, st.dev. 13 ml (N = 459). Prostate volumes in men who 
were biopsied twice were considerably larger than prostate volumes in the 
other men who were biospied in the 2nd screening round. This in combination 
with the low PPV in the former group supports the view that these men have 
high PSA levels primarily related to their large prostate volumes (Benign 
Prostatic Hyperplasia) [5]. 
 
Table I shows that both DRE and TRUS have a relatively high PPV but a low 
NPV,  both tests miss many cancers that can be detected by means of a 
biopsy (between 50-80% depending on screening round and having had a 
previous negative biopsy). Family history has a slightly lower PPV and an 
even lower NPV.  
 
The outcomes of the logistic regression analysis (Table II) shows that the 
predictor that was used to select men for a biopsy in the first screening round 
(a PSA >= 3.0 ng/ml) is not an effective predictor for biopsy outcome in the 2nd 
screening round if men were biopsied in the first screening round. Its positive 
predictive properties with respect to biopsy outcome persist (at least 
qualitatively) if a man was not biopsied in the first screening round. Given the 
large spread in confidence interval we doubt whether the difference in OR 
between first and 2nd round PSA parameters (2.3 vs 6.9, Table II) signifies a 
real difference. 
Apparently first round biopsies effectively removed many cancers that were 
related to high PSA levels. These cancers were not or to a very limited extent 
replaced by “new” cancers with relatively high PSA levels in the 4 year 
screening interval. Were this not the case PSA level would have been an 
important predictor for biopsy outcome in the second screening round in men 
previously biopsied.  
 
Interestingly high “increases in PSA with respect to the first screening round 
PSA levels (PSA velocity)” are not a strong predictor for biopsy outcome in the 
2nd screening round (irrespective if a man was biopsied in the 1st screening 
round). This can be appreciated from the logistic regression analysis (Table II, 
increase in PSA is not listed as its p-value was > 0.2 and so it was removed in 
the backwards deletion procedure). This Table highlights the relative 
unimportance of PSA levels and PSA velocity with respect to repeat screen 
biopsy outcome when compared to being biopsied before. In short “PSA 
increase over time” is certainly not a strong predictor for biopsy outcome in 
this pre screened cohort of men.  
 
This contrasts strongly with some reports on the issue [6, 7, 8]. The 
discrepancy may be explained by differences in study setups. Most studies 
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reporting the predictive value of PSA velocity (i.e. PSA2 – PSA1) are based 
on a retrospective analysis of serum bank data and clinically detected cancers. 
In such a setup not all men are biopsied, and amongst men who are biopsied 
the indications for doing so very likely differ considerably. The setup of the 
present study is completely different. All men were biopsied on the condition 
of PSA >= 3.0 ng/ml, i.e. the study is a prospective one. Another possible and 
likely explanation has to do with the type of statistical analysis that was used. 
From Table III it may be concluded that PSA2 – PSA1 is a (rather weak) 
predictor for biopsy outcome, at least in men who were not biopsied before. 
But in appreciating the independent value of PSA velocity we must also take 
into consideration the predictive value that other parameters have given a 
specific PSA velocity value. One such parameter is the PSA level measured 
at the 2nd screening round (this parameter shows a comparably weak 
predictive effect as PSA velocity in men without a previous negative biopsy). If 
this parameter (i.e. PSA level) and the other parameters (previous biopsy, 
volume, DRE, TRUS etc) are jointly taken into consideration (as was done in 
the logistic regression analysis) the predictive value of PSA velocity is virtually 
reduced to zero. Maybe the explanation for the discrepancy is simply related 
to the fact that the studies reporting the effect of PSA velocity did not analyze 
the data in a multivariate fashion. Still another possible explanation for the fact 
that PSA velocity is no predictor for biopsy outcome in an early detection 
setting is related to the pathological characteristics of the cancers detected in 
this study. Postma et al. [9] found that 29% of the cancers detected at repeat 
screening can be classified as focal cancers. Their detection is most probably 
many years before they might become clinically detectable (lead time). Carter 
et al. [6,10] using data from the Baltimore Longitudinal Study of Aging (BLSA) 
found that a cancer specific exponential rise in PSA is observed at the time of 
the first symptoms, i.e. close to the time of clinical detection. Since the 
cancers detected at repeat screening in the ERSPC are in general many 
years before this stage [11] this can be an explanation for the fact that the 
range of PSA velocity values of the cancers detected is comparable to the 
range of PSA velocity values of men with a benign biopsy result. 
If this 3rd explanation holds, PSA velocity is of no additional use in identifying 
men with an elevated risk of having prostate cancer in an early detection 
program but there is the possibility that it may be a valuable tool in identifying 
cancers with possible aggressive characteristics. Within ERSPC-Rotterdam 
studies to confirm this putative relationship between PSA velocity and adverse 
pathological characteristics of the cancers found are ongoing. 
 
Although a direct comparison between the outcomes as reported in this paper for the 
1st screening round data is not possible a recent paper on the same subject yielded 
qualitatively comparable results [12]. We note in this respect that the positive 
predictive properties of a high PSA level combined with the negative predictive 
properties of a high volume equate to a high positive predictive value of PSA density 
(PSA/Volume). 
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Conclusions. 
 
 
In this study we have found that the predictive value of PSA that is a dominant 
predictor for biopsy outcome in men biopsied for the first time loses its 
predictive value in repeat screening in the subgroup of men who were 
biopsied at the initial screening. The PPV in these men is 10% which may be 
considered high or low depending on one’s point of view. It is definitely true 
that having had a previous negative biopsy four years before does not rule out 
the detection of prostate cancer at repeat screening. On the other hand it 
strongly reduces this probability when compared to men who are biopsied 
using the same PSA related biopsy threshold and who were not biopsied 
before. 
The present analysis indicates the following: 
1) prostate cancer is a common disease (many cancers can be found, 
even at relatively low PSA values and even after a previous negative 
biopsy) 
2) It is hard to detect all cancers by means of one screening test. In 
repeat screening cancers are even harder to detect by means of one 
screening test than at the initial screen. 
3) If finding prostate cancer efficiently were the aim the analysis of the 
predictors for biopsy outcome in repeat screens indicates that it may 
make sense to include “having had a previous negative biopsy” and 
e.g. estimated prostate volume, DRE and TRUS outcomes and 
positive family history in the indication for a repeat screen biopsy. 
Such a modified biopsy criterion would very likely detect quite a few 
other cancers than the ones presently detected with fewer biopsies. 
Other cancers (those that are currently detected at low PPV’s) will be 
missed.  
Here it must be kept in mind that the conclusions drawn above extend to a 
PSA range that was not studied in this paper (biopsies done in men with a 
PSA <= 3.0 ng/ml). Whether or not a man with a PSA level between 2.0 – 3.0 
ng/ml, a small prostate volume and a suspicious DRE and TRUS is indeed 
more likely to have prostate cancer than a man with a PSA level of eg. 6.0 
ng/ml, a normal prostate volume and a previous negative biopsy remains to 
be shown. 
In view of the above mentioned future biopsy protocols may instead of being 
PSA- threshold based, “detection probability based”. Such protocols would 
minimize the number of negative biopsies at a given PPV (which is the 
probability threshold used).  The use of such a biopsy protocol requires that in 
addition to PSA, prostate volume, DRE and TRUS have to be determined for 
every man. Alternatively the following hybrid approach is feasible: In men 
without a previous negative biopsy PSA >=3.0 ng/ml is used as a biopsy 
indication. In men with a previous negative biopsy and a PSA >= 3.0 ng/ml the 
probability of cancer detection is calculated and a probability threshold based 
biopsy indication is used. It seems logical to set this threshold equal to the 
PPV of the PSA >= 3 ng/ml biopsy indication (which is roughly 20%). At 
present a nomogram is being developed to aid in the calculation the prostate 
cancer detection probability (as an easy to use alternative for the logistic 
regression model that is presented in this paper).  
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Until the ongoing randomized studies have finished the analysis of the primary 
study endpoint (the achievement of a significant prostate cancer mortality 
reduction by screening) we will not know for sure whether, and if so, which 
cancers may be missed or need to be found. In the future knowledge of 
predictors for biopsy outcome may however be of value to optimize screening 
procedures. Especially for prostate cancer such optimization seems 
particularly important as at present it is evident that many more cancers will 
be detected by screening than expected on the basis of pre PSA screening 
prostate cancer incidence statistics (overdiagnosis).  
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Introduction. 
Four pilot studies were conducted in Rotterdam, The Netherlands, prior to the 
initiation of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). The main purpose of these studies was to establish the feasibility of 
randomization and of the testing procedures. The pilot studies were not part of 
the ERSPC, and they were not carried out according to a predesigned 
evaluation plan. Here, we present the data from these trials in an effort to 
prevent publication bias. 
 
Material and Methods. 
The four pilot studies were conducted from October 24, 1991, to November 
30, 1993; a total of 2367 men aged 55 – 75 years were identified in the 
population registry, invited to participate, and, after providing written informed 
consent, randomly assigned to receive screening for prostate cancer or no 
screening (control group). Screening procedures varied among the four pilot 
studies and are reported in detail elsewhere [1]. All protocols were approved 
by the local medical ethical committee. Men who reported that they had been 
diagnosed with prostate cancer were excluded. Men who were randomly 
assigned to screening were tested by determination of their serum level of 
prostate- specific antigen (PSA), a digital rectal examination, and transrectal 
ultrasonography. Biopsy indications differed among the four pilot studies. 
 
Results. 
A total of 2367 (38%) of the 6229 invited men agreed to be randomly 
assigned, and 94.5% of men who had an indication for biopsy underwent the 
procedure. This proportion varied only slightly between the initial screening 
and rescreening, which took place at 4-year intervals. Rectal examination and 
transrectal ultrasonography were not used in the second and third rounds of 
screening; instead, participants were offered lateralized sextant biopsies if 
their serum PSA value was 3.0 ng/mL or higher [2,3]. Selected data are 
shown in Table 1 . Of the 111 prostate cancers found in men who were 
randomly assigned to screening, 16 were interval cancers, six occurred in 
men who were not compliant with biopsy indications during the second or third 
rounds of screening, and 89 were detected by screening. Interval cancers 
were defined as cancers found during the screening intervals or within the 4 
years after men who had complied with the screening protocol had passed the 
75-year age limit. The 16 interval cancers were equally distributed over the 
approximately 10 years of the total study period. 
This follow-up period is the same as that envisaged for the ERSPC as a 
whole.  
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Table I:  Results of pilot studies 1 – 4 of ERSPC, Rotterdam, with median and 
average follow-ups of 11.1 years and 9.9 years, respectively * 
 
 
Diagnoses of prostate cancer among men in the control arm were based on 
cancer registry data and were confirmed by chart review. The differences in 
treatment between the screening and control arms reflect, in large part, the 
different stage distributions of prostate cancers in the two arms. The death 
rate from any cause was not statistically significantly different between the 
screening and control arms. Prostate cancer deaths were verified by an 
independent committee whose members were blinded with respect to the 
randomization assignment. There were 12 verified prostate cancer deaths in 
the control arm and three in the screening arm. In each of the arms, one 
patient is still alive with clinically diagnosed metastatic disease. Statistical 
testing was not applied to the reported data because of the obvious lack of 
statistical power.  
 
 
Conclusion. 
 
Nonetheless, these data support the continuation of the European 
Randomized Study of Screening for Prostate Cancer [4] by international study 
groups in eight European countries in the hope that it will ultimately prove the 
efficacy of prostate cancer screening and establish a useful preventive 
regimen for men at risk of this disease.  
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Population based screening for prostate cancer has not been adopted in most 
health care systems because of the uncertainty regarding its efficacy in 
decreasing prostate cancer specific mortality at an acceptable effect on quality 
of life and cost. Several studies have been undertaken to determine the 
validity of mass screening [1, 2, 3, 4]. One of these studies is the “European 
Randomized study of Screening for Prostate Cancer (ERSPC) which apart 
from addressing the main endpoint (prostate cancer mortality), aims to 
improve the test procedures used for early detection of prostate cancer. 
In a population based setting, where many participants and considerable 
amounts of money are involved, specificity is a crucial issue. This thesis 
focuses on the ability of the available screening tests in ERSPC (section 
Rotterdam) to discriminate between men with or without an elevated risk of 
having prostate cancer and upon their screening algorithm. 
 
Chapter 2 provides an overview of problems and controversies of screening 
for prostate cancer, the anatomy of the prostate, certain aspects of prostate 
cancer (epidemiology, staging and grading), and available screening tests and 
applicable statistical techniques. 
 
Chapter 3 describes the different screening protocols and the first round 
screening results of ERSPC (section Rotterdam).  
At initial screening the cancer detection rate and PPV increased with 
increasing PSA level. In other words PSA is a positive predictor for the 
frequency of a positive biopsy outcome. In fact PSA was the best positive 
predictor for biopsy outcome ( cancer yes or no) in men screened for the first 
time [5, 6, 7] when comparing DRE, TRUS and serum PSA level. This is also 
confirmed in other studies [8, 9]. The PPV of the sextant biopsy in men with 
PSA levels above 4.0 ng/ml was acceptable (3.6 biopsies to detect one case 
of prostate cancer) Using PSA derivatives improved the specificity to some 
degree, but, as specificity and sensitivity are generally inversely related, 
always resulted in a more complicated screening algorithm and a loss of 
detectable cancers [10, 11].  
The positive predictive value of the sextant biopsy at low PSA levels was also 
a topic of several studies at the initial screening round (1991 – 1999). Already 
in 1993/1994 it became clear that DRE and/or TRUS had very low PPV’s in 
men with PSA levels < 2.0 ng/ml [12]. By the end of the year 1995, when data 
of app. 11,500 men were available it became evident that screening with DRE 
and/or TRUS in men with PSA levels < 1.0 ng/ml was very inefficient (43 
sextant biopsies were necessary to detect one prostate cancer). From that 
point in time men with PSA levels < 1.0 ng/ml were not screened any further 
and were reinvited four years later [5]. This resulted in many less DRE/TRUS 
examinations and biopsy procedures and, as mentioned earlier, in a 
considerable increase in the recruitment rate.  
A major change in the screening algorithm was introduced in May 1997 after 
studies were completed on the effect of changing the PSA threshold for 
biopsy indication. The high PPV of the sextant biopsy at the PSA range 3.0 – 
3.9 ng/ml, the overall cancer detection rate and the favourable tumor 
characteristics of cancers found by DRE at low PSA levels were the 
justifications for the change [7, 13, 14, 15, 16]. DRE and TRUS were omitted 
as screening tests and the PSA threshold was lowered to a cut off of 3.0 ng/ml.  
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If a screening program is applied to the whole population a basic requirement 
is of course an acceptable participation rate. This will be measured against 
the costs involved in setting up such a program. The participation rate in 
ERSPC Rotterdam was 47.9% which may give rise to concern about the 
feasibility of a population based screening program. It must however be kept 
in mind that this participation rate is the result of a recruitment procedure 
where it is obligatory by law to obtain informed consent before randomization. 
In other ERSPC centers where this is not a requirement participation rates in 
men allocated to screening are considerably higher (60.0 - 70.1 %)[1]. The 
latter type of recruitment is more comparable to a situation where prostate 
cancer screening becomes population based. 
The motives for attending or not attending the screening study [17, 18] were 
evaluated. Urological complaints as a reason for attending or not were part of 
the motives and men recruited for the trial turned out to be healthier than men 
in the target population [19].  
Therefore although the data of the trial may not be automatically generalizable 
to the whole population, they may be considered representative of those who 
readily participate in a population based screening program [20]. If prostate 
cancer will become population based a good health education of the general 
population with regard to having urological complaints and attending 
screening will be of great importance. 
 
It is obvious from the Rotterdam data that participation rates are influenced 
not only by the randomization procedure and screening tests offered but also 
by the screening algorithm. Minimizing the number of visits to a screening 
centre by using peripheral screening locations and making the screening 
algorithm a stepwise procedure resulted in a considerable increase of the 
recruitment rate. Obviously the knowledge that one may belong to a group in 
whom no further testing is necessary at this point in time lowers the barrier to 
participate in a screening program.  
 
 
Chapter 4 describes the comparison of cancer detection rates of the “old 
screening protocol” (DRE and/or TRUS as screening test at PSA <= 4.0 ng/ml) 
and the “new screening protocol” (PSA cut off >= 3.0 ng/ml, data of 7,943 
men). As predicted in the studies mentioned above the overall detection rate 
remained almost unchanged (5.0 % vs. 4.7% in the new screening protocol). 
In the old protocol 6.4% of all cancers detected were found (with DRE/TRUS) 
in the PSA range 3.0 – 3.9 ng/ml. In the new protocol this percentage was 
18%, an almost threefold increase.  
After completion of the first screening round (December 1999) the complete 
numbers were respectively: 10191 men screened according to the new 
protocol, with an overall cancer detection rate of 5.3%. The PPV of the PSA 
range 3.0 – 3.9 ng/ml was 21.8%. Twenty five percent of all cancers detected 
in this new protocol were detected in the PSA range 3.0 – 3.9 ng/ml. Omitting 
DRE and TRUS as screening tests and lowering the PSA cut off level did not 
result in detecting fewer prostate cancers, in fact the overall cancer detection 
rate increased as more cancers were found at the relatively low PSA values of 
3.0 – 3.9 ng/ml.  
A point of concern within the new protocol was the increase in men refusing 
the biopsy procedure. In the old screening protocol 10.7 % of the men eligible 
for biopsy refused. In the new screening protocol this percentage increased to 
 - 123 -
16.1%. However, complete data of the initial screening round, and thus 
eliminating the effect of a delay in biopsy processing, showed a refusal rate of 
12.0 %, comparable to the rate at the old screening protocol.  
A protocol change which permits the missing of otherwise detectable tumors 
must be carefully monitored, because it could result in missing cancers with 
the potential to contribute to the reduction in disease specific mortality. 
Vis et al. [21] compared tumor characteristics of cancers found with and 
without rectal examination at low PSA levels. The tumors were categorized 
according to a predictive model, which included pathological tumor stage, 
tumor volume and the proportion of high grade cancer [22]. In this model 
minimal tumors were defined as small ( < 0.5 ml), organ-confined, without 
Gleason pattern 4 and 5, whereas advanced cancers were tumors invading 
adjacent organs , cancers of >= 1.0 ml in tumor volume extending through the 
prostatic capsule and/or tumors containing large amounts (>= 0.5 ml) of  
poorly differentiated cancer (Gleason pattern 4 or 5). All cancers with tumor 
characteristics in between were classified as moderate (i.e. potentially 
aggressive and curable) disease. Subsequently moderate and advanced 
cases were classified as clinically significant. Vis found that when DRE and 
TRUS were used as initial screening tests at low PSA levels the proportion of 
cancers detected with any poorly differentiated components (i.e. Gleason 
scores 7 to 10) in the biopsy specimen, increased from 0% in men with PSA 
levels between 0.0 – 1.0 ng/ml, 18.6% in the PSA range 1.0 -1.9 ng/ml, to 
37% in the PSA range 2.0 – 2.9 ng/ml and even 44.2% in the PSA range 3.0 – 
3.9 ng/ml.  
A suspicious DRE and/or TRUS led to the detection of significantly more 
moderately and poorly differentiated cancers (as determined on the biopsy) 
than PSA based screening. This conclusion was based on the comparison of 
the two different screening protocols in the PSA range 3.0 – 3.9 ng/ml. The 
percentage of cancers detected with Gleason score 7 to 10 in the old protocol 
(biopsy DRE and/or TRUS driven) was as noted 44.2 % compared to 18.2% in 
the PSA driven biopsy protocol.  
A low rate of aggressive cancers was also seen in a side study done during 
the second screening round [23]. During a period of 20 months, men with a 
PSA level between 2.0 – 2.9 ng/ml (n= 576) were also systematically biopsied. 
This resulted in the detection of 75 cancers (cancer detection rate 13.0 %) of 
which only 6.7 % had a Gleason score of 7 or more.  
The percentages of clinically significant cancers mentioned above however do 
not reflect the number of men screened necessary to detect these clinically 
significant cancers. Relating the number of cancers to the total number of men 
screened in these low PSA ranges results in the following numbers: In the 
PSA range 1.0 – 1.9 ng/ml 3051 men were screened with DRE/TRUS, 511 
men were biopsied (335 men had abnormal DRE), 43 cancers were 
diagnosed of which 8 had a Gleason score of >= 7. This implies that the 
cancer detection rate of clinically significant cancers found with DRE and/or 
TRUS is 8/3051 = 0.26 % in men with PSA levels between 1.0 – 1.9 ng/ml. 
For the PSA ranges 2.0 – 2.9 ng/ml and 3.0 – 3.9 ng/ml this figure is res. 0.83 
% and 3.0 %.  
These studies show that clinically significant cancers are present at low PSA 
ranges ( especially in the PSA range 3.0 – 3.9 ng/ml) but when DRE was used 
as biopsy indication; the ability to detect these potentially aggressive tumors 
was extremely low (289 rectal examinations were required to detect one case 
of clinically significant disease). 
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These findings are comparable to a study of Carvalhal et al [24]. This group 
examined biopsy results of 1905 men with a PSA <= 4.0 ng/ml and a 
suspicious DRE.  244 cancers were detected (13%); all cases were clinically 
localized and 62% had moderately differentiated biopsy Gleason scores (5-7). 
3% of the cancer cases were poorly differentiated (Gleason scores of 8-10). 
The PPV of the DRE increased with increasing PSA levels from 5% in the 
PSA range 0.0 – 1.0 ng/ml to 14.2% in the PSA range 1.1 – 2.5 ng/ml. They 
conclude that DRE may detect tumors that have histopathological features of 
clinically important and still curable disease in men with low PSA levels. The 
PPV of the DRE is considered sufficiently high at PSA levels > 1.0 ng/ml to 
continue the use of DRE with PSA testing for the early detection of prostate 
cancer. 
Additional evidence of the presence of clinically significant prostate cancers at 
low PSA levels came from a study of Thompson et al [25].  In a side-study of 
the Prostate Cancer Prevention Trial (PCPT) they considered the prevalence 
of prostate cancer among 2950 men randomized to the placebo group. These 
participants had a PSA < 3.0 ng/ml at entry and during the seven-year study 
period never had a PSA value =>4.0 ng/ml or an abnormal DRE (measured 
and examined annually). At the end of the study all these men underwent 
prostate biopsy (sextant biopsy technique). Prostate cancer was diagnosed in 
15.2% of the participants, of whom 14.9% had a Gleason score >=7. The 
prevalence of prostate cancer increased with the PSA level (from 7% at PSA 
<= 0.5 ng/ml to 27% at PSA 3.1-4.0 ng/ml). The prevalence of high-grade 
cancers also increased with the PSA level from 12.5% (PSA <= 0.5 ng/ml) to 
25.0% (PSA 3.1 to 4.0 ng/ml).  
It was concluded that biopsy-detected prostate cancer, including high-grade 
cancer, is not rare among men with PSA value <= 4.0 ng/ml and even in men 
with PSA values below 2.0 ng/ml. However it is important to relate the number 
of high grade cancers to the total number of men in the different PSA ranges. 
In the PSA range < 0.5 ng/ml, 4 high grade cancers were found in a total of 
486 men (0.82%) and in the PSA range 3.1 – 4.0 ng/ml this percentage was 
6.7% (13/193). 
Within ERSPC Rotterdam 69% of the men had a PSA <= 2.0 ng/ml. Knowing 
that approximately 44-83% of men in the age range 55 – 79 years have latent 
prostate cancer [26] it is very possible that these small cancers, even if they 
are Gleason grade >= 7, can be detected later in time still in a curable stage 
(chapter 6).  
Data on detection rates and tumor characteristics of cancers detected in the 
second round (4 years later) or perhaps even better in the third round of 
screening (8 years later) differentiating between the two different initial 
protocols will give more answers on the effect of omitting DRE as a screening 
test at low PSA levels. So far results show no increased interval cancer rate, 
nor an increase in poorly differentiated cancers detected at repeat screening 
when comparing men screened during the initial round with the “old protocol” 
and the “new protocol” [27]. 
 
The question remains why these cancers do not cause an elevated PSA level.  
A study by Sokoloff et al. [28] showed that prostatectomy specimens of men 
with a pre-operative PSA < 4.0 ng/ml or PSA > 4.0 ng/ml were impossible to 
differentiate on immunohistological staining for tissue-PSA. The intensity of 
PSA staining in the radical prostatectomy specimens was identical, implying 
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that tissue-PSA production was comparable. Why then are the serum PSA 
levels different? 
In men with normal prostates only small amounts of serum PSA are 
detectable. However, for men with prostatic disease serum PSA is often 
elevated. On average normal prostatic epithelium contributes 0.1 ng/ml/gm 
tissue to serum PSA. Corresponding figures for BPH tissue and cancer tissue 
have been estimated to be 0.3 and 3.5 ng/ml/gm respectively. Furthermore it 
is known that tissue PSA (being 106 times as high as serum PSA levels) 
decreases and serum PSA increases with increasing tumor volume and 
cytological grade [29,30].  
Using tissue from fine needle biopsies Stege et al. [31] also found this 
negative association between serum PSA and tissue PSA and concluded that 
serum PSA values mainly reflect the degree of leakage from the tumor tissue 
rather than the intracellular concentration of PSA. Factors such as tumor 
volume, gland structure, and vascularization may thus be more important than 
the production of PSA in the prostatic tissue. It is very possible that a small 
high graded tumor causes no serum PSA elevation simply because the gland 
structure is not (yet) disrupted by tumor growth. This latter observation was 
confirmed by comparing tumor volumes and serum PSA levels in radical 
prostatectomy specimens of cancers detected at the initial and repeat 
screening visits in ERSPC Rotterdam [32]. This study showed a significant 
relationship between PSA level at diagnosis and tumor volume in the radical 
prostatectomy specimen. At a PSA level of 3.0 ng/ml the mean tumor volume 
was 0.32 ml while at a PSA level of 10.0 ng/ml or higher the mean tumor 
volume was 1.06 ml (data from initial screening).   
 
The observer dependent character of the DRE and low PPV at low PSA levels, 
together with the knowledge that prostate cancers amenable for curable 
treatment are present in this PSA range [14] makes a more specific and 
objective screening test desirable. Fang et al [33] suggested that the PSA 
velocity could be of use in men with low PSA levels.  
 
Chapter 5 is the result of two side studies done during the second screening 
round of ERSPC (Rotterdam). The value of the PSA velocity (calculated with 
the PSA levels of the initial and second screening) as a predictor for biopsy 
outcome in men with low PSA levels was retrospectively assessed. This study 
again showed that the risk of biopsy detectable prostate cancer in these low 
PSA ranges (PSA < 4.0 ng/ml) was high, with an overall PPV of 19.3%. PSA 
velocity however was, in this dataset, not a significant predictor for biopsy 
outcome. When using a PSA velocity cut-off of > 0.1 ng/ml/yr the relative 
sensitivity would have been 85.2% with a relative specificity of only 17.9%. 
These observations were confirmed by a study of the rate of four year PSA 
progression from an initial value < 3.0 ng/ml towards the cut off point of 3.0 
ng/ml (Schröder et al. [34]). From this study it became clear that the most 
pronounced PSA increase e.g. from 0.0 – 0.9 to > 3.0 ng/ml in the 4-year 
interval was not associated with a higher PPV.  
Our observations on PSA velocity are not in line with the observations by 
Carter et al. and Fang [33, 35] from the Baltimore Longitudinal Study of Aging 
(BLSA). The most plausible explanation for this difference is the difference in 
the two study populations. Cancer cases in the ERSPC study were detected 
by a PSA driven protocol (n= 149), whereas the cancer cases in the BLSA 
study (n= 21) were either clinically detected or detected by an abnormal DRE.  
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Prostate cancer is a disease with a relatively long pre clinical detectable 
phase. This is the time between the first detectable patho-physiologic change 
( e.g. an elevation of the serum PSA level) and the first symptoms and or 
signs ( e.g. a palpable nodule). Using data from the Finnish arm of the 
ERSPC the mean duration of the pre clinical detectable phase was estimated 
to be 10-14 years [36]. 
Data from the Baltimore Longitudinal Study of Aging (BLSA) showed that men 
with BPH have a linear or moderate exponential increase in PSA level with 
time, whereas patients with prostate cancer have a similar linear or moderate 
exponential increase with a subsequent exponential increase in PSA level at 
the time of the first symptoms i.e. the time of clinical detection [37,38]. PSA 
based early detection results in an advance of the diagnosis by many years. 
This so called lead time is on average at least half of the time of the preclinical 
detectable phase or less than one half because more easily diagnoseable 
larger tumors are likely to occur toward the end of this period. Its estimations 
vary from 5 – 7 years [36,39] to 11 years [40], depending on the histological 
grade of the tumor and age of the patient at time of diagnosis. This would 
mean that the cancers detected by screening are on average detected before 
the exponential, cancer specific, increase of the PSA level. (figure 4) 
This hypothesis is further confirmed by a univariate analysis of the Rotterdam 
data where the outcome variable was not cancer yes or no, but no cancer 
versus cancer stage T2C or higher and/or Gleason score 7 or higher (where it 
is assumed that the latter group reflects a more clinical situation). In this 
analysis, PSA velocity had an odds ratio > 1.0 and was significant. This 
significance is however lost in a multivariate setting (unpublished results). 
 
 
 
Figure 4: PSA course in prostate cancer and BPH 
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These findings together with the considerable intra individual biological 
variation [41, 42, 43, 44], resulting in the necessity of long term sampling and 
preferably three consecutive measurements for a reliable calculation of the 
PSA velocity [43] makes PSA velocity less suitable as a screening test for 
prostate cancer in a population based setting.   
It must however be noted that the proper way to assess the value of PSA 
velocity in identifying men with an elevated risk of having prostate cancer is to 
use a PSA velocity cut off as the indication for biopsy in an unscreened 
population preferably starting at a younger age.  
PSA velocity or doubling time was shown to be of value in men already 
diagnosed with prostate cancer and treated with radical prostatectomy or 
expectant management. In the first case DÁmico et al. [45] reported that the 
preoperative PSA velocity predicts the risk of dying of prostate cancer after 
radical prostatectomy and that this measurement may be used to enhance the 
identification of aggressive prostate cancer. Expectant management of 
localized prostate cancer has evolved during the last decade as a treatment 
option because screening and biopsy sampling strategies were shown to lead 
to a large amount of overdiagnosis. PSA velocity or PSA doubling time may 
improve the identification of men who are likely to have a low rate of 
progression at repeat biopsy and rendering them eligible for continuing 
expectant management [46].  
 
The omission of further screening in men with PSA levels < 1.0 ng/ml was a 
protocol change that could have resulted in missing cancers that can be life 
threatening when not detected whilst in an organ confined state.  
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Chapter 6 describes the results of screening of men with a PSA level <= 1.0 
ng/ml at initial screening after an 8 year follow-up period (n = 1703). In two 
subsequent screening visits 47 men had a PSA increase above the cut off 
level of 3.0 ng/ml ( 2.8%) and 8 cancers were detected (0.47%). More 
importantly no additional clinically detected cancer arose during the 8 years. 
Omitting further screening, at least for 8 years, in men with PSA levels <= 1.0 
ng/ml implies a minimal risk of missing aggressive cancers in a curable state. 
This study again confirms the observations mentioned earlier: PSA 
progression in men with very low PSA levels is rare, but cancer and clinically 
significant cancer is, although in low percentages, present at these low PSA 
ranges. PSA velocity is of no additional value in this cohort of men.  
Delaying the biopsy procedure until PSA increases to a certain cut off value, 
saves a lot of unnecessary biopsies, but does not seem to lead to an increase 
in the detection of incurable prostate cancer cases. Searching for effective 
prostate cancer screening tests, especially in men with these very low PSA 
levels (which represent 42% of the screening cohort!), is important. Testing 
should in the future become more selective for those cancers with aggressive 
features to further decrease the rate of biopsies, their complications and over 
diagnosis. One can estimate that the lifetime risk for prostate cancer would be 
even greater than the present 16 % in the US, if all men with a PSA > 1.0 
ng/ml were biopsied [47]. 
These data together with the data presented in the PSA progression paper [34] 
suggest that the ERSPC can give an answer to the issue of detection of 
cancers with aggressive patterns as seen in the end of study biopsies done in 
the placebo arm of the PCPT [25]. The available data suggest that it is an 
option to observe men with very low PSA values until they reach a biopsy 
threshold of 3.0 ng/ml. 
 
Another concern within a prostate cancer screening program are those men 
who fulfill the criteria for further investigation (in this case an elevated PSA 
level) and are actually biopsied, but have a benign biopsy result. Knowing that 
the sextant biopsy procedure is not 100% sensitive, one must consider the 
appropriateness of the sextant technique and the dilemma of re-biopsying.  
Many studies have dealt with these topics. Computerized biopsy simulations 
on a series of radical prostatectomy specimens showed that the chance of 
missing a cancer by sextant biopsy is about 25% [48]. This knowledge 
resulted in the development of refinements to the sextant biopsy technique. 
Biopsies should be directed more laterally [49, 50], perhaps with eight [51], 
thirteen [52] or even 18 or more cores [53,54,55,56]. 
Prostate volume became an issue in determining the adequate number of 
cores, as the relative amount of gland that is sampled is determined by the 
size of the prostate. Two groups [57,58] retrospectively found that the 
systematic sextant biopsy in larger prostates detected significantly fewer 
tumors than in smaller prostates. Computer generated models and 
nomograms were developed to predict the appropriate number of biopsies for 
a given volume [59,60].  
While midline biopsy cores have been shown to be the least frequently 
affected by prostate cancer, lateral biopsies, directed towards apex and base 
combined with standard sextant biopsies are currently used by most urological 
centers. 
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If, despite the number of biopsy cores taken, the result of the biopsy is still 
benign there is always the option of repeating the biopsy session. Several 
studies have addressed this topic [61, 62, 63, 64, 65, 66, 67]. Overall, 
between 10 and 34% of men (depending on the particular features of the 
patient and type of biopsy) are found to have cancer on a second TRUS 
biopsy after an initially negative biopsy. A third and fourth sequential biopsy 
identified 5% additional cancers [68]. 
All studies have drawn a more or less similar conclusion: increasing the 
number of biopsy cores and biopsy sessions increases the cancer detection. 
The critical question is whether the cancers detected with increasing number 
of cores or sessions are clinically significant and need to be detected at this 
point in time, later or at all. 
ERSPC data have the potential to investigate the effect of not taking more 
cores and not performing immediate repeat biopsy procedures, since the 
protocol with regard to the number of cores and the indication for repeat 
biopsy (dubious malignant or high grade PIN) has not changed since the start 
of the study. 
 
This issue of repeat biopsy sessions is addressed in Chapter 7 which reports 
on a cohort of men (n = 272) biopsied for the second time after a benign 
biopsy result four years earlier (sextant technique). If the technique of 
lateralized sextant biopsies and the policy of not performing an immediate re- 
biopsy would be ineffective this should result in a considerable number of  
(advanced) interval cancers or an increased detection rate and/or more 
advanced cancers at repeat screening four years later.  The PPV at 4-year 
repeat screening was 8.3 % (all cancers detected, except one, were organ 
confined). The number of interval cancers was certainly not negligible (8 
cases in 312 men = 2.6%) but they were mainly found in men older than 74 
years of age and in men who had refused biopsy at initial screening.  
The data confirm the importance of prostate volume as a negative predictor. 
Men with a benign biopsy result had significantly larger prostate volumes 
which could indicate that the sextant technique misses cancer in this cohort of 
men. However making decisions on more biopsy cores or repeated biopsies 
based on an elevated PSA level and prostate volume will also imply more 
unnessecary biopsy sessions in a group of men with a persistently elevated 
PSA level caused by BPH.  
Again refinement of the screening algorithm is desirable and data presented in 
chapter 7 (based on low numbers) show the possible use of PSA velocity, but 
perhaps even more specific for this particular cohort of men, the PSA density 
velocity.  
With the completion of the second screening round in December 2003 more 
data became available. Analysis of a data set of 434 men with an initial PSA 
>= 4.0 ng/ml and a benign biopsy result and a biopsy indication at second 
round screening resulted in the detection of 46 cancers (PPV = 10.6%). The 
change in PSA values (PSA velocity, ng/ml/yr) and PSA density values (PSAD 
velocity, ng/ml2/yr) in the 4 year interval were significantly different res. p= 
0.037 and 0.038 (Mann-Whitney U test). Between the first and second screen 
however the overlap in values between cancer and non-cancer cases was 
considerable. These data indicate that PSA, PSA velocity and PSAD velocity, 
despite the significant differences shown, have no real discriminating effect 
between cancer or no cancer ( determined by a lateralized sextant biopsy) in 
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this particular cohort of men (unpublished results). These results are similar to 
an earlier published study of Hayek et al [69].  
As mentioned it was not possible to evaluate free PSA as a possible predictor 
for biopsy outcome. 
 
The free/total PSA ratio (F/T ratio) to discriminate BPH from cancer is a 
concept extensively investigated in the past few years. Total PSA consists of 
Complex PSA (cPSA) and Free PSA (fPSA). cPSA is  serum PSA that is 
bound to circulating proteins, usually alpha-1-antichymotrypsin. The 
remainder is classified as fPSA. It has been shown that the proportion of 
circulating cPSA is higher in patients with carcinoma than in those with BPH 
[70]. Studies comparing the diagnostic efficacy of cPSA with total PSA and the 
free to total (F/T) ratio report diverging results. Superior performance for cPSA 
over total PSA or the F/T ratio [71, 72], superiority of cPSA over total PSA, but 
not over the F/T ratio [73], equivalence of cPSA with total PSA and the F/T 
ratio [74], as well as equivalence of cPSA with total PSA but superiority of the 
F/T ratio over cPSA [75] have all been reported. 
Within ERSPC the value of the F/T ratio was also been examined during a 
certain period. Bangma et al. [11] found that with the application of a threshold 
of 0.20 the number of biopsies would have increased substantially, especially 
in the PSA range below 4.0 ng/ml.  The use of an F/T ratio for men with a total 
PSA of 4.0 ng/ml or higher would miss 11% of the cancers and reduce the 
number of biopsies by 37%. The Swiss group of ERSPC looked at men with 
PSA levels between 1-3 ng/ml and a F/T ratio of 0.20 or less. They found an 
almost identical F/T ratio in men with or without cancer [76]. Hugosson et al. 
[77] found that in a cohort of men with a PSA level >= 3.0 ng/ml, the use of a  
F/T ratio < 0.22 cut off level decreased the number of unnecessary biopsies 
31%.   
The Italian center of ERSPC [78] concluded, on the basis of their screening 
data, that the F/T ratio was not a reliable predictor for biopsy outcome. Using 
different F/T ratio cut-off values indeed could reduce the number of benign 
biopsies but as a result would lead to missing a comparable percentage of 
prostate cancer cases. In the Dutch center free PSA was also measured 
during a certain time period at repeat screening in men with total PSA values 
of 2.0 – 3.9 ng/ml. This study [79] suggested a moderate role for the F/T ratio 
in avoiding benign biopsies but confirmed that the F/T ratio was predictive in 
assessing tumor aggressiveness. This observation is similar to the study of 
Khan et al [46].  
 
Also the F/T ratio may be of use in men with a previous negative biopsy. 
Catalona et al. [80] concluded that using a free PSA cut-off of less than 25%, 
twenty percent of unnecessary biopsies could be prevented with a loss of 5% 
of detectable cancers. Djavan et al. [81] used a cut-off of 30% and could 
eliminate 50% of the biopsies while detecting 90% of the cancers. 
In addition to the very divergent results in prostate cancer screening the 
concept of F/T ratio has several other flaws. Pre-analytical and clinical factors 
may influence the F/T ratio, e.g. instability of free PSA both at 4°C and at 
room temperature, assay characteristics, and a dilution effect in large 
prostates due to concomitant BPH.  
Processing of free PSA to complex PSA is different during the release of PSA 
from benign and malignant tissue [82, 83]. This makes a specific 
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determination of various forms of free PSA in serum a potential way to 
improve the specificity of prostate cancer detection. So far assays for the 
different forms of free PSA are not generally available and are thus not suited 
for a population based screening setting at this point in time. 
 
Human glandular kallikrein 2 (hK2) and PSA (human kallikrein 3), belong to 
the human tissue kallikrein family. It has been reported that hk2 expression 
increases incrementally during the change from benign prostatic epithelium to 
primary cancer and lymph node metastasis [84]. Several studies have been 
done to establish the value of hk2 in prostate cancer detection. Kwiatkowski 
and Recker reported a significant difference in hk2 level between prostate 
cancer cases ( 0.135 ng/ml) and BPH (0.09 ng/ml) in men with PSA levels of 
4.0 – 10.0 ng/ml. Also specificity of the ratio of hk2 to free PSA was 
significantly better compared with the F/T PSA ratio and total PSA [85,86]. 
One flaw of these studies was the fact that sextant prostate biopsies were not 
performed routinely, thus leaving the possibility of an attribution bias. 
On the other hand Partin and Bangma [87,88] found, that the utility of hK2 
was limited.  
Because the serum concentrations of hK2 are 50-100 fold lower than those of 
PSA, determination of hK2 is quite demanding. Variable results in various 
studies may thus be caused by differences in assay performance.  
Though hk2 or derivates of hk2 might contribute to improvements in the 
accuracy of prostate cancer detection a standardized test will be needed 
before hK2 could be used in a population based setting.  
 
 
The observation that the predictive value of serum PSA in men previously 
biopsied is lost at the second screening round makes the use of a simple PSA 
cut –off as an indication for biopsy in this particular cohort of men debatable.  
 
Chapter 8 studies the phenomenon of a changing relation between PSA 
levels and prostate cancer detection in a multivariate setting including men 
who had a previous negative biopsy at initial screening.  
These data show that the cohort of men screened for the second time in fact 
consists of two groups where predictors for biopsy outcome act completely 
differently. Analyzing these men together will thus lead to false conclusions 
with regard to the value of the different predictors. The key finding is that in 
men not previously biopsied predictors for biopsy outcome are comparable to 
those at initial screening. The cohort of men previously biopsied is clearly 
different; PSA lost its predictive value completely, increasing the relative 
importance of other predictors (DRE, TRUS and prostate volume). PSA 
kinetics do not contribute to the prediction of biopsy outcome at repeat 
screening. 
The above mentioned data suggest that the decision to perform a prostate 
biopsy based on an algorithm could be more efficient than performing a 
biopsy based on one predictor, especially in men who already had a negative 
biopsy procedure.  
The estimated cancer detection probability can be used as a biopsy indication 
instead of the present PSA threshold. In that case prostate volume, DRE and 
TRUS have to be determined for every man. Alternatively the following 
approach is feasible: In men without a previous negative biopsy PSA >=3.0 
ng/ml is used as a biopsy indication. In men with a previous negative biopsy 
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and a PSA >= 3.0 ng/ml the probability of cancer detection is calculated. A 
biopsy is indicated if the calculated probability is higher than a certain 
threshold. E.g. 215 men with a previous negative biopsy and a PSA >= 3.0 
ng/ml (46.8 % of cohort under study) have an estimated cancer detection risk 
of < 8% in the presented data set. In these men only 13 cancers were 
detected (6.5 % of the cancers detected in the 2nd screening round). 
 
The loss of the predictive value of PSA in the detection of prostate cancer has 
also been observed in the United States in areas where screening is prevalent. 
Stamey et al [89] claim that the PSA era is over and that PSA was related to 
the presence of prostate cancer 20 years ago, but at present is only related to 
BPH. This observation is however based on data coming from an area where 
screening has been common practice for many years (with relatively short 
intervals and aggressive screening algorithms) and the data relating to the 
present time are thus most likely based on a heavily pre-screened cohort.  
Even the 4-year interval of the ERSPC is too short for the remaining cancers 
to re-grow to the same volume as the cancers detected at initial screening that 
caused the positive correlation between the chance of cancer detection (PPV) 
and PSA level. This will certainly be the case in the United States where 
screening intervals are much shorter and men with very low PSA levels are 
biopsied.  
The concept that the era of PSA is over therefore needs some specification, 
PSA is still a valuable tool in the early detection of prostate cancer on a 
population based level and is related to the presence of prostate cancer, 
especially in men screened/biopsied for the first time. Due to PSA increase 
over time it was shown that the (arbitrary) cut-off value of PSA in second 
round screening has a PPV of 20-25% as in round 1 [34]. 
 
Also used in the multivariate analyses in this thesis, is a positive family history 
( i.e. brother(s) and/or father with prostate cancer).  
At the initial screening round in Rotterdam, men with a positive family history 
had a relative risk (RR) of 1.59 for detecting prostate cancer as compared to 
men with a negative family history. This conclusion was based on 19,815 filled 
in questionnaires in which 1,364 men reported a positive family history. At 
repeat screening the relative risk for men with a positive family history was 
1.30 [90,91]. These data are comparable to a large cohort study of 5,496 sons 
of Swedish men found to have prostate cancer between 1959 and 1963. A 
significantly increased overall standardized incidence ratio (SIR) of 1.70 (95% 
confidence interval, 1.51-1.90) was seen for prostate cancer in this cohort [92]. 
Selective screening of this subgroup would increase the specificity of the 
screening program, but will result in a very low sensitivity because only a 
small proportion of the men eligible have a positive family history.  
A positive family history was not associated with prognostic indicators such as 
Gleason score and clinical stage in our data set [93]. This latter observation is 
confirmed by other studies [94,95,96]. Longer follow up will give more insight 
into the prognostic impact of the tumour characteristics of men with a positive 
family history. This will be important to decide whether a more intensive 
screening algorithm in this group of men possibly starting at an earlier age is 
necessary.   
Opposite findings with regard to having had a negative biopsy are also found 
within the ERSPC [97]. Mäkinen et al. found that a PSA level >= 4.0 ng/ml and 
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having had a negative biopsy at initial screening was associated with an up to 
9-fold risk of cancer in re-screening relative to those with lower PSA levels at 
baseline ( and therefore not biopsied at initial screening).These differences 
however can be explained by the differences in the screening algorithm used 
at initial screening and the fact that calculations are based on groups of men 
with different percentages of men actually biopsied, as is explained in an 
editorial [98]. Data shown here make it clear that the PPV in men previously 
biopsied is lower than that of men biopsied for the first time (i.e. men whose 
PSA raises above the cut-off level of 3.0 ng/ml in the 4-year interval).  
 
It is clear that the current methods used to diagnose prostate cancer have 
their limitations, resulting not only in missed cases of prostate cancer, but also 
in the diagnosis of cancers whose natural history is not likely to be life-
threatening. Extensive research is ongoing to refine the current tools, and to 
develop new, more reliable tests. 
In recent years, pro PSA has been investigated as a means to better 
differentiate prostate cancer from BPH. Pro PSA represented approximatively 
3% of total PSA when measured in malignant tissue, while it was detected 
only in minimal amounts in benign tissue. Moreover, the truncated (-2) pro 
PSA form accounts for 25–95% of the free PSA in the serum of prostate 
cancer patients, but only for 6–19% of free PSA in the serum of patients 
without prostate cancer. Recently, some clinical studies have suggested that 
the use of pro PSA could improve the detection rate of prostate cancer. Sokoll 
et al. [98] evaluated the impact of pro PSA on the detection of prostate cancer 
in men with a total PSA between 2.5 and 4 ng/ml. Archival serum samples 
from 119 men (non-cancer 88, cancer 31), obtained before biopsy, were 
assayed for total PSA, fPSA, and pro PSA. Pro PSA was defined as the sum 
of the (-2), (-4), and (-7) pro PSA forms, and %pPSA as proPSA/fPSA. Total 
PSA and %fPSA values were similar between the non-cancer and the cancer 
groups. Although %pPSA tended to be higher in the cancer group (50.1% 
versus 35.5%), this difference was not statistically significant (p = 0.07). On 
the other hand, at a fixed sensitivity of 75%, the specificity was significantly 
greater for %pPSA compared with %fPSA (59% versus 33%, p < 0.0001). 
 
The hK11 protein is encoded by the KLK11 gene, which belongs to the human 
kallikrein family along with PSA (hK3) and other kallikrein. In a study were the 
serum hk11 level was compared between men with prostate cancer and BPH 
showed that the hK11: total PSA ratio and percentage of free PSA were much 
stronger predictors of the presence of prostate cancer than total PSA. These 
preliminary data suggest that the hK11: total PSA ratio could be a useful 
tumor marker and could be combined with percentage of PSA to further 
reduce the number of unnecessary prostatic biopsies [100]. 
Insulin-like growth factor-1 (IGF-1) and IGF bindingprotein- 3 (IGFBP-3) play 
an important role in the regulation of prostate cancer cell growth. However, 
whether these molecules represent tumour markers or aetiological factors has 
been a subject of debate. In a study done within the ERSPC section 
Rotterdam the measurement of serum IGF-I and/or IGFBP-3 concentrations in 
addition to PSA did not improve the identification of men at high risk to 
develop early stages of prostate cancer. In addition, the results indicated that 
the endocrine IGF-I system is not directly involved in the growth of the early 
stages of prostate cancer [101,102]. 
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The diagnostic potential of somatic changes that occur in prostate cancer cells 
should not be forgotten, with changes becoming more common as the disease 
progresses. Of particular note is differential display code 3 (DD3PCA3), which 
is highly over expressed in prostate cancer tumours, but is not expressed in 
normal human tissue. DD3PCA3 could potentially play an important role in the 
early identification of malignancy, although this is not yet tested in an 
asymptomatic population. Use of a new molecular urine assay test to detect 
prostate cancer based on the presence of urinary DD3PCA3 showed a 
sensitivity of the assay of 67%. Furthermore, a negative predictive value of 
90% was calculated (tested in men with a PSA level > 3.0 ng/ml) [103]. 
Other markers under investigation are, Neuroendocrine tumor markers i.e. 
chromogranin A (CgA) and estrogen inducible pS2 protein [104, 105], 
Prostate stem cell antigen (PSCA) and transient receptor potential p8 (trp-p8) 
[106,107,108] and Prostate-specific membrane antigen [PSMA, 109, 110]. 
 
The diagnostic tools discussed so far have mainly relied on the use of 
established scientific approaches. However, the latest technology—gene 
chips (DNA microarrays) and proteomics [111]—has opened up completely 
new diagnostic avenues. These powerful tools are likely to accelerate 
identification of new molecular diagnostic and therapeutic targets. Gene chip 
analysis allows the pattern of gene expression in tumours to be profiled, with 
thousands of genes monitored simultaneously. This technique can be used to 
compare the level and types of genes expressed in tumours compared with 
normal tissue, and to follow changes in prostate cancer cells during disease 
progression. 
One important new gene has been identified using gene chip analysis; this is 
a-methylacyl-CoA racemase (AMACR). AMACR is up regulated in prostate 
cancer and has been shown to increase confidence in the diagnosis of 
malignant disease [112,113].  
The definite need of more specific biomarkers for prostate cancer is 
underlined by the start of the so-called P-mark project [114].  
In the P-Mark project, several recently developed; promising markers will be 
evaluated using clinically well defined bio repositories. Following successful 
evaluation, these markers will be validated on a sample set derived from two 
large, European, prostate cancer studies and used for the identification of 
special risk groups in the general population.  
 
Chapter 9 describes the results of the first four pilot studies of ERSPC. These 
pilot studies are not included into the European Randomized Study of 
Screening for Prostate Cancer (ERSPC). The results of these pilot studies 
cannot replace the final outcome of ERSPC because of a drastic lack of 
power. The data may however serve as an encouragement to continue the 
ERSPC and at the same time as a trigger to start thinking about the future of 
prostate cancer screening. As said before it is unrealistic to think that prostate 
cancer screening will be discontinued, even if the ERSPC shows no 
significant mortality reduction. In that case screening almost certainly will not 
lead to national, population based, screening programs, but opportunistic 
screening will probably continue. If however the ERSPC shows a significant 
mortality reduction the impact of this message will be important. Many men 
will search for a possibility to be screened, making an effective screening 
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algorithm a first priority. It must however be kept in mind that this possible 
prostate cancer specific mortality reduction will be the result of a major effort 
with respect to the number of necessary screening tests. Also perhaps more 
importantly a considerable amount over-diagnosis and subsequent over-
treatment will result. It is therefore of great importance that research continues 
using available data of the ERSPC. The value of screening tests, tumor 
characteristics, treatment, mortality and not least the serum and tissue 
repositories will be invaluable in developing an acceptable and effective 
screening algorithm which either drastically decreases over diagnosis or 
identifies with an acceptable degree of certainty those patients which are 
preferably managed by watchful waiting. 
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Conclusions: 
 
Based on the data presented in this thesis the following conclusions can be 
drawn: 
Population based screening for prostate cancer is feasible, participation rates 
are acceptable and the screening tests well tolerated. 
Screening with the use of total PSA is at this moment the most efficient 
approach in unscreened populations. 
PSA kinetics are of no additional value in the early detection of prostate 
cancer at least as long as cut-off values are used as biopsy indications. 
Screening in men with low PSA values is sub optimal because of low PPV’s of 
the sextant biopsy.  
The role of DRE at low PSA values needs further investigation.  
New markers, to improve specificity, are urgently needed in the low PSA 
range, which represent a large proportion of men eligible for prostate cancer 
screening. 
Longer screening intervals are possible men with PSA levels <= 1.0 ng/ml. 
Men with a previous benign biopsy result form a separate group and a 
screening test which is able to discriminate between BPH and prostate cancer 
is needed.  
A screening algorithm, especially at repeat screening, should be more 
“tailored” to the individual using a combination of several (new) predictors.  
It must however be kept in mind  that whenever a test or combination of tests 
for diagnosing prostate cancer approaches 100% sensitivity and specificity, 
there is the concern that insignificant cases of prostate cancer may be 
diagnosed. The development of a method to determine which cancers are 
clinically relevant and need to be detected at an early stage would represent 
an important breakthrough in prostate cancer research. After that the optimal 
biopsy technique and screening interval could also be evaluated further.  
The data from the initial and repeat screening visits in ERSPC, the 
established serum and tissue repositories as well as the clinical follow-up of 
the cancers diagnosed will provide valuable data with respect to the above 
mentioned needs.   
Until these data from the ongoing randomized trial become available the 
guideline in prostate cancer screening should be “less is more” and men who 
wish to be screened should be properly informed to enable them to evaluate 
the possible harms and benefits of prostate cancer screening. 
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Although the concept of early detection of cancer sounds intuitively logical it is 
not automatically so in the case of prostate cancer despite the fact that the 
data on incidence and mortality show that it is an important health problem. 
The fact that prostate cancer is in general a slow growing tumor mainly in 
elderly men raises the question whether early detection and available 
treatment (with related morbidity) will improve prostate cancer specific survival. 
The identification of PSA as a diagnostic tool, and an increased awareness of 
the disease by patients and doctors resulted in an increase in incidence of 
prostate cancer. Whether such early detection and treatment of prostate 
cancer will save lives can only be answered by a well performed randomized 
controlled trial. The European Randomized study of Screening for Prostate 
Cancer (ERSPC) is a multi centre study that has the power to investigate the 
impact of screening for prostate cancer on disease specific mortality. The 
ERSPC also provides a means to study the performance of screening tests in 
identifying men with an elevated risk of having prostate cancer in an 
asymptomatic population. This thesis concentrates on this subject (chapter 1). 
Chapter 2 gives background information on the prostate, prostate cancer, 
screening and the statistical methods used in this thesis. 
Chapter 3 describes the history of the ERSPC (section Rotterdam) trial. 
During the course of the study it was shown that the initially chosen screening 
algorithm based on the available knowledge at that time, was not optimal.  
The evaluation of the screening data that became available identified groups 
of men in which the screening algorithm primarily chosen was not very 
effective. Two major changes were put into effect: screening was omitted in 
men with PSA values < 1.0 ng/ml and the use of DRE and TRUS as screening 
tests together with the lowering of the PSA cut-off value from 4.0 ng/ml to 3.0 
ng/ml as an indication for sextant biopsy. The changes in the screening 
algorithm led to a more efficient screening procedure (with regard to 
unnecessary visits and biopsy procedures) and also increased the 
participation rate.      
In Chapter 4 the two different screening algorithms are compared with regard 
to cancer detection rate and tumor characteristics of the cancers detected. 
Omitting DRE and TRUS as screening tests and lowering the PSA cut off level 
did not result in detecting fewer prostate cancers. In fact the overall cancer 
detection rate increased as cancers previously missed were found at the 
relatively low PSA values of 3.0 – 3.9 ng/ml. Furthermore it was found that the 
overall characteristics of the cases detected at the lowered PSA cut-off 
differed very little from those detected with the algorithm based on PSA, DRE, 
and TRUS. 
In chapter 5 the value of PSA velocity as a predictor for biopsy outcome in the 
low PSA ranges (PSA < 4.0 ng/ml) is evaluated in both a univariate and 
multivariate setting. Data from a side study at the second screening round 
were used. In this side study men with a PSA above 2.0 ng/ml or a doubling of 
the PSA value within the 4-year interval were biopsied. The study confirmed 
the relatively high prevalence of biopsy detectable prostate cancer (PPV = 
19.3 %) at these low PSA ranges and showed that both in the univariate and 
multivariate setting an increased PSA velocity was no significant predictor for 
biopsy outcome.     
Chapter 6 evaluates the effect of a protocol change implemented 8 years 
earlier. As mentioned in chapter 3 it was decided to stop further screening 
with DRE, TRUS and sextant biopsy in men with a PSA level < 1.0 ng/ml. The 
omission of further screening this particular cohort of men is again a protocol 
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change that can lead to missing cancers that can be life threatening if not 
detected in an organ confined state. The conclusion of this study was that 
delaying the biopsy procedure until PSA increases to a certain cut off value 
( in this case 3.0 ng/ml), and thus saving a lot of unnecessary biopsies, does 
not seem to lead to an increase in the detection of incurable prostate cancer 
cases. In fact prolonging the screening interval to e.g. 8 years will lead to a 
considerable decrease of screening visits with a minimal risk of missing 
aggressive cancers in a curable stage. 
Chapter 7 evaluates the results of re-screening in men with a PSA >= 4.0 
ng/ml and a benign biopsy result at initial screening. If the sextant biopsy 
technique and the policy of not performing an immediate re- biopsy would be 
ineffective this could result in a considerable number of  (advanced) interval 
cancers or an increased detection rate and/or more advanced cancers at 
repeat screening four years later.  It turned out that the PPV at repeat 
screening was 8.3 % (overall PPV at repeat screening was 18.9 %). The 
number of interval cancers was certainly not negligible ( 8 cases in 312 men = 
2.6%) but they were mainly found in men older than 74 years of age and in 
men who refused biopsy at initial screening. The results of this study did not 
provide a reason to adjust the screening protocol with regard to repeat 
biopsies in men with an elevated PSA level (4.0 mg/mL or more) and a benign 
biopsy result.  
Chapter 8 studies the change of the predictive value of information known 
before a biopsy is taken in a multivariate setting by comparing the value of the 
available predictors for biopsy outcome at initial and repeat screening. The 
data show that the cohort of men screened for the second time in fact consists 
of two groups where predictors for biopsy outcome act completely differently. 
Analyzing these men together will thus lead to false conclusions with regard to 
the value of the different predictors at repeat screening. The key finding of this 
study is that in men not previously biopsied predictors for biopsy outcome are 
comparable to those at initial screening. The cohort of men previously 
biopsied is clearly different; PSA loses its predictive value completely. Finally 
chapter 9 gives possibly a glimpse to the future. The results after a mean 
follow-up period of 9.9 years show a considerable decrease in prostate cancer 
mortality in the screening arm compared to the control arm. It must be noted 
that the screening algorithm used in the pilot studies reported is definitely not 
comparable with the screening algorithms used in the whole of ERSPC. It is 
however not unthinkable that, when analysing the data from ERSPC as a 
whole, a significant mortality reduction will be achieved within a few years 
based on earlier detection and effective treatment of aggressive cancers. This 
certainly will not mean the end of our investigations; to the contrary test 
evaluation must continue. This possible mortality reduction will be the result of 
a major effort with respect to the number of necessary screening tests. Also 
perhaps more importantly a considerable amount of over-diagnosis and 
subsequent over-treatment will result. Information coming from the ERSPC on 
the value of screening tests, tumor characteristics, treatment, mortality and 
not in the least the serum and tissue repositories will be invaluable in 
developing an acceptable and effective (in the context of both cancer 
detection and costs) screening algorithm. Until these data from the ongoing 
randomized trial become available the guideline in prostate cancer screening 
should be “less is more”and men who wish to be screened should be properly 
informed to enable them to evaluate the possible harms and benefits of 
prostate cancer screening. 
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Het concept van vroege opsporing lijkt voor de hand liggend, een vroege 
diagnose leidt tot een betere kans op genezing. Dit is echter niet altijd het 
geval bij de diagnose van prostaatkanker. De reden hiervoor is niet omdat de 
ziekte zo weinig voorkomt, in tegendeel, de incidentie- en mortaliteitscijfers 
tonen aan dat prostaatkanker een veel voorkomende aandoening is. Het feit 
dat prostaatkanker een tumor is die vaak  langzaam groeit en voornamelijk 
voorkomt bij de wat oudere man, is aanleiding tot het zetten van vraagtekens 
bij de waarde van vroege opsporing. Het is namelijk zeer de vraag of een 
vroege opsporing en behandeling, die gepaard kan gaan met vervelende 
bijwerkingen, de sterfte aan prostaatkanker zal verminderen. Ondanks deze 
onduidelijkheden over de waarde van vroege opsporing van prostaatkanker is 
de incidentie de laatste jaren toegenomen. Dit niet in de laatste plaats als 
gevolg van de ontdekking van het prostaat specifieke antigeen (PSA) en de 
toegenomen bekendheid van prostaatkanker onder de bevolking en bij 
medisch specialisten.  
De vraag of de vroege opsporing van prostaatkanker levens kan redden,  kan 
alleen beantwoord worden door middel van een correct uitgevoerd 
gerandomiseerd onderzoek. De European Randomized study of Screening for 
Prostate Cancer (ERSPC) is een gerandomiseerde studie die wordt 
uitgevoerd in verschillende Europese centra. De studie heeft als hoofddoel het 
effect van vroege opsporing op de prostaatkankerspecifieke sterfte te 
onderzoeken. Daarnaast kunnen de resultaten ook inzicht geven in de waarde 
van verschillende screeningtesten en van waarde zijn in het identificeren van 
mannen met een verhoogde kans op prostaatkanker uit een populatie zonder 
specifieke klachten. Dit proefschrift richt zich op het laatstgenoemde 
onderwerp  
(hoofdstuk 1). 
 
Hoofdstuk 2 geeft algemene informatie over de prostaat, prostaatkanker en 
het fenomeen van vroege opsporing of screening. Tevens worden de 
statistische technieken, gebruikt in dit proefschrift, besproken. 
Hoofdstuk 3 geeft een overzicht van de screeningresultaten van het 
Nederlandse deel van de ERSPC. De screeningtesten en het algoritme, 
gekozen bij de start van de studie, zijn gedurende het verloop van de studie 
geëvalueerd. Dit heeft geleid tot twee belangrijke veranderingen in het 
screeningalgoritme. Al vrij snel na de start van de studie werd bij mannen met 
een serum PSA waarde van minder dan 1.0 ng/ml afgezien van verder 
onderzoek. De tweede verandering in het screeningalgoritme betrof het 
verlagen van de drempelwaarde van het PSA die leidt tot het doen van een 
prostaatbiopsie. Halverwege de studie werd deze drempelwaarde verlaagd 
van 4.0 ng/ml naar 3.0 ng/ml. Bovendien werd bij mannen met een PSA lager 
dan 3.0 ng/ml afgezien van verder onderzoek. De veranderingen in het 
screeningalgoritme leidden tot een vermindering van het aantal benodigde 
bezoeken aan het screeningbureau en tot een meer efficiënte identificatie van 
mannen met een mogelijk verhoogd risico op prostaatkanker. Dit resulteerde 
in een vermindering van het aantal onnodige biopsieën en tevens een hogere 
opkomst.  
In hoofdstuk 4 wordt het originele screeningalgoritme, een prostaatbiopsie bij 
een serum PSA waarde van 4.0 ng/ml of hoger, of bij een lagere serum PSA 
waarde een afwijkend rectaal toucher en/of echo, vergeleken met het nieuwe 
screeningalgoritme (alleen een prostaatbiopsie bij een serum PSA waarde 
van 3.0 ng/ml of hoger). Er  werd gekeken naar het aantal gevonden kankers 
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en hun karakteristieken. Het bleek dat de verandering van screeningalgoritme 
niet leidde tot de detectie van minder kankers, ondanks het feit dat bij mannen 
met een serum PSA waarde lager dan 3.0 ng/ml geen verder onderzoek 
plaats vond. Het aantal diagnoses nam zelfs toe doordat er veel meer kankers 
werden gevonden in de mannen met een serum PSA waarde tussen de 3.0 
en 3.9 ng/ml. De karakteristieken van de gevonden kankers in de twee 
verschillende screeningalgoritmen waren vergelijkbaar. 
Hoofdstuk 5 beschrijft een onderzoek naar de waarde van de verandering van 
het serum PSA over tijd in het voorspellen van de uitkomst van een 
prostaatbiopsie. De studie richt zich met name op mannen met relatief lage 
serum PSA waarden. De benodigde gegevens voor deze studie kwamen uit 
een zijstudie, gedaan tijdens de tweede screening ronde. In deze zijstudie zijn 
tijdelijk alle mannen met een serum PSA waarde van 2.0 ng/ml of hoger of 
mannen die een verdubbeling van hun PSA waarde hadden gedurende de 
periode tussen de twee screeningbezoeken, gebiopteerd. De resultaten tonen 
aan dat ook bij lage serum PSA waarden prostaatkanker niet zeldzaam is en 
dat de verandering van het  serum PSA over tijd geen goede voorspeller was 
voor de uitkomst van de prostaatbiopsie. 
Hoofdstuk 6 evalueert de mogelijke gevolgen van de eerste 
protocolverandering, namelijk geen verder onderzoek bij mannen met een 
serum PSA lager dan 1.0 ng/ml.  Het niet verder onderzoeken van een 
bepaalde groep mannen kan leiden tot het missen van diagnoses, die op hun 
beurt weer een effect kunnen hebben op de prostaatkankerspecifieke sterfte. 
Voor deze studie werd een cohort van mannen gebruikt die al aan drie 
screeningronden hadden deelgenomen en die bij hun eerste screeningbezoek 
een serum PSA gehalte hadden van 1.0 ng/ml of lager. Het aantal mannen, 
wiens PSA na 8 jaar boven de drempelwaarde voor een biopsie was gestegen 
bleek na analyse van de data heel laag te zijn. Het zou dus mogelijk zijn om 
de tijd tussen twee screeningbezoeken in deze groep mannen te verlengen 
met enkele jaren, zonder dat er een grote kans bestaat dat de diagnose, van 
nog te genezen kanker, te laat zou zijn. 
Hoofdstuk 7 richt zich op een andere groep mannen binnen de screening-
populatie, namelijk mannen met een serum PSA waarde hoger of gelijk aan 
4.0 ng/ml en een eerdere prostaatbiopsie met een goedaardig resultaat. Het 
zou kunnen zijn dat de gebruikte sextant biopsietechniek, of het niet direct 
herhalen van de biopsie, niet toereikend is voor de tijdige diagnose van 
prostaatkanker. Dit zou dan leiden tot een verhoogd aantal diagnoses van, 
mogelijk vergevorderde, prostaatkankergevallen in het screeninginterval of bij 
het tweede screening-bezoek. Biopsieresultaten van de tweede ronde van 
deze groep mannen toonden aan dat het aantal diagnoses van 
prostaatkanker relatief laag was ( 8.3%). Het aantal klinisch gevonden 
prostaatkankers in het 4 jaar interval was zeker niet laag. Deze 
prostaatkankergevallen werden echter wel gevonden in mannen die een 
biopsie hadden geweigerd bij hun eerste screeningbezoek, of die ouder waren 
dan de leeftijd waarop een vroege diagnose nog zinvol wordt geacht. 
Conclusie van deze studie is dan ook dat er geen aanleiding is om het aantal 
biopten per biopsieprocedure te verhogen of om de biopsieprocedure binnen 
korte tijd te herhalen. 
In hoofdstuk 8 worden de voorspellers voor de uitkomst van een biopsie in 
eerste en tweede ronde bestudeerd en vergeleken. Uit deze studie blijkt dat 
het cohort mannen dat voor de tweede keer wordt onderzocht in feite uit twee 
verschillende groepen bestaat. De eerste groep bestaat uit mannen die nog 
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niet eerder gebiopteerd zijn en de tweede groep bevat mannen met een 
eerder goedaardig biopsieresultaat. Tussen deze twee groepen is de 
voorspellende waarde van de verschillende screeningtesten geheel 
verschillend. Het gezamenlijk analyseren van alle mannen in een tweede 
screening ronde kan dus leiden tot verkeerde conclusies met betrekking tot de 
voorspellende waarde van de verschillende screeningtesten. Het blijkt dat de 
voorspellende waarde van de screeningtesten in mannen die niet eerder 
gebiopteerd zijn, vergelijkbaar is met die in mannen die voor het eerst 
gescreend worden. In de groep mannen met een eerder negatief biopt verliest 
het serum PSA zijn voorspellende waarde. 
Hoofdstuk 9 beschrijft de resultaten van de eerste 4 pilotstudies gedaan in de 
periode 1991 – 1993. Na een vervolgperiode van gemiddeld 9,9 jaar blijkt er 
een aanzienlijke daling in de prostaatkankersterfte in de screeninggroep te 
zijn. Ondanks het feit dat de manier van screenen in deze vier pilotstudies niet 
te vergelijken is met het uiteindelijk gekozen screeningalgoritme, kan de 
uitkomst van deze pilotstudies ons toch een idee geven over de uiteindelijke 
uitkomst van de gehele ERSPC studie. Het is niet ondenkbaar dat  vroege 
opsporing van prostaatkanker uiteindelijk leidt tot een vermindering van de 
prostaatkanker-specifieke sterfte. Dit  betekent echter niet dat het onderzoek 
gestopt kan worden. Deze eventuele daling van de prostaatkankersterfte is 
dan het resultaat van een enorm aantal screeningbezoeken en een 
aanzienlijke hoeveelheid overdiagnose en overbehandeling.  
De data van de ERSPC, en dan met name de gegevens over de waarde van 
de verschillende screeningtesten, de karakteristieken van de gevonden 
tumoren, resultaten van behandeling- en sterftecijfers en niet te vergeten de 
opgebouwde serum- en weefselbank, zullen van grote waarde zijn voor het 
verdere ontwikkelen van een acceptabel en betaalbaar screeningprogramma. 
Tot de tijd dat deze data gecompleteerd en geanalyseerd zijn dient het aan-
beveling om terughoudend te zijn met betrekking tot de vroege opsporing van 
prostaatkanker. Mannen die er voor kiezen om gescreend te worden dienen 
goed geïnformeerd te worden over de megelijke risico’s en voordelen die de 
vroege diagnose van prostaatkanker met zich meebrengt.   
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Ik ben geboren op een zonnige zondagochtend, 22 oktober 1961, vlak naast 
het Feyenoord stadion (Clara ziekenhuis). Met mijn ouders, twee zussen en 
twee broers ben ik opgegroeid in Rotterdam Alexanderpolder. In 1979 
behaalde ik het HAVO diploma aan de scholengemeenschap Prins Alexander 
te Rotterdam. Hierna volgde ik de HBO analisten opleiding ( botanische studie 
richting) te Delft. Het diploma behaalde ik in 1982. Aangezien het vinden van 
een baan in die tijd iets heel bijzonders was besloot ik door te stromen naar 
de HLS ( Hogere Landbouw School) te Dordrecht. Na een jaar ploegen, 
lassen, zaaien en koeien melken bleek dat ook in deze studie richting werk 
alleen te vinden was voor degene met een boerenbedrijf in de familie.  
Een ommezwaai was dus nodig wilde er ooit brood op de plank komen. Van 
1983 tot 1985 heb ik daarom de opleiding tot apothekersassistente gevolgd. 
Tijdens deze opleiding vond ik in februari 1985 werk als research analist en 
wel op de afdeling Immunologie van het Erasmus MC. In 1987 ben ik 
getrouwd met Wouter Roobol en op 9 april 1991 werd Stefan geboren. 
Hierdoor ontstond de wens om part time te gaan werken en ben ik als 
datamanager begonnen bij de afdeling Urologie (september 1991). Op 11 
februari 1994 werd Dennis geboren. Mijn loopbaan binnen Urologie moge 
duidelijk zijn; na het opzetten en praktisch uitvoeren van het Nederlandse deel 
van de “European Randomised study of Screening for prostate Cancer 
(ERSPC)” werd het analyseren en interpreteren van de data steeds 
interessanter. In 1998 schreef ik mijn eerste abstract en al snel daarna kwam 
de mogelijkheid om promotie onderzoek te doen ter sprake. Aangezien een 
universitaire graad in mijn cv ontbrak, heb ik in de zomer van 2003 mijn 
Masters Degree in de Epidemiologie gehaald. Het promotieonderzoek is nu  
afgerond en dit boekje is het resultaat. Na mijn promotie blijf ik werken op de 
afdeling Urologie en zal mij voornamelijk bezig houden met het voltooien van 
het rotterdamse deel van de ERSPC.  
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Voor degene die eerst het CV hebben gelezen is het al duidelijk, ik werk al 
vele jaren binnen het ErasmusMC en heb dan ook al veel promoties mogen 
meemaken. Dat houdt in dat ik dus ook veel proefschriften heb gezien en 
dankwoorden heb gelezen (ik zal eerlijk zijn). Soms dacht ik bij het lezen van 
die dankwoorden: Nou, nou, is er wel iets dat je zelf hebt gedaan? Hoe naief 
kon ik zijn? 
Natuurlijk schrijf je je proefschrift zelf maar voordat je zover bent heb je van 
heel veel mensen steun en hulp ontvangen, dat is mij nu wel duidelijk. Dus 
ook in dit proefschrift een woord van dank aan iedereen die mij heeft 
geholpen met raad en daad tijdens de jaren die ik heb gewerkt aan dit 
proefschrift. 
Allereerst natuurlijk een hele grote BEDANKT aan mijn geniale, onnavolgbare, 
nimmer vermoeide, prettig gestoorde maar bovenal buitengewoon aardige 
professor. Professor Schröder, het is eigenlijk heel simpel, zonder u zou dit 
boekje er nooit zijn gekomen. Allereerst was u zo moedig om mij aan te 
nemen om uw eerste pilotstudies op te zetten en uit te voeren. Ik zal u eerlijk 
zeggen dat ik destijds wel gelogen heb tijdens het sollicitatie gesprek: ik wist 
helemaal niets van computers, laat staan databases. Gelukkig is dat redelijk 
goed gekomen. Ten tweede bent u de man geweest die inzag dat ik 
misschien wel wat meer kon dan het beheren van de databases. Ik bedank u 
dan ook voor de mogelijkheid om abstracts en artikelen te schrijven en 
congressen te bezoeken. Verder is het natuurlijk ongelooflijk dat ik, vaak 
tijdens werktijd en op uw kosten, de master opleiding kon volgen, die nodig 
was om überhaupt in aanmerking te komen voor een promotie. Uw 
vertrouwen, steun en advies zijn voor mij van onschatbare waarde geweest 
en ik hoop dan ook dat we na mijn promotie de samenwerking kunnen 
voortzetten en de ERSPC studie kunnen afronden. 
Een tweede man die ook zo’n BEDANKT verdient is Ries Kranse. Ries jouw 
kennis, ideëen en motivatie waren, en zijn natuurlijk, van onschatbare waarde. 
De discussies die ik met jou heb gehad over allerlei onderwerpen omtrent de 
screening en daarbuiten, waren uitermate leerzaam. Jij bent altijd mijn eerste 
vraagbaak en klankbord geweest en had altijd tijd voor me. Ries wat we 
verder ook gaan doen, ik hoop dat ik altijd contact met je zal blijven houden. 
Voordat ik verder ga met het bedanken van andere collega’s wil ik eerst toch 
een woord van dank richten aan alle deelnemers van het Nederlandse deel 
van de ERSPC: Mannen jullie waren fantastisch, in de breedste zin van het 
woord, zonder jullie bereidheid tot deelname had de ERSPC nooit van de 
grond gekomen en waren er geen data geweest om te analyseren. 
Al die deelnemers zijn eens allemaal uitgenodigd en gerandomiseerd. Bij de 
helft is bloed afgenomen en zijn er verdere onderzoeken gedaan. Vele 
tienduizenden brieven zijn verzonden en gegevens ingeklopt in de computer. 
Dit gebeurde op het screeningbureau waar in die ruim 14 jaar vele mensen 
hebben gewerkt. 
Wim Kirkels bedank ik voor zijn begeleiding en steun bij het draaiende houden 
van het screeningbureau, vooral gedurende de eerste jaren van de 
screeningstudie was je onmisbaar. 
Wilma Roobol was mijn eerste collega en we hebben dan ook 10 jaar 
samengewerkt.  Natuurlijk blijf je altijd mijn schoonzus, maar je bent ook een 
heel prettige collega geweest die ik eerlijk gezegd nog steeds wel eens mis op 
het screeningbureau. Jouw geduld met de deelnemers en collega’s was 
fantastisch en de manier waarop je een groot deel van mijn taken in de loop 
van de tijd hebt overgenomen bewonderingswaardig. Zonder jou had ik nooit 
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genoeg tijd gehad om ook maar te denken aan onderzoek. Wil, heel hartelijk 
dank daarvoor en ik ben blij dat jij mijn paranimf bent. 
Na Wilma volgden er vele collega’s om de stroom van mannen te kunnen 
pitten, loten, plannen, prikken, screenen, follow-uppen en de data in te voeren. 
John, Arto en Geert-Jan ik denk nog vaak terug aan onze gezamelijke 
lunches met de vele Jiskefet grappen. De hoeveelheid mannen die jullie 
hebben gescreened zijn ongeëvenaard. Ada en Vera, jullie vergeet ik niet snel, 
de een een onfeilbaar geheugen voor deelnemernummers, de andere een 
moordend werktempo, bedankt voor jullie inzet. Ingrid, naast collega ben je 
een goede vriendin geworden, ondanks de verwachting van velen dat wij, als 
twee echte bitches, elkaar in de haren zouden vliegen. Ik hoop dat ook jij snel 
je boekje afhebt. Ook de andere artsen wil ik bedanken voor hun collegialiteit 
en inzet op het screeningbureau; Michiel, Carl, Mike, Gile, René, Stijn, André, 
Renske, Claartje en Stijn 2, bedankt. 
Ellen en Lakshmi jullie zijn nu de twee drijfveren van de screening. Ook jullie 
ben ik  zeer dankbaar dat alles zo goed loopt en ik veel van mijn tijd kan 
besteden aan onderzoek. Als laatste de follow-up dames, Conja (is het 
Nederlands goed?), Marlies en Bianca. Het werk wat jullie doen verdient veel 
respect en ik heb dan ook grote bewondering voor jullie.  
Ook mijn tweede paranimf Ellen vd Berg heeft op het screeningbureau 
gewerkt als stagiaire. Ellen jouw inzicht en werktempo waren ongelooflijk en 
de term stagiaire was na zeer korte tijd niet meer van toepassing. Ook nu ben 
je nog onmisbaar voor de ERSPC. Voor mij ben je nu een collega die eigenlijk 
overal wel een oplossing voor heeft, alles relativeerd en mij altijd weer moed 
inspreekt tijdens wat mindere momenten. Ik ben heel blij dat je mijn paranimf 
wilt zijn. 
Harry de Koning wil ik bedanken voor zijn begeleiding tijdens de 
masteropleiding en Chris Bangma als nieuw afdelingshoofd van de afdeling 
Urologie, bedankt voor het in mij gestelde vertrouwen.  
Verder wil ik ook de medewerkers van Urologie, Pathologie, Klinische Chemie, 
Maatschappelijke Gezondheidszorg en Directie Informatie bedanken voor de 
prettige samenwerking. 
Ook wil ik nog graag een woord van dank richten aan mevr. Bonnema voor 
het mogelijk maken van onze promovendi avonden die voor mij tot nu toe heel 
leerzaam waren en aan Philip Smith. Philip, many, many thanks for reading 
my thesis and correcting my use of the English language. 
Om goed te functioneren op het werk is het natuurlijk belangrijk dat op het 
thuisfront alles blijft doordraaien, zeker voor een moeder van twee kinderen. 
Hiervoor wil ik ten eerste mijn moeder en schoonouders hartelijk danken. 
Oma Flat, Oma Poes en Opa heel hartelijk dank voor alle oppasuren, lekkere 
maaltijden, gestreken was en ritjes naar sportverenigingen en vriendjes. 
Zonder jullie hulp en die van Mabel was het thuis een chaos geworden.  
 
Dan blijven mijn drie mannen nog over. Allereerst Stefan en Dennis. Tja 
jongens wat moet ik zeggen tegen jullie? Bedankt dat jullie het met zo’n 
moeder hebben kunnen volhouden. Als ik niet op het werk was zat ik of achter 
de computer of was op reis. Ik vind jullie kanjers en ben trots dat jullie wel 
inzien dat mama geen mama is om hele dagen thuis te zitten. Last but not 
least mijn Wout. Ik ga je niet bedanken omdat je ervoor hebt gezorgd dat alles 
thuis bleef doorgaan zoals het moest, want dat deed je niet ☺. Dat is echter 
geen verwijt want je eigen baan is zo mogelijk nog drukker dan die van mij. 
Wat je wel deed was fungeren als klankbord zodat ik regelmatig stoom kon 
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afblazen. Ook heb jij mij alles geleerd op computer gebied, wat veel geduld 
vergde en zeker geen overbodige luxe was in de beginjaren !! De term “read 
the fucking screen” wordt nog steeds gebruikt op het screeningbureau. Ook 
ben je van onschatbare waarde geweest in het opmaken van artikelen, 
posters en presentaties en niet te vergeten; de database van de follow-up en 
website van de ERSPC komen van jouw hand! Ook de opmaak van dit 
proefschrift en de voorkant hebben je weer menig uurtje gekost. Voor dit alles 
ben ik je dan ook zeer veel dank verschuldigd en ik zal proberen in de 
toekomst iets minder vaak achter “jouw” PC te zitten mits jij het ook doet! 
 
 
